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Abstract 
 
Leukemia is a malignant disease of the bone marrow and blood where immature white blood 
cells which are not able to develop into normal functioning blood cells are overproduced and 
build up in the bone marrow and blood. The most common treatment for most types of 
leukemia is intensive chemotherapy. This therapy can itself be life-threatening since only 
relatively few patient-specific and leukemia-specific factors are considered in current 
protocols; choice of chemotherapy, intensity and duration often depends on the treating 
physician‟s experience with significant international protocol variability. With the advent of 
novel treatments and large amounts of patient- and leukemia-specific genomic data, there is a 
clear need for a systematic approach to the design and execution of chemotherapy regimens. 
We have developed a model for the simulation of patients with Acute Myeloid Leukemia 
(AML) undergoing treatment with two standard chemotherapy protocols, one intensive and 
the other non-intensive. The proposed model combines critical targets of drug actions on the 
cell cycle, together with pharmacokinetic (PK) and pharmacodynamic (PD) aspects providing 
a complete description of drug diffusion and action after administration. Tumour-specific and 
patient-specific characteristics are incorporated into the model in order to gain insights into 
the personalised cell dynamics during treatment. 
Sensitivity analysis of the developed model identifies cell cycle times as the critical 
parameters that control treatment outcome. For model analysis, clinical data of 6 patients who 
underwent chemotherapy are used for the estimation of cell cycle time distribution. 
The chemotherapy process is formulated as an optimisation scheduling algorithm aiming to 
obtain the chemotherapeutic schedule which would maximise leukemic cell kill (therapeutic 
efficacy) whilst minimising death of the normal cell population, thereby reducing toxicities.  
This optimisation algorithm is solved for all the patient case studies and the results clearly 
demonstrate the potential improvement of treatment design through optimisation.  
 
  
5 
 
Acknowledgments 
 
Completing my PhD degree is probably the most challenging activity of my first 29 years in 
life. Thankfully along the way I had the pleasure and the luck to share the best and worst 
moments with great people who helped me reach the end of this wonderful experience. First 
and foremost, I would like to thank my supervisors Professor Stratos Pistikopoulos and Dr. 
Nicki Panoskaltsis for encouraging me to work in an interesting and challenging field of drug 
delivery systems. Prof. Pistikopoulos‟ enthusiasm, passion for work, innovative ideas, great 
leadership qualities have always inspired me to strive for extra and try to make my own mark. 
This PhD would have been impossible without his and Dr. Panoskaltsis‟ support, consistent 
feedback and guidance. I am really grateful for the discussions I had with Dr. Panoskaltsis on 
the scientific and ethic principles of the medicine field (completely unknown to me) that have 
been instrumental not only for the successful completion of the project but had a key role in 
shaping me as a researcher. I would also like to thank prof. Sakis Mantalaris and the BSEL 
laboratory for their help on the cell cycle part of my model and for their consistent support 
throughout the project.  
I would like to thank the European Research Council (MOBILE, ERC Advanced Grant, No: 
226462) for the financial support of the project.  
Starting from the early days of my PhD I would like to thank the senior Greek committee of 
the office consisting of Dr. Kouramas, Dr. Koutinas, Dr. Kiparissides, Dr. Panos and Matina 
Zavitsanou. Our meetings in the LG, G or even the Queens Lawn grass the one sunny day of 
the year made me feel like back home and made the first years of my PhD the most 
enjoyable. I would also like to thank Romain Lambert for our daily coffees in the common 
room and Maria, Nick and Eirini for making the days of my last year in Imperial less grey! 
Although away from home the last 5 years I would like to specially thank my close friends 
Maro, Eirinaios, Maria, Manolis, Vasilis, Fani for always being there for me and for making 
my holidays really special. A special thanks to Yannis for his patience and support during all 
this transition period from completing my PhD – to making job applications and finally start 
working. Thank you as this was a stressful period and you have made it a lot easier for me! 
Lastly, I would like to express my deepest gratitude to my father Dimitris, my sisters and 
advisors Efi and Artemis and my brother-in-law Panagiotis who have always been in my side 
supporting me with all their possible means. Of course I would have to thank the two most 
adorable and younger members of my family, my nephew Stavros and our new baby girl who 
I patiently wait to meet this Christmas!  However, special thanks go to the most important 
person in my life, my late mother Rita. She brought us up with love, she armed us with 
morals in life and she taught us to always be ambitious and try for the best.  This thesis is too 
little to thank her for all her sacrifices and for the nights she spent being stressed for mine and 
my sisters‟ future. I will always love her with all my heart and although her loss is the hardest 
and the most painful event in my life I am grateful to God for giving me this mother even for 
only 25 years.  
6 
 
Contents 
Abstract ...................................................................................................................................... 4 
Acknowledgments...................................................................................................................... 5 
List of tables ............................................................................................................................. 10 
List of figures ........................................................................................................................... 12 
List of abbreviations ................................................................................................................ 17 
Chapter 1 .................................................................................................................................. 18 
Introduction .............................................................................................................................. 18 
1.1Project Objective ............................................................................................................. 18 
1.2 Project deliverables and thesis structure ........................................................................ 21 
Chapter 2 .................................................................................................................................. 24 
Literature Review..................................................................................................................... 24 
2.1 Introduction .................................................................................................................... 24 
2.2 Leukemia – disease principles and patient variability ................................................... 24 
2.3 Chemotherapy for the treatment of AML ...................................................................... 29 
2.3.1 Introduction to clinically used anticancer agents for chemotherapy treatment ...... 29 
2.3.2 Studied chemotherapy treatment protocols ............................................................. 30 
2.4 Mathematical modelling of chemotherapy treatment for AML ..................................... 32 
2.4.1 Cell Cycle modelling .............................................................................................. 33 
2.4.1.1 Cell Cycle principles in normal and abnormal BM cells ..................................... 33 
2.4.1.2 Cell Cycle mathematical models ......................................................................... 36 
2.4.2 Pharmacology of anti-leukemic drugs .................................................................... 38 
2.4.3 Pharmacokinetic (PK) modelling ............................................................................ 40 
2.4.3.1 PK modelling principles ...................................................................................... 40 
2.4.3.2 PK mathematical modelling ................................................................................. 42 
2.4.4 Pharmacodynamic (PD) modelling ......................................................................... 48 
7 
 
PART I: .................................................................................................................................... 50 
Chemotherapy Treatment as a Process Systems Application .................................................. 50 
Chapter 3 .................................................................................................................................. 51 
Mathematical Model Formulation ........................................................................................... 51 
3.1 Introduction .................................................................................................................... 51 
3.2. Framework for the development of optimal personalised chemotherapy protocols ..... 52 
3.3 Physiologically based patient model for the treatment of AML with DNR and Ara-C 54 
3.3.1 Mathematical model for IV and SC dose applications of DNR and Ara-C anti-
leukemic agents ................................................................................................................ 55 
3.3.2 Patient and disease characteristics .......................................................................... 60 
3.3.3 Model Assumptions ................................................................................................ 62 
3.4 Model Sensitivity Analysis ............................................................................................ 65 
3.5 Simulation results for two hypothetical patient case studies ......................................... 67 
3.5.1 Model parameters for the patient case studies ........................................................ 67 
3.5.2 Simulation results of Patient H1 undergoing LDAC and DA induction treatments
 ......................................................................................................................................... 70 
3.5.3 Simulation results of Patient H2 using LDAC and DA treatment protocols .......... 83 
3.6 Discussion ...................................................................................................................... 92 
Chapter 4 .................................................................................................................................. 94 
Chemotherapy process as an optimisation problem................................................................. 94 
4.1 Optimisation scheduling algorithm of chemotherapy process ....................................... 94 
4.2 Optimisation Results for the two hypothetical patients ................................................. 96 
4.2.1 Optimisation results of Patient H1 over the LDAC and DA treatment protocols .. 96 
4.2.2 Optimisation results of Patient H2 with LDAC and DA treatment protocols ...... 106 
4.3 Discussion .................................................................................................................... 110 
PART II:................................................................................................................................. 113 
8 
 
Model Analysis with Patient Data ......................................................................................... 113 
Chapter 5 ................................................................................................................................ 114 
Model Analysis with Patient Data ......................................................................................... 114 
5.1 Introduction .................................................................................................................. 114 
5.2 Patient data and model analysis assumptions .............................................................. 115 
5.2.1 Patient Data ........................................................................................................... 115 
5.2.2 Model Analysis Assumptions ............................................................................... 115 
5.3 Estimation of patient cell cycle distribution parameters .............................................. 117 
5.3.1 Cell cycle estimation for Patient P001 .................................................................. 118 
5.3.2 Cell cycle estimation for patient P002 .................................................................. 119 
5.3.3 Cell cycle estimation for Patient P006 .................................................................. 120 
5.3.4 Cell cycle estimation for Patient P011 .................................................................. 122 
5.3.5 Cell cycle estimation for Patient P016 .................................................................. 123 
5.3.6 Cell cycle estimation for patient P026 .................................................................. 125 
5.4 Optimal induction treatment design for the studied patients ....................................... 128 
5.4.1 Optimal personalised chemotherapy protocol for Patient P001 ........................... 129 
5.4.2 Optimal personalised chemotherapy protocol for Patient P002 ........................... 136 
5.4.3 Optimal personalised chemotherapy protocol for Patient P006 ........................... 138 
5.4.4 Optimal personalised chemotherapy protocol for Patient P011 ........................... 142 
5.4.5 Optimal personalised chemotherapy protocol for Patient P016 ........................... 144 
5.4.6 Optimal personalised chemotherapy protocol for Patient P026 ........................... 148 
5.5 Cytarabine (Ara-C) is more effective when given in continuous daily 24-hour infusions 
than in short 12-hourly infusions ....................................................................................... 150 
5.6 Concluding Remarks .................................................................................................... 152 
Chapter 6 ................................................................................................................................ 155 
Conclusions and Future Directions ........................................................................................ 155 
6.1 Project Summary .......................................................................................................... 155 
6.2 Key Contributions ........................................................................................................ 157 
9 
 
6.3 Future Directions ......................................................................................................... 158 
6.3.1 Model elaboration ................................................................................................. 158 
6.3.2 The ChemoApp ..................................................................................................... 160 
Publications from this thesis .................................................................................................. 168 
References .............................................................................................................................. 170 
Appendix A: ........................................................................................................................... 181 
Appendix B: ........................................................................................................................... 201 
Appendix C: ........................................................................................................................... 208 
 
 
  
10 
 
List of tables 
Table 2.1: Schedule of standard DA treatment protocol .......................................................... 31 
Table 2.2: Schedule of LDAC treatment protocol ................................................................... 32 
Table 2.3: PK models for cancer drugs .................................................................................... 47 
Table 2.4: Formulas of PD models (Holford et al., 1982) ....................................................... 49 
Table 3.1: List of model parameters ........................................................................................ 55 
Table 3.2: Organ blood flow variability (Dedrick et al., 1971) ............................................... 61 
Table 3.3: PK, PD, cell cycle parameters and inter-individual ranges used for model 
sensitivity analysis and sensitivity index results ...................................................................... 66 
Table 3.4: Pharmacology (PK – PD) parameters for Ara-C and DNR anti-leukemic agents .. 67 
Table 3.5: Parameters of the compartmental model for the normal BM cell population ........ 68 
Table 3.6: Hypothetical patient case study based on published data (Clarkson et al, 1967) ... 69 
Table 3.7: Simulation results for the the full course of treatment of Patient H1 with LDAC. 75 
Table 3.8: Simulation results for the full course of treatment of patient H1 under the DA 
clinical protocol ....................................................................................................................... 82 
Table 3.9: Simulation results for the full course of treatment of patient H2 using the LDAC 
clinical protocol ....................................................................................................................... 87 
Table 3.10: Simulation results for the full course of treatment of Patient H2 with DA clinical 
protocol .................................................................................................................................... 91 
Table 4.1: Chemotherapy process optimisation algorithm ...................................................... 95 
Table 4.2: Optimal LDAC induction treatment protocol for Patient H1 ................................. 96 
Table 4.3: Optimisation results for the full course of LDAC treatment for Patient H1 ........ 102 
Table 4.4: Optimisation results for the full course of treatment of protocol DA for Patient H1
................................................................................................................................................ 104 
Table 4.5: Optimisation results for the full course treatment of LDAC for Patient H2 ........ 106 
Table 4.6: Optimisation results for the throughout treatment of protocol DA for Patient H2
................................................................................................................................................ 108 
Table 5.1: Leukemic population of Patient P001 based on model analysis and clinical data 119 
Table 5.2: Leukemic population of Patient P002 based on model analysis and clinical data.
................................................................................................................................................ 120 
Table 5.3: Leukemic population of Patient P006 based on model analysis and clinical data 122 
Table 5.4: Leukemic population of Patient P011 based on model analysis and clinical data 123 
Table 5.5: Leukemic population of Patient P016 based on model analysis and clinical data 125 
11 
 
Table 5.6: Leukemic population of Patient P026 based on model analysis and clinical data 126 
Table 5.7: Cell cycle times fitted for the clinical data of 6 patients undergoing LDAC and DA 
protocols (Appendix B).......................................................................................................... 127 
Table 5.8: Optimal LDAC induction treatment protocol for Patient P001 ............................ 131 
Table 5.9: Leukemic and normal cell populations for P001, over the simulation and 
optimisation treatment protocols............................................................................................ 135 
Table 5.10: Optimal LDAC induction treatment protocol for Patient P002 .......................... 137 
Table 5.11: Leukemic and normal cell populations for P002, over the simulation and 
optimisation induction treatment protocols ........................................................................... 137 
Table 5.12: Optimal LDAC induction treatment protocol for Patient P006 .......................... 139 
Table 5.13: Leukemic and normal cell populations for P006, over the simulation and 
optimisation induction treatment protocols ........................................................................... 139 
Table 5.14: Optimal DA induction treatment protocol for Patient P011 ............................... 142 
Table 5.15: Leukemic and normal cell populations for P011, over the simulation and 
optimisation induction treatment protocols ........................................................................... 143 
Table 5.16: Optimal schedule of the 1
st
 chemotherapy cycle for Patient P016 ..................... 144 
Table 5.17: Optimal LDAC induction treatment protocol for Patient P016 .......................... 145 
Table 5.18: Leukemic and normal cell populations for P016, over the simulation and 
optimisation DA followed by LDAC treatment protocols ..................................................... 146 
Table 5.19: Optimal schedule of the full-length treatment for Patient P026 ......................... 148 
Table 5.20: Leukemic and normal cell populations for P026, during the simulation and 
optimisation DA treatment protocols ..................................................................................... 149 
 
  
12 
 
List of figures 
Figure 1.1: Schematic representation of project objectives and thesis structure ..................... 23 
Figure 2.1: The Hematopoietic System: The HSC has the capability to replicate into two new-
born cells, proceed to natural death (apoptosis) or differentiate towards progenitor cells. 
Progenitor cells afterwards differentiate into lineage-specific cells (myeloid and lymphoid) 
which mature to form the blood cells (Williams et al., 1983). ................................................ 25 
Figure 2.2: Key advances in the development of chemotherapy treatment. ............................ 30 
Figure 2.3: Description of the Cell cycle.. ............................................................................... 34 
Figure 2.4: Representation of the full model of the HSC behaviour.. ..................................... 35 
Figure 2.5: Schematic diagram of PK and PD: blue boxes are for the PK model and they are 
connected to the red cycle that represents the PD part of drug action. Adapted from (Ratain, 
Plunkett, 2003) ......................................................................................................................... 39 
Figure 2.6: The process of drug delivery. ................................................................................ 41 
Figure 2.7: Representation of a two-compartment pharmacokinetic model. Adapted from 
(Saltzman, 2001) ...................................................................................................................... 43 
Figure 2.8: Representation of a physiological PK model with organs represented as one-
compartment models. Adapted from (Saltzman, 2001) ........................................................... 45 
Figure 2.9: Schematic representation of an illustrative example of PD dose-response curves 48 
Figure 3.1: Framework for the derivation of optimal personalised chemotherapy protocols. . 53 
Figure 3.2: Schematic representation of Ara-C PK model following either i.v. or sc 
administration route ................................................................................................................. 60 
Figure 3.3: Representation of compartmental model for the normal cell population .............. 64 
Figure 3.4: Representation of compartmental model for the AML cell population ................ 64 
Figure 3.5: Patient H1 behaviour over the first cycle (days 1-11) of LDAC induction 
treatment .................................................................................................................................. 70 
Figure 3.6: Patient H1 behaviour over the 2
nd
 cycle (days 36-46) of LDAC induction 
treatment .................................................................................................................................. 71 
Figure 3.7: Patient H1 behaviour over the third cycle (days 71-81) of LDAC treatment ....... 72 
Figure 3.8: Patient H1 behaviour over the 4
th
 cycle (days 106-116) of LDAC treatment ....... 73 
Figure 3.9: Patient H1 cell population dynamics during a course of treatment with LDAC ... 74 
Figure 3.10: Patient H1 behaviour over the first cycle (days 1-11) of DA induction treatment
.................................................................................................................................................. 76 
Figure 3.11: Normal proliferating and non-proliferating cell populations of Patient H1 
undergoing the 1
st
 cycle of DA induction treatment ................................................................ 77 
Figure 3.12: Transition rate from normal non-proliferating to proliferating cell population of 
Patient H1 under the 1
st
 cycle of DA induction treatment ....................................................... 78 
Figure 3.13: Patient H1 behaviour over the second cycle (days 36-46) of DA treatment. ...... 79 
Figure 3.14: Patient H1 behaviour over the third cycle (days 71-81) of DA treatment. ......... 80 
Figure 3.15: Patient H1 behaviour over the fourth cycle (days 106-116) of DA treatment. ... 81 
Figure 3.16: Patient H1 cell population dynamics under the full-length course of treatment 
with the DA clinical protocol ................................................................................................... 82 
Figure 3.17: Patient H2 behaviour over the first cycle (days 1-11) of LDAC induction 
treatment .................................................................................................................................. 83 
13 
 
Figure 3.18: Patient H2 behaviour over the second cycle (days 36-46) of LDAC treatment. . 84 
Figure 3.19: Patient H2 behaviour over the third cycle (days 71-81) of LDAC treatment. .... 85 
Figure 3.20: Patient H2 behaviour over the fourth cycle (days 106-116) of LDAC treatment86 
Figure 3.21: Patient H2 cell population dynamics under the full course of LDAC treatment. 87 
Figure 3.22: Patient H2 behaviour over the first cycle (days 1-11) of DA induction treatment.
.................................................................................................................................................. 88 
Figure 3.23: Patient H2 behaviour over the second cycle (days 36-46) of DA treatment. ...... 89 
Figure 3.24: Patient H2 behaviour over the third cycle (days 71-81) of DA treatment. ......... 90 
Figure 3.25: Patient H2 cell population dynamics under the full course of treatment with the 
DA clinical protocol ................................................................................................................. 91 
Figure 4.1: Optimisation results for patient H1 over the 1
st
 cycle of LDAC. The black straight 
line represents the leukemic population over the simulation protocol with a duration of 10 
days (day 1 to 11), whereas, the dashed line is for the optimisation protocol with duration of 
20 days (day 1 to 21). ............................................................................................................... 97 
Figure 4.2: Optimisation results for patient H1 over the 2
nd
 cycle of LDAC. The black 
straight line represents the leukemic population over the simulation protocol with a duration 
of 10 days (day 36 to 46), whereas, the dashed line is for the optimisation protocol with 
duration of 20 days (day 46 to 66). .......................................................................................... 98 
Figure 4.3: Optimisation results for patient H1 over the 3
rd
 cycle of LDAC .The black straight 
line represents the leukemic population over the simulation protocol with a duration of 10 
days (day 71 to 81), whereas, the dashed line is for the optimisation protocol with duration of 
10 days (day 91 to 101). There is a 20 day delay between the optimisation and simulation 
protocols due to the increased duration of the previous 2 cycles of 10 days each. ................. 99 
Figure 4.4: Optimisation results for patient H1 over the 4
th
 cycle of the LDAC protocol. The 
black straight line represents the leukemic population over the simulation protocol with a 
duration of 10 days (day 106 to 116), whereas, the dashed line is for the optimisation protocol 
with duration of 10 days (day 126 to 136). There is a 20 days delay between the optimisation 
and simulation protocols due to the increased duration of the previous 2 cycles of 10 days 
each. ....................................................................................................................................... 101 
Figure 4.5: Simulation and optimisation results for Patient H1 over the LDAC protocol. The 
straight line represents the simulation results and the black dashed line represents the 
optimisation results. The figure is separated for the 4 cycles of the optimisation treatment that 
present a lag period compared with the simulation protocol as the first 2 cycles last 10 days 
more for each optimised cycle. Grey cross symbols indicate the start date of each 
chemotherapy cycle for the simulation protocol and black cross symbols indicate the end of 
each cycle. .............................................................................................................................. 103 
Figure 4.6: Simulation and optimisation results for Patient H1 over the DA protocol. The 
straight line represents the simulation results and the black dashed line represents the 
optimisation results. ............................................................................................................... 105 
Figure 4.7: Optimisation results for Patient H2 over the LDAC protocol with daily continuous 
infusions sc of 40 mg for 10 days (optimisation results: black dashed line) instead of doses 
every 12 hrs of 20 mg for 10 days (simulation results: straight line). ................................... 107 
14 
 
Figure 4.8: Optimisation results for Patient H2 over the DA protocol with continuous daily 
infusion doses of 200 mg/m
2
 iv Ara-C for 10 days (optimisation results: straight line) instead 
of doses every 12 hrs of 100 mg/m
2
 for 10 days (simulation results: dashed line). .............. 109 
Figure 5.1: Comparison of simulation results and clinical data for Patient P001.................. 118 
Figure 5.2: Comparison of simulation results and clinical data for Patient P002.................. 120 
Figure 5.3: Comparison of simulation results and clinical data for Patient P006.................. 121 
Figure 5.4: Comparison of simulation results and clinical data for Patient P011.................. 123 
Figure 5.5: Comparison of simulation results and clinical data for Patient P016.................. 124 
Figure 5.6: Comparison of simulation results and clinical data for Patient P026.................. 126 
Figure 5.7: Patient P001 behaviour over the 1
st
 chemotherapy cycle (days 1-11) and the 
recovery period afterwards (days 11-38) for the simulation and optimisation chemotherapy 
protocols. The dashed line is for the leukemic cell population over the optimised protocol; the 
straight black line is for the leukemic cell over the simulation of the clinical applied protocol; 
the circle signs are for the normal population at the start and end date of the optimisation 
protocol; the x signs are for the normal population at the start and end date of the simulation 
protocol and the grey line represents the BM hypoplasia objective. ..................................... 130 
Figure 5.8: Patient P001 behaviour over the 2
nd
 chemotherapy cycle (days 38-48) and the 
recovery period afterwards (days 38-71) for the simulation and optimisation chemotherapy 
protocols. The dashed line is for the leukemic cell population over the optimised protocol; the 
straight black line represents leukemic cells over the simulation of the clinically applied 
protocol; the circle signs are for the normal population at the start and end date of the 
optimisation protocol; the x signs are for the normal population at the start and end date of 
the simulation protocol and the grey line represents the BM hypoplasia objective. ............. 132 
Figure 5.9: Patient P001 behaviour over the 3
rd
 chemotherapy cycle (days 71-81) and the 
recovery period afterwards (days 81-107) for the simulation and optimisation chemotherapy 
protocols. The dashed line represents the leukemic cell population over the optimised 
protocol; the straight black line represents the leukemic cells over simulation of the clinically 
applied protocol; the circle signs are for the normal population at the start and end date of the 
optimisation protocol; the x signs are for the normal population at the start and end date of 
the simulation protocol and the grey line represents the BM hypoplasia objective .............. 133 
Figure 5.10: P001 behaviour over the 4
th
 chemotherapy cycle (days 107-117) and the 
recovery period before the last BM aspirate (days 117-150). The dashed line represents the 
leukemic cell population over the optimised protocol; the straight black line represents the 
leukemic cells during simulation of the clinically applied protocol; the circle and x signs are 
for the normal population at the start and end date of the optimisation and the simulation 
protocol, respectively. ............................................................................................................ 134 
Figure 5.11: Patient P001 behaviour for the full course of treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents leukemic cells 
during simulation of the clinically applied protocol; the circle signs are for the normal 
population at the start and end date of the optimisation protocol; the x signs are for the 
normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 136 
15 
 
Figure 5.12: Patient P002 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. Duration of the simulation protocol is 10 days from 
days (1-11) and the end is indicated by a vertical straight line. The vertical dashed line 
indicates the end of the optimisation cycle with 13 days duration. The dashed line represents 
the leukemic cell population over the optimised protocol; the straight black line represents 
leukemic cells during the simulation of the clinically applied protocol; the circle signs are for 
the normal population at the start and end date of the optimisation protocol; the x signs are 
for the normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 138 
Figure 5.13: Patient P006 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents leukemic cells 
during simulation of the clinically applied protocol; the circle signs are for the normal 
population at the start and end date of the optimisation protocol; the x signs are for the 
normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 141 
Figure 5.14: Patient P011 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents leukemic cells 
during simulation of the clinically applied protocol; the circle signs are for the normal 
population at the start and end date of the optimisation protocol; the x signs are for the 
normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 143 
Figure 5.15: Patient P016 behaviour over the 1
st
 chemotherapy cycle (days 1-11) and the 
recovery period prior the 2
nd
 chemotherapy cycle (days 11-67). The dashed line represents the 
leukemic cell population over the optimised protocol; the straight black line represents 
leukemic cells during simulation of the clinically applied protocol; the circle signs are for the 
normal population at the start and end date of the optimisation protocol; the x signs are for 
the normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 145 
Figure 5.16: Patient P016 behaviour over the 2
nd
 chemotherapy cycle (days 67-77) and the 
recovery period prior to the BM aspirate at treatment completion (days 77-100). The dashed 
line represents the leukemic cell population over the optimised protocol; the straight black 
line represents leukemic cells during simulation of the clinically applied protocol; the circle 
signs are for the normal population at the start and end date of the optimisation protocol; the 
x signs are for the normal population at the start and end date of the simulation protocol and 
the grey line represents the BM hypoplasia objective ........................................................... 147 
Figure 5.17: Patient P026 behaviour for the full course of treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents leukemic cells 
during simulation of the clinically applied protocol; the circle signs are for the normal 
population at the start and end date of the optimisation protocol; the x signs are for the 
normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective ................................................................................ 150 
16 
 
Figure 5.18: Comparison of the concentration profile in BM over the 1
st
 day of the LDAC 
standard protocol and over the optimised protocol ................................................................ 151 
Figure 5.19: S-phase dynamics over the 1
st
 day of the LDAC standard protocol and over the 
optimised protocol. The straight black line represents the model simulation of the standard 
protocol and the grey dashed line represents the optimisation results. Over the continuous 
daily infusions of Ara-C for the optimised protocol, a constant concentration profile is 
maintained that results in a continuous death rate of cells in S-phase which, from the end of 
the 1
st
 day, reach a lower state compared with that of the simulation results of standard 
treatment. ............................................................................................................................... 152 
Figure 6.1: Schematic representation of the proposed closed loop system for the design of 
optimal patient- and leukaemia-specific chemotherapy protocols......................................... 160 
Figure 6.2: ChemoApp – Library model version 0.1 (v.0.1) ................................................. 163 
Figure 6.3: ChemoApp – Illustration of simulator for version v.0.1 ..................................... 164 
Figure 6.4: ChemoApp – Illustration of optimiser for version v.0.1 ..................................... 165 
 
  
17 
 
 
List of abbreviations 
 
ALL  - Acute Lymphoid Leukemia 
AML  - Acute Myeloid Leukemia 
Ara-C  - Cytosine Arabinoside anti-leukemic agent 
BM - Bone Marrow 
CLL - Chronic Lymphoid Leukemia 
CML - Chronic Myeloid Leukemia 
DA Protocol - Protocol with mixed DNR and Ara-C anti-leukemic agents 
DNR - Daunorubicin anti-leukemic agent 
Go-phase - Cells in the quiescent phase 
G1-phase - Cells in the RNA synthesis phase (non-proliferation state) 
G2-phase - Cells in the pre-mitotic phase (proliferation state) 
HSC - Hematopoietic Stem Cells 
iv - Intravenous 
LDAC Protocol - Protocol with low doses of Ara-C sc administered 
M-phase - Cells in the mitosis phase (proliferation state) 
PD - Pharmacodynamics 
PK - Pharmacokinetics 
S-phase - Cells in the DNA synthesis phase (proliferation state) 
sc - Subcutaneous 
Tc - Duration of the full length cell cycle process 
TG1 - Duration of the Go / G1-phase 
TG2M - Duration of the G2 / M-phase 
Ts - Duration of the S-phase 
SPC - Summary of product characteristics 
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Chapter 1 
Introduction 
 
1.1Project Objective 
 
In the UK (Cancer Research UK data, 2008), it is estimated that more than 1 in 3 people will 
be afflicted with cancer in their lifetime. For one such cancer, leukemia - a neoplasm of the 
blood and bone marrow (BM) - 1 in 71 men and 1 in 105 women will be affected, with 
incidence sharply rising in adults over the age of 50. Approximately 40% of those affected 
with leukemia will have Acute Myeloid Leukemia (AML).  
Leukemia is a cancer of the BM and blood wherein blood cells are unable to develop or 
function normally, are overproduced at an immature stage of development and overtake any 
normal elements remaining in the BM and blood. This uncontrolled growth compounds the 
morbidity and mortality due to the disease by inhibiting development of healthy blood and 
immune cells through multiple mechanisms (Panoskaltsis et al., 2003; Panoskaltsis et al., 
2005).  
The most effective treatment for most types of leukemia is intensive chemotherapy 
administered through the vein (intravenous). This therapy can be life-threatening since only 
relatively few patient-specific and leukemia-specific factors are considered in current 
protocols; choice of chemotherapy, intensity and duration often depends on either the 
availability of a clinical trial, the treating physician‟s experience or the collective experience 
of the treating centre, with significant international protocol variability. Inter-patient and 
intra-leukemia variability add complexity to these treatment decisions and are not yet 
adequately addressed, possibly accounting for the 30-45% long-term survival rates in young 
people with one type of BM cancer, AML. For those whom are cured, there is a lifetime of 
increased risks of secondary cancers, cardiovascular disease and diabetes due to the adverse 
effects of treatment.  
In order to overcome these limitations, there is a need for personalised treatments that 
incorporate both the individual patient characteristics and features specific to the patient’s 
leukemia (different for every patient).  
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Personalised healthcare is expected to deliver a “step change” in a) quality and value of care, 
with more precise/personalised diagnostics and cost-effective/targeted therapies and will also 
benefit the pharmaceutical industry via efficient drug development processes based on 
modelling of patient- specific and disease-specific biomarker endpoints. Towards this end 
systematic work is required from clinicians, experimentalists and engineers in order to (i) derive 
experimental in vivo and in vitro methods that will give the ability to gain further insight to the 
disease dynamics (ii) identify the factors that are highly correlated to the treatment outcome (ii) 
design and validate automated systems that can a priori capture patient and treatment outcome 
and (iv) suggest the most efficient treatment protocol as defined by specific measurement of 
patient and disease characteristics. 
Mathematical modelling is undoubtedly a useful tool that can be used for the automation of 
chemotherapy treatment due to its advantages in systematically exploring extensive datasets 
in order to capture a system‟s dynamics and subsequently provide better insight for process 
enhancement. Towards this direction various mathematical models have been developed for 
different biomedical systems  (Dua et al., 2008; Ledzewicz, Schattler, 2007; Harrold, Parker, 
2009; Sherer et al., 2006; Parker, Doyle, 2001; Krieger et al., 2013) with aim to describe the 
disease under chemotherapy and afterwards propose the optimal treatment design. The aim of 
the optimisation algorithms is to minimise the number of cancer cells at treatment completion 
subject to dynamic constraints that include the drug PD, PK and toxicokinetic effects. A 
powerful methodology is developed  and presented in the work of (Harrold, Parker, 2009) on 
the conversion of a dynamic model to a mixed-integer algorithm for the scheduling of 
chemotherapy treatment with inclusion of clinical relevant constraints.  Moreover, in the 
work of (Dua et al., 2008) a dynamic optimisation problem is presented for the control of 
breast tumour progression while constraining the toxicity of the bone marrow.  Lastly, 
optimisation works exist that consider the optimisation problem of cancer disease as a 
stochastic system. Such an algorithm is presented in the work of (Coldman, Murray, 2000)  
where the tumour population is described by a set of various cell mutation probabilities and 
the optimal treatment is based on the probability of drug effect on each cell type i.e. mutant 
cell type, resistant cell type and sensitive to the treatment cell type. 
 In their majority, these systems aim to describe the disease dynamics of a hypothetical 
average patient case study. Under this assumption, these models do not include patient- and 
disease-specific characteristics as parameters in the model but rather they use mean values 
derived from a number of patient/volunteers studied. To our knowledge, there is a lack of 
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models that include personalised patient and disease information and use optimisation 
methods in order to design optimal personalised chemotherapy protocols. 
The representation of human cancers with mathematical models that involve individualised 
patient-specific parameters can be used for detailed simulation and optimisation studies. This 
valid mathematical representation of disease behaviour may then be used by physicians as 
an assistive device in decision making of more effective and less toxic chemotherapeutic 
strategies.  
The desired mathematical model for the simulation of patient behaviour and tumour response 
during chemotherapy should consist of three parts: (i) the cell cycle model, which is the target 
of drug action, (ii) PK and (iii) PD aspects that provide the complete description of drug 
diffusion and action after administration. Cell cycle is the process under which the cell 
replicates its genetic material, divides into two daughter cells and is separated into four 
phases: the growth phase (G1-phase), the DNA synthesis phase (S-phase), the pre-mitotic 
phase (G2-phase) and the mitosis phase (M-phase). The most interesting branches of 
pharmacology essential for both drug development and modelling of chemotherapy treatment 
are PK and PD. PK generally gives time-concentration history of the drug throughout the 
body while PD describes drug effects on the body. The two descriptors are intimately 
connected as the effect of a drug on the body depends on drug concentration at the target site 
of action. A PK-PD model combines the two elements and gives the time-profile of drug 
action on cell populations and is used to improve and direct management of individual 
patients. 
The objective of the current project is to combine the available cell cycle and 
pharmacologic information (PK and PD aspects) to develop a mathematical model able to 
capture AML disease dynamics during chemotherapy treatment for different patient and 
disease characteristics. Moreover, this model will serve as a basis for the formulation of an 
optimal control problem with aim to obtain the chemotherapeutic schedule which would 
maximise leukemic cell kill (therapeutic efficacy) whilst minimising death of the normal 
cell population, thereby reducing toxicities. 
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1.2 Project deliverables and thesis structure 
 
In this project a mathematical model is presented that captures the AML disease dynamics 
during treatment with two anti-leukemic agents; cytarabine (Ara-C) and daunorubicin (DNR). 
The chemotherapy protocols followed are consistent with standard clinical practice (Milligan 
et al, 2006) and include one intensive and one non-intensive protocol: (a) DNR and Ara-C 
used in standard intravenous (iv) doses (DA 3+10) and (b) low dose Ara-C (LDAC) 
administered subcutaneously (sc). Both DNR and Ara-C are cell-cycle specific agents. 
Specifically, Ara-C acts on the proliferation phase of the cell cycle (S-phase) (Kufe et al, 
2006) and DNR acts on the S-phase and the growth phase of the cell cycle (G1-phase) 
(Huffman, Bachur, 1972). The specificity of the drugs indicates that cell cycle undoubtedly is 
an important factor that needs to be included in the mathematical model together with the 
pharmacology aspects of PK and PD that provide the complete description of drug diffusion 
and action after administration.  
Sensitivity analysis of the developed model identifies cell cycle times as the critical 
parameters that control treatment outcome. In order to improve effectiveness of AML therapy 
and reduction of toxicity, treatment with chemotherapy is presented as an optimal control 
problem with the main aim of obtaining a treatment schedule which could maximise 
leukemic cell kill, yet minimise death of the normal cell population in the BM. The aim of 
remission induction therapy described by the current presented model is to achieve the rapid 
restoration of normal BM function. By treatment completion, the leukemic population should 
be reduced to a level of approximately 10
9 
cells, defined as a complete morphologic 
remission and at which point BM hypoplasia is achieved. Moreover, the normal population 
should be higher than that of the leukemic and a 3-log reduction is the maximum permissible 
level of population reduction. 
For model analysis, historical clinical data of 6 patients who underwent chemotherapy are 
used for the estimation of cell cycle time distribution. The patient data is comprised of 
disease characteristics (tumour burden, cell cycle times, normal cell population) as well as 
patient-specific characteristics (gender, age, weight and height). The optimisation algorithm 
is formulated and solved for all patients for both intensive and non-intensive treatment 
protocols with maximal and minimal thresholds set for efficacy and toxicity, respectively. For 
iv Ara-C, total drug administration is set between 50mg and 4000mg, with infusion duration 
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between 1 min to 24 hours. The time window for DNR dose optimisation is stricter due to 
potential toxic effects and the only independent variable is dose with 30mg – 90mg per 
infusion. For sc Ara-C, the maximum dose per day is 40mg and doses are permitted up to 
four times daily for a maximum period of 20 days. Optimisation treatment protocols are 
obtained for all the analysed patient case studies and clearly reveal the usefulness of 
optimisation methods for treatment improvement.  
The rest of the thesis is organised as follows. Chapter 2 presents a literature review of the 
modelling and optimisation of AML. This chapter concentrates on the description of AML as 
a disease system and discusses the sources of patient and disease variability to treatment 
outcome. Moreover, mechanisms of action of anti-cancer agents are analysed in this chapter 
together with the chemotherapy treatment protocols in use in standard current clinical 
practise. Part I focuses on chemotherapy treatment as a process systems application. 
Chapter 3 presents the framework for the design of personal optimised chemotherapy 
protocols by combining drug information together with patient and disease characteristics in 
order to develop the proper optimal dosing schedule for each individual. The developed 
mathematical model for the two chemotherapy protocols, the non-intensive (LDAC) and the 
intensive (DA) protocols is presented in this chapter and simulation results are presented for 
two hypothetical patient case studies with data found in the literature. Furthermore, Chapter 
4 presents the chemotherapy process as an optimisation problem and the derived algorithm is 
solved for the two hypothetical patient case studies analysed in the previous chapter. In 
Appendix A the model simulation and optimisation results of the two hypothetical patients 
are listed in detail. For the clinical data the project is submitted and approved by the North 
West London Hospitals Trust for the provision of anonymised health records of patients 
diagnosed with AML and treated within Northwick Park Hospital, London UK, using DNR 
and Ara-C anti-leukemic agents in the DA or LDAC regimens. The obtained data are 
presented in Part II - Chapter 5 and are listed in detail in Appendix B of the current thesis. 
The already presented modelling and optimisation methods are used for the simulation of the 
different treatment outcome dynamics for the studied patients using primary data and also for 
the optimisation of treatment protocols taking account of individual characteristics 
(physiological and disease) for each case study. The simulation and optimisation results for 
these patients are listed in detail in Appendix C. Last but not least, some concluding remarks 
are presented in Chapter 6 together with the future potential extensions of the current work.  
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Figure 1.1: Schematic representation of project objectives and thesis structure 
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Chapter 2 
 Literature Review 
 
2.1 Introduction 
 
This chapter presents a literature review of the modelling and optimisation of AML. Section 
2.2 presents an overview of leukemia as a cancer and the probable sources of patient 
variability are analysed. Moreover, section 2.3 presents the concept of chemotherapy as the 
means of treatment for AML, wherein section 2.3.1 presents the available drugs for AML 
treatment and section 2.3.2 presents the stages of chemotherapy treatment and the 
chemotherapy protocols as clinically applied. Section 2.4 proposes a mathematical model for 
AML disease dynamics under the influence of chemotherapy. This section is separated into 
four subsections; section 2.4.1 presents an overview of the literature regarding modelling of 
cell cycle, section 2.4.2 presents the principles of pharmacology of the existing anti-leukemic 
agents and sections 2.4.3 and 2.4.4 present the PK and PD aspects, respectively.  
2.2 Leukemia – disease principles and patient variability 
 
Blood is unquestionably one of the most vital factors for human life due to its ability to 
transport the necessary ingredients between the different organs of the human body. The 55% 
of human blood volume consists of the blood plasma that serves as the reservoir for the 
ingredients of the blood fluid where important proteins such as serum, albumin, hormones, 
clotting factors, enzymes and other nutritive materials exist. The remaining 45% consists of 
the erythrocytes, leukocytes and platelets which are the most important blood cells and 
indicators of the health state of an individual. Erythrocytes or red blood cells are the oxygen 
carrier-cells that transport the oxygen from the lungs to the body‟s capillaries. Leukocytes or 
white blood cells are the immune system‟s cells with primary function in the human defence 
against infectious diseases. Lastly, platelets or thrombocytes have a primary role in the 
formation of blood clots to prevent bleeding (Williams et al., 1983).  
The daily demand of an adult human for blood cells amounts to 2.5 billion red blood cells, 
2.5 billion platelets and 1 billion granulocytes per kg of body weight (Panoskaltsis et al., 
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2005). This demand is covered by the proliferation of hematopoietic stem cells (HSCs) and 
haematopoietic progenitor cells which are cells with extensive proliferation capacity and 
ability to self-renew into three different cell lineages: leukocytes, platelets and erythrocytes 
(figure 2.1).  
Blood production has to be robust to cover the daily individual needs and durable i.e. to be 
maintained throughout adult life. HSCs replicate to produce two daughter cells with the same 
capabilities as the parent cell and also differentiate into different blood cells. These two 
abilities make HSCs capable of both maintaining and restoring blood production. After the 
proliferation state, HSCs differentiate into lymphoid and myeloid progenitor lineages that 
form blood cells through the maturation process (Williams et al., 1983). Haematopoiesis 
occurs on BM stroma that is organised into niches which provide the supportive 
microenvironment for HSC function and also regulate the balance between cell proliferation 
and differentiation.  
 
Figure 2.1: The Hematopoietic System: The HSC has the capability to replicate into two new-
born cells, proceed to natural death (apoptosis) or differentiate towards progenitor cells. 
Progenitor cells afterwards differentiate into lineage-specific cells (myeloid and lymphoid) 
which mature to form the blood cells (Williams et al., 1983). 
Leukemia subtypes are divided into myeloid and lymphoid depending on the stem cell 
pathway leading to myeloid or lymphoid cells, respectively (Bain, 2003). Moreover, blood 
cancers are divided into chronic and acute leukemias (Bain, 2003). In the case of acute 
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leukemia, the BM extensively produces and provides the body with malfunctioning blood 
cells. Acute leukemia is an aggressive and fast growing cancer for which immediate 
treatment is required for survival of the host. In contrast, chronic leukemia has slower growth 
and usually requires prolonged treatment or periods of active monitoring without the need for 
specific therapy. In that way leukemia cancer types are broadly divided into chronic or acute, 
and further subdivided into lymphoid or myeloid leukemias.  The four categories are: Chronic 
Myeloid Leukemia (CML), Chronic Lymphoid Leukemia (CLL), Acute Myeloid Leukemia 
(AML) and Acute Lymphoid Leukemia (ALL). 
AML is a biologically and clinically heterogeneous disease with diverse morphologic, 
immunophenotyping and cytogenetic characteristics. The main characteristic of AML is the 
excessive number of abnormal cells unable to differentiate into functional mature cells, such 
as granulocytes or monocytes. These cells reveal a high proliferating capacity that has driven 
researchers during the last decade to the conclusion that leukemic population expansion is 
due to their enhanced capability to self-renew. Based on this cell characteristic, similarities 
between leukemic and hematopoietic stem cells (HSC) have been investigated leading to 
current theories which mark the origins of leukemia in a stem cell with an initial 
chromosomal mutation and which requires further mutational (either genetic or epigenetic) 
change for the full leukemic phenotype and heterogeneous clonal progression (Bonnet, Dick, 
1997; Horton, Huntly, 2012). 
The excessive numbers of malfunctioning white cells replace normal cells in BM and/or 
disrupt the production of normal cells. This abnormal behaviour of the BM causes 
haematopoietic and immune system insufficiency since there is a loss of red cells, white cells 
and platelets. Depending on the decrease in these cell populations, AML symptoms can 
consist of fatigue, haemorrhage, infections and fever. Moreover, dyspnoea or other symptoms 
may occur due to the severe anemia and as leukemic cells circulate in the body and infiltrate 
tissues. The health condition of the patient depends on the amount of normal blood cells 
compared with those that are cancerous or leukemic. Thus, in the BM of patients with AML, 
cancer cells can be described as the highly proliferative fraction and mal-functioning cells 
whereas normal cells are the normally functioning and normally proliferating cells.  
Numerous chromosomal abnormalities have been detected that lead to AML and are 
correlated to treatment outcome. For this reason, attempts have been made to classify the 
disease into certain subtypes using these recurrently identified chromosomal and genetic 
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mutations (WHO defined classification) (Nakase et al., 2000; Marcussi et al., 2005; Weinberg 
et al., 2009) towards the promotion of more specialised treatment design.  
There are three mutation subgroups related to treatment success: favourable, unfavourable, 
and standard/intermediate prognostic subgroup (Hoffbrand et al., 2006,). The favourable 
subgroup consists of patients with chromosomal translocations t(15; 17), t(8; 21), or inv(16) 
having a high probability of cure (~80%) and lower probability of relapse (30-40%). The 
unfavourable subgroup is comprised of patients with AML with cytogenetic abnormalities in 
more than two chromosomes where the probability of cure is less than 20%. Such cytogenic 
abnormalities are either monosomies in chromosomes 5 or 7 or deletion of the long arm of 
chromosome 5 or of chromosome 3. The third subgroup is the standard subgroup that consists 
of patients with various types of translocations, different from those of the other groups and 
whose probability of being cured is unpredictable. 
Although the above described classification is based on sophisticated methodologies used for 
patient diagnosis incorporating morphologic features and molecular genetics, a thorough BM 
genetics examination still remains essential for disease evaluation. These three subgroups, 
i.e., favourable, unfavourable and standard/intermediate prognosis, are too sparse and fail to 
include the appropriate level of disease heterogeneity. Recently, intra-patient disease 
heterogeneity has been acknowledged due to the multiple clones of leukemic stem cells 
within the same patient (Kennedy, Barabe, 2008; Horton, Huntly, 2012).  
This inconsistency and heterogeneity of molecular genetic abnormalities in AML make the 
development of targeted individual therapies extremely challenging. Several works have 
shown a high correlation between the level of disease heterogeneity, treatment outcome and 
the existence of residual disease after treatment (Hoffman et al., 2012; Vo et al., 2012). This 
is due to the fact that even a small subpopulation of cells with diverse molecular properties 
may be of importance for relapse of disease and should be considered in treatment design.  
Moreover, in addition to the stochastic behaviour of the leukemic cells, the disease is also 
controlled by the pathologic connection of the cells‟ behaviour with the microenvironment 
that surrounds them, partly defined by the BM stroma. Under normal conditions 
hematopoietic cells are produced in the BM within a complex microenvironment, organised 
in “niches” regulating survival, self-renewal, proliferation and differentiation (Panoskaltsis et 
al., 2005). Deregulated growth of normal cell development within this functional space 
generates neoplastic clones which contribute to leukemogenesis (Olsen et al., 2008).  Genetic 
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and epigenetic alterations in the leukemic blast cells are the biological basis of pathological 
disease (Kennedy, Barabe, 2008), but recently it has been shown that the BM 
microenvironment has a fundamental role in hematopoietic cell fate regulation (Doan, Chute, 
2012). In particular studies, it has been revealed that myelodysplastic (pre-leukemic) stromas 
can initiate malignant cell differentiation of normal cord blood cells (Borojevic et al., 2004). 
This abnormal microenvironment, through the production of specific signalling molecules, 
growth factors and cytokines supports the malignant phenotype and suppresses normal 
haematopoiesis (Colmone et al., 2008). Alterations of the hematopoietic environmental 
pathways can further affect drug responses in AML; in fact stromal cells sustain proliferation 
and delay terminal differentiation which leads to disease expansion and can confer multi-drug 
resistance phenotype (Nair et al., 2010).   
This disease heterogeneity and effects of stroma on cancer cells make the disease 
uncontrollable in terms of chemotherapy efficiency, resistance to the treatment and residual 
disease. All these three clinical states are linked to the number of cancer cells in dormancy 
before and during the treatment process.  
All cells can broadly be grouped into two states: the proliferating and the dormant state. After 
the completion of the proliferative state, the cell has the possibility of either entering the 
proliferation cycle again and follow another cycle of duplication of genetic material, or to 
become inactive and, therefore, enter the dormant state (Eisen, 1979). When extracellular 
conditions are such that there is no necessity for further cell division, metazoan cells enter 
this state (Lewin et al., 2007). During this dormancy (or quiescence), the cell can be 
described as inactive and the process of proliferation is ceased. When a cell is in dormancy, it 
may differentiate or it may stay unchanged until it undergoes apoptosis. Moreover, when 
there is an inadequate number of cells due to abnormal conditions, nutrients and signals are 
supplied that activate cells in dormancy and they re-enter cell cycle through transition to the 
growth phase. Generally these cells stay in reserve in case of lack of cells, e.g. in the case of 
BM depletion. However, conditions that activate dormant cells are still under investigation.  
When cells are in dormancy they cannot be affected by chemotherapeutic agents and thus are 
not susceptible to these drugs. The leukemic population contain a proportion of slow 
proliferating cells that are largely in the dormant state (Komarova, Wodarz, 2005; Michor, 
2008). These experimental works also indicate that the success of chemotherapy treatment 
depends on the initial proportion of cells in the quiescent state and the transition rate into 
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proliferation. Specifically, patients whose BM samples presented a higher proliferating 
population at the point of biopsy or even during the early chemotherapy cycles were the ones 
most likely to be cured of AML after chemotherapy, whereas the remainder of patients 
relapsed after treatment (Stryckmans et al., 1970; Cheung et al., 1972; Hayes et al., 1977).  
2.3 Chemotherapy for the treatment of AML  
2.3.1 Introduction to clinically used anticancer agents for chemotherapy treatment 
 
A sequence of research led to the design and use of chemotherapy treatment as cure for 
cancer. The first chemotherapy drug was synthesised in 1940, by Goodman and Gilman in the 
USA department of defence as a chemical weapon during World War I and it was found to be 
effective for cancer treatment (DeVita, Chu, 2008). This was an important breakthrough 
especially for leukemic patients who received treatment with that drug as at that time 
leukemia was considered to be incurable. In the subsequent decade, anticancer agents were 
evaluated based solely on empirical applications on diseased animals. 
The cell cycle as an important factor of clinical medicine was first introduced in 1855 when 
Rudolph Carl Virschow presented the “omnis cellula e cellula” (every cell stems from a cell) 
theory, stating that all diseases stem from changes in normal cells (Nurse et al., 1998). This 
theory launched the field of cellular pathology, the first stage of which was to assess disease 
as a product of changes in normal cells. During this decade, research was focused on the 
observation of cell function and the identification of model organisms on the premise that 
simple organisms could be studied to gain knowledge on more complex organisms. In 1953, 
an important breakthrough was achieved with the description of the DNA double helix by 
Watson and Crick. This discovery gave rise to the full description of the mitotic cycle that 
formed the basis for expanded research of the cell cycle and, by extension, the burgeoning 
sector on anticancer drug discovery. 
The description of cell cycle mitosis upgraded the level of knowledge and insight into cancer 
biology leading to the synthesis of cell-cycle specific agents applied even today in clinical 
practice (DeVita, Chu, 2008). Further advances in the in vitro study of cancer cellular 
dynamics developed from the successful isolation and growth of cancer cell lines in 
laboratory conditions. Various cultures and pre-clinical methods have been established that 
provide the infrastructure for the study of a drug on cellular culture and the development of 
the PK model of  drug action on tumour populations (figure 2.2).  
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Figure 2.2: Key advances in the development of chemotherapy treatment. Cell-cycle specific 
drugs used in current clinical practice were synthesised in the 1960’s. PK models simulating 
drug concentration and action profiles were thereafter developed in the 1970’s. This change in 
drug development is undoubtedly connected to advances in cell cycle research with the most 
important being the delineation of DNA structure by Watson & Crick.  
Chemotherapy cell-cycle specific agents discovered in the 1970‟s are still used in current 
clinical practice for the treatment of cancer. For AML, the most commonly used agents 
consist of Ara-C, DNR, mitoxantrone, etoposide, idarubicin, fludarabine and amsacrine. The 
analysis of all these agents is out of the scope of the current work. However, the profile of 
Ara-C and DNR is presented in this section as these are the agents used for analysis in the 
current thesis. Section 2.3.2 gives a general presentation of the chemotherapy treatment 
stages for AML and presents the induction treatment that is modelled and optimised in the 
current study. 
2.3.2 Studied chemotherapy treatment protocols 
 
As described above, AML is the cancer of the BM and blood wherein blood cells are unable 
to develop or function normally, are overproduced at an immature stage of development and 
overtake any normal elements remaining in the BM and blood. This uncontrolled growth 
compounds the morbidity and mortality due to the disease by inhibiting development of 
healthy blood and immune cells through multiple mechanisms (Panoskaltsis et al., 2003; 
Panoskaltsis et al., 2005). 
Treatment for AML aims at the cure of the disease i.e. the complete eradication of the 
abnormal cells from the BM. The first stage of treatment is induction chemotherapy treatment 
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which aims to achieve the rapid restoration of normal BM function. Induction therapy in the 
acute leukemias aims to reduce the total body leukemic cell population by a 3-log level 
during which BM hypoplasia will be achieved (10
9
 leukemic cells). The desired hypoplastic 
marrow will be characterised by a reduced and weakened leukemic population and a higher 
proportion of normal BM cells normally functioning to support blood production and the 
immune system. It is generally assumed, however, that after completion of induction 
treatment a substantial burden of leukemia cells will remain undetected (minimal residual 
disease). Postremission therapy is therefore directed towards further reduction in the residual 
leukemic cell number, which may be as high as 10
8
 to 10
9
 cells at initial Complete 
Morphologic Remission (CR). The elimination of these residual leukemic cells may be 
accomplished by either cytotoxic chemotherapy, causing significant myelosuppression or by 
replacement of a patient's stem cells through allogeneic transplantation, a procedure 
combining myeloablation and immunotherapy (Williams et al., 1983).  
For more than 20 years, standard remission induction chemotherapy has included an 
anthracycline (e.g. DNR) and Ara-C. The most common regimen combines 3 days of DNR 
with 10 days of Ara-C. This is known as the DA 3+10 regimen (Milligan et al., 2006), and is 
presented in Table 2.1. 
Table 2.1: Schedule of standard DA treatment protocol  
 
However, the DA protocol is suitable only for patients with adequate performance status (i.e., 
who are fit) and for those who choose to have intensive chemotherapy treatment. For elder 
patients or those less fit with a high probability of not being able to withstand the toxicity of 
chemotherapy, a lower intensity induction treatment is used, such as low doses of Ara-C 
subcutaneously administered. The low dose Ara-C (LDAC) protocol is presented in Table 
2.2. 
Protocol Dose Applicat
ion 
duration 
Route Application Schedule 
DA 3 + 10     
DNR 60 mg/m
2 
1 hr  IV 1 daily application for days 1,3,5 
of treatment 
Ara-C 100 mg/m
2
 Short-
duration 
(push) 
IV Two daily applications, every 12 
hours, for days 1-10 
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Table 2.2: Schedule of LDAC treatment protocol  
2.4 Mathematical modelling of chemotherapy treatment for AML 
 
Motivated by the challenge to define the most appropriate anticancer drug combination, 
dosing regimen and chemotherapy schedule in order to minimise drug toxicity and maximise 
efficacy of treatment, cure rate and the patient‟s life expectancy, engineers have tried to 
represent cancer using mathematical models. These mathematical models should describe the 
disease dynamics as they evolve for individuals by including patient-specific and disease-
specific parameters. These models can be used afterwards for detailed simulation and 
optimisation studies that will provide a better insight of disease progression as a first step and 
will set the basis for the derivation of automated tools for the design of optimised treatment 
protocols. 
To this end, mathematical models have been developed as early as the 1970‟s (Eisen, 1979). 
However, none of these models have found use in clinical applications. One of the main 
reasons for this failure in application is the lack of  knowledge of the actual values of crucial 
parameters, making the developed models empirical in most cases. These models include 
algorithms which are based on poor information of the system and they succeed only to 
simulate the behaviour of a standard patient case study. However, both the complexity of 
cancer as a disease and the intricacy of the human body indicate that such a gross response of 
a treated patient would be quite different than that of the majority of individuals.  
Three types of information are required for the derivation of these models: (i) information of 
the distribution of proliferating cells at the time of drug action (ii) the drug concentration 
profile of the drug in the tumour location and (iii) the active drug efficiency when reacting 
with cancer cells.  These three aspects comprise the cell cycle model, the PK and the PD, 
respectively. In the case of AML the existing models, to our knowledge, fail to include this 
information in detail and usually cover either the pharmacology or the cell cycle part in detail 
combined with empirical equations for the other components (Afenya, 2001; Andersen, 
Mackey, 2001; Ledzewicz Schattler, 2007; Sherer et al., 2006; Coldman, Murrary, 2006). 
Protocol Dose Application 
duration 
Route Application Schedule 
Ara-C 20 mg Short-
duration 
(push) 
SC Two daily applications, every 12 
hours, for days 1-10 
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Optimisation applications in this area are expectedly limited as well since, for an optimisation 
algorithm to be accurate, a valid model is necessary (Harrold, Parker, 2009; Gardner, 
Fernades, 2003; Swierniak et al., 2009; Parker, Doyle, 2001). 
The following sections review the current state of mathematical models for the cell cycle of 
leukemic cells and the pharmacology aspects (PK, PD) of anti-leukemic drugs.  
2.4.1 Cell Cycle modelling 
 
Cell cycle is a set of cell mechanisms that results in duplication of cellular material and the 
division into two daughter cells with the main purpose to either preserve or expand the cell 
population. Cancer is unavoidably connected to the cell cycle as the origin of the disease is 
unregulated cell growth due to an abnormality in the process of cell proliferation. The macro-
effect of this abnormal cell proliferation is the uncontrollable regulation of tissue growth 
leading to the creation of tumours, i.e. masses of malfunctioning cells that are harmful to the 
body. Hence, better insight into the cell cycle will provide more information on cancer cell 
dynamics which would inform chemotherapy treatment design. In section 2.4.1.1, a 
description of the cell cycle and modelling principles are presented, whereas section 2.4.1.2 
presents a literature review of mathematical models for the characterisation of the cell cycle. 
2.4.1.1 Cell Cycle principles in normal and abnormal BM cells 
 
The cell cycle is separated into four phases: the growth phase (G1-phase), the DNA synthesis 
phase (S-phase), the pre-mitotic gap phase (G2-phase) and the mitosis phase (M-phase). Each 
phase is governed by the timed expression of phase-specific cyclins, which are degraded 
upon completion of their task. G1-phase is the interval phase between the newborn cell and 
the duplication of its genetic material where RNA and proteins (e.g. cell enzymes) are 
produced. The next phase is S-phase where the DNA material is duplicated. This phase is the 
most common target of cell-cycle specific chemotherapeutic drugs - if DNA synthesis is 
blocked then the cell is forced to undergo apoptosis. Afterwards, G2-phase occurs which is a 
gap phase between DNA-synthesis and M-phase wherein cell division takes part and two 
daughter cells are formed (Figure 2.3).  
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Figure 2.3: Description of the Cell cycle. Cell cycle populations have the capability to preserve 
the number of the population or re-populate through the proliferation process. This process 
includes the replication of the genetic material and the division of the cell into two new-born 
cells. The cell cycle is separated into four phases the G1-, S-, G2- and M- phases which serve as 
standpoints for the description of the cell cycle proliferation process. After the mitosis phase 
(M-) the new-born cells either immediately proceed to a new proliferation cycle or they are 
transferred to the quiescent phase where they remain in dormancy. 
Another important state of the cell is the quiescent state, a phase wherein the cell is dormant 
and the procedure of proliferation is temporarily or permanently prevented. When 
extracellular conditions are such that there is no necessity for further cell division, metazoan 
cells enter the Go phase, a state between mitosis and growth phase (Lewin et al., 2007). 
During the Go phase, the cell can be described as inactive and the process of proliferation 
stops. When a cell is in dormancy, it may differentiate or it may stay unchanged until it 
undergoes apoptosis. Moreover, when there is an inadequate number of cells due to abnormal 
conditions, nutrients and signals are supplied that activate Go cells and they re-enter cell cycle 
through transition from Go to G1 phase. Conditions that activate cells in Go are still under 
investigation - generally these cells are likely in reserve in case of depletion of cells, e.g. in 
the case of BM failure states. In order to both maintain a supply of mature blood cells and not 
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to exhaust HSCs throughout the lifespan of the organism, most HSCs remain quiescent and 
only limited numbers enter the cell cycle (Ezoe et al., 2004).  
Extensive literature exists on the modelling of the HSC replication process, the majority of 
which represent the HSC pool as containing cells which can replicate, differentiate or die 
(Ezoe et al., 2004; Andersen, Mackey, 2001; Colijn, Mackey, 2005; Adimy et al., 2009; 
Catlin et al., 2011). These cells are grouped into two compartments, proliferating (P) and 
non-proliferating (Q) cells (figure 2.4). Non-proliferating cells are the quiescent HSCs which 
differentiate in progenitor cells with a differentiation rate (v), to generate into granulocytes. 
These cells are activated and transmitted to the proliferating compartment in a rate (β(Q)) that 
is reciprocal to the number of the quiescent cells i.e. when the number of cells is low, more 
cells will be activated in order to preserve the stem cell population. Both proliferating and 
quiescent cells have a death rate (γ and δ respectively). However, proliferating cells are 
affected by chemotherapeutic drugs and are forced into apoptosis.  
 
Figure 2.4: Representation of the full model of the HSC behaviour. The HSC has the capability 
to replicate into two newborn cells (proliferation compartment), proceed to natural death (γ) or 
differentiate into progenitor cells (ν). Progenitor cells afterwards differentiate into granulocytes 
i.e. white blood cells, erythrocytes, lymphocytes and platelets.  
In principle, leukemic cells are malfunctioning HSCs (Bonnet, Dick, 1997; Horton,Huntly, 
2012), thus the same modelling principles can be used for the description of leukemic 
function. However, the set of parameters characterising leukemic cells will differ in the 
abnormal percentage of cells in quiescence and also in proliferation capacity. The kinetics of 
leukemic cells have been evaluated experimentally and a great inter-patient and intra-patient 
variability has been reported (Preisler et al., 1993; Chiorino, Lupi, 2002; Raza et al., 1987). 
This variability concerns the percentage of cells in the quiescent and proliferating phases, as 
well as on the distribution of the cell population in the cell-cycle phases and on the duration 
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of each cell cycle phase. As a consequence, the derivation of a set of values for parameters 
that would adequately describe the cell cycle of all patients is not feasible. To make matters 
even more complex, these reports also prove the existence of intra-patient variability of cell 
cycle characteristics i.e. two cells of the same leukemic population will have different cell 
cycle distribution, proliferation potential and transition rates.  
This variability in the kinetics of the tumour population is also correlated to treatment 
outcome and in particular disease resistance. For example, BM samples of 21 children with 
leukemia were analysed before and after chemotherapy treatment with vincristine, Ara-C and 
corticosteroids (Lampkin et al., 1969). The experimental aim was to observe the effect of 
these drugs, alone and in combination, on the cell cycle of leukemic cells of the patients. The 
results revealed that drugs used successively is preferable to the simultaneous use of two 
drugs acting on different cell cycle phases (Lampkin et al., 1969). Hence, drugs acting on a 
particular cycle phase will affect the entire cell cycle making it more efficient to “attack” the 
cell population in two different phases successively than at the same time. This is one of the 
first works in the open literature to suggest that the knowledge of the time course of the 
mitotic cycle could give rise to the improvement of treatment design. Work dating back to the 
1960‟s and 1970‟s correlate characteristics of the cell cycle with treatment outcome (Hayes et 
al., 1977; Stryckmans et al., 1970; Cheung et al., 1972; Lampkin et al., 1969; Raza et al., 
1990). Thus, the patient-specific characterisation of leukemic cell kinetics is of utmost 
importance for the treatment effectiveness and the design of personalised treatment protocols.  
2.4.1.2 Cell Cycle mathematical models 
 
Chemotherapy drugs aim to stop the uncontrollable cell proliferation by interfering within the 
cell cycle and killing the cells in replication. Chemotherapeutic drugs are classified according 
to the cell cycle phase in which they are active. Some drugs act selectively with cells on a 
particular cell-cycle phase (cell-cycle specific drugs), whereas others act with cells in all 
phases (cell-cycle nonspecific drugs). Some examples of commonly used cell-cycle-specific 
drugs are the anthracyclines, such as DNR, doxorubicin and idarubicin that inhibit DNA and 
RNA synthesis i.e. S- and G1-phases; antimetabolites such as methotrexate and Ara-C that are 
S-phase specific drugs, whereas cell-cycle non-specific drugs are drugs such as platinum 
drugs (ex. carboplatin) that react with all phases of the cell cycle. The drug specificity makes 
the role of cell cycle a critical factor for the efficacy of the treatment.  
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The advance of new experimental tools and protocols gave rise to more sophisticated 
experiments and research in the 1980‟s and 1990‟s focused mainly on the characterisation of 
patient variability on cell cycle kinetics.  
Mathematical models that describe the cell cycle have been developed from when the very 
first experimental data were obtained. The most common type of modelling approach is the 
compartmental one where compartments are used to describe the different cell phases or 
combination of phases into clusters. The mathematical model consists of the mass balances of 
cells in each compartment of the model. The simplest mathematical model assumes that the 
entire cell cycle forms one compartment (Swierniak et al, 1994), whereas the most detailed 
model considers each phase as a separate compartment (Sherer et al., 2006).  
However, compartmental models fail to account for system heterogeneity and a rigid 
population is assumed with common characteristics of size, age, mass etc. Population-based 
models (PBM) are another modelling type which describes the effect of the cell heterogeneity 
on the cell culture dynamics. In these models the cell cycle is organised in population 
balances differentiated over time and one other property that evolves in parallel with the cell 
cycle progression, i.e. mass for the mass-structured cell cycle (Sidoli, 2006).  
Although the PBM are more robust and accurate than compartmental models, they introduce 
a considerable number of unknown parameters, some of which are difficult to be 
experimentally measured.  
In general for both types of models (compartmental and PBM) the required parameters for the 
cell cycle mathematical model consist of the transition rates of cells between cell cycle 
phases, the proliferation rate of the cells, the distribution of cell populations (normal and 
abnormal) into the cell cycle phases and the natural apoptotic rate of each cell cycle phase. 
For the calculation of these parameters, the experimental measurement available is the 
duration of the cell cycle phases. If the time-history profile of each cell cycle phase is known, 
thereafter the distribution of cell population into phases, proliferation and transition rates can 
be estimated (Basse et al., 2003). As far as the natural cellular apoptotic rate is concerned, 
since the model purpose is chemotherapy action on cells, a valid assumption often used is that 
there is only a small probability that the cell will follow the path of natural apoptosis and the 
apoptotic rate equals zero (Basse et al., 2003). In that sense, the prevailing system 
measurement required is the duration of each phase in the mitotic cycle. 
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Models in the literature assume constant cell cycling times and transition rates between the 
phases which make the model purely deterministic (Dua et al., 2005; Fister, Paneta, 2000; 
Ledzewicz, Schattler, 2002; Swierniak et al., 2003). These models fail to capture the intra-
patient variability in the duration of the cycle phases and are adequate only at capturing the 
behaviour of a mean cell cycle function. Work with a more accurate approach considers the 
cycle duration as a stochastic distribution between a minimum and maximum range (Basse et 
al., 2003; Kimmel, Swierniak, 2003; Sherer et al., 2006). In this approach, cells of the same 
population have different distribution characteristics. However, a large window still remains 
for the improvement of the compartmental models to account for intra-patient variability, let 
alone the PBM that should include this variability as functions over both time and another 
system characteristic. 
 
2.4.2 Pharmacology of anti-leukemic drugs 
 
The in-depth knowledge of individual cell dynamics will demonstrate the level of system 
malfunction and will suggest the optimal treatment requirements for patient treatment, i.e., 
will suggest the time and effect that the treatment should reach. For these requirements to be 
achieved, management of the pharmacology information of available drugs is needed. The 
most crucial branches of pharmacology essential for both drug development and management 
of drug information are PK and PD. PK generally aims to give the time-concentration history 
of the drug throughout the body while PD aims to describe the drug effects on the body. PK 
and PD are intimately connected as the effects of the drug on the body depend on the drug 
concentration at the molecular site of action.  
The combination of PK and PD characterise of the complete action of drug on the human 
body, i.e., the time-dependent procedure for a drug to reach the target (tumour location) and 
act. This information will provide the appropriate insight for the design of treatment with 
respect to the most efficient drug combination, the optimal route of dose administration (iv, 
sc, intrathecal etc.), and the appropriate dose regimens in terms of both efficacy and 
toxicokinetic information of the agents.  
The steps of the drug action in the body are as follows and they are described in figure 2.5 
(Ratain, Plunkett, 2003), 
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1. Drug administration 
2. Drug absorption and metabolism through gastrointestinal tract in case of oral 
administration of a drug 
3. Metabolism of the drug in the liver  
4. Drug delivery in cell environment and protein-binding to act on the cell 
5. Drug action (PD) 
6. Drug returned either to the liver or to the kidney and excreted by biliary or urinary 
excretion  
 
Figure 2.5: Schematic diagram of PK and PD: blue boxes are for the PK model and they are 
connected to the red cycle that represents the PD part of drug action. Adapted from (Ratain, 
Plunkett, 2003) 
Initially the drug is dispensed into the patient‟s body. There is a variety of drug 
administration methods such as IV infusion, intraperitoneal infusion, intrathecal 
administration, intra-arterial infusion, oral administration, sc or intramuscular drug injection. 
The means of drug administration mainly affects the PK model as for example for the case of 
iv infusion the drug is directly injected into the blood and so the PK is described by the blood 
flow, whereas for intrathecal administration, the drug is injected into the spinal canal and the 
PK is different. The route of administration is chosen with the main goal to inject the drug as 
close as possible to the tumour site, if practical. 
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After its administration the drug has to be delivered to the tumour site. The drug delivery 
begins with absorption and metabolism from the liver and, in the case of oral administration, 
the gastrointestinal tract contributes to the drug metabolism. The active metabolites reach the 
systemic circulation and through distribution they are delivered to the desired site of action. 
Drug distribution mainly depends on the degree of blood flow in the vicinity of the tumour 
(vascularisation). It also depends on the flow across micro-vessel walls and the interstitial 
compartment from where it will finally be transferred to the site of action, that is inside the 
cell (Workman et al., 1993). 
When the drug reaches the cell, transmembrane movement transports it into the cell where it 
acts. At the end of drug action, the drug is deactivated and is excreted from the human body 
mainly through urinary excretion and/or by biliary excretion. Drugs may also be excreted 
through lungs, breast milk, saliva and sweat.   
In summary, the procedures of the drug being administrated, metabolised, delivered and 
excreted from the body comprise the PK part of the modelling while the drug action on cell 
level is the PD part.  
2.4.3 Pharmacokinetic (PK) modelling 
2.4.3.1 PK modelling principles 
 
The major mechanisms of the PK drug action in the body consist of the drug absorption, 
distribution, metabolism and excretion (figure 2.6). Drug absorption is considered in cases of 
non-iv dose administration (sc, oral etc.) where the drug inflow reaches the systemic 
circulation with a certain time delay (absorption rate) and in a decreased amount 
(bioavailability) as some of the initial drug given is bound during absorption. Thereafter, the 
drug is distributed throughout the fluids and tissues of the body and is then metabolised in the 
liver and the kidneys. Finally, the drug is eliminated and excreted either by urinary (kidneys) 
or biliary (liver) route (Saltzman, 2001). 
41 
 
 
Figure 2.6: The process of drug delivery. Drug delivery is governed by four mechanisms: 
absorption, distribution, metabolism and excretion, each derived of further mechanisms. Inter- 
and intra-patient variability in these mechanisms is the probable source of PK variability. 
High inter-patient variability exists in the amount of drug concentration produced by the 
same dose administered. This inter-patient variability is certainly correlated to the above 
described PK mechanisms although the exact source of variability is yet to be defined. 
Extensive works (Undevia et al., 2007; Garattini, 2006) review the probable patient 
information that could correlate with drug concentration at the tumour site and consequently 
in treatment outcome.  
To begin with, absorption depends on the drug absorption rate and bioavailability. Absorption 
rate represents the time delay from the time of administration until the drug reaches the 
systemic circulation when it is given non-intravenously. This term has meaning mainly for 
the case of oral administration where the drug is firstly inserted to the gastrointestinal (GI) 
tract, while for the case of sc dosage, this rate represents a drug leak from the sc tissues into 
the blood. Bioavailability refers to the final amount of drug reaching the blood compartment. 
Again this term is mostly applied to oral administration where drug losses occur in the GI 
tract. Both bioavailability and absorption rate vary between different patients and depend on 
factors such as the absorptive area, the transition time of the drug into the blood, the blood 
flow and the GI environment, which are all probable sources of patient variability.  
Moreover, drug distribution involves drug transition from the intravascular to the 
extravascular space. The amount of distributed drug will define the distribution volume of 
drug and depends on the level of binding proteins where proportion of the drug is bound and 
the amount of free drug is reduced. The drug metabolism takes place on the remaining free 
drug that reaches the liver and in some cases the kidney. The metabolism kinetics depends on 
the patient hepatic blood uptake and enzymatic activity. Lastly, excretion is related to kidney 
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action to eliminate and remove the inactive drug and will again differ between patients, 
resulting in varying drug clearance rates.  
In summary, there is patient variability in all four mechanisms of drug delivery described 
above. This patient variability definitely contributes to an extent to the different treatment 
outcomes between patients. Especially for the anticancer agents, the variability in the amount 
of active drug that reaches the tumour location (without the drug bound during absorption and 
distribution) will finally affect the concentration of the active metabolite produced and the 
drug intra-cellular activation.  
2.4.3.2 PK mathematical modelling 
 
Currently two types of PK model are used, the compartmental and the physiological models. 
In compartmental modelling, body organs are grouped into compartments and drug is 
assumed to be absorbed, distributed and eliminated in these compartments.  For the case of 
the one compartmental model, body organs form one compartment and the model equations 
are as indicated below (Gardner, Fernandes, 2002): 
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In this example, “i" is the number of dose applications and the drug is injected into the patient 
with a rate “y”. Dose duration is “h” and the total drug concentration in the body is calculated 
as the sum of the current dose plus the residual dose from the previous drug administration 
given “tAD” hours ago. The drug concentration declines exponentially at a rate “λ”,  the drug 
decay characteristic coefficient. The residual concentration is calculated as the sum of the 
concentration in the body from the first application (i=1) until the last of the previous 
applications (i=PA).  
A case of a higher compartmental model is the two-compartmental model (figure 2.7). 
Another term should be added to the concentration equation that will account for the mass 
balance between these two compartments but the principles of the model will remain 
unchangeable. In general, compartmental models group organs with the same action towards 
the drug into compartments and the mathematical algorithm includes the mass balances 
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between these compartments. More information could be added, for example to account for 
blood concentration in each compartment or include absorption and distribution rates. 
However, the level of detail depends on the purpose of the model and the data availability. 
 
Figure 2.7: Representation of a two-compartment pharmacokinetic model. Adapted from 
(Saltzman, 2001) 
Compartmental models represent the body as a set of compartments where the drug is 
inserted, diffused and then excreted. Empirical expressions relating drug concentration to 
time are afterwards derived for the hypothetical system. The parameters of these expressions 
are then estimated using the available system information that consists of drug dose, plasma 
drug concentration and drug clearance rate.  
These are standardised models in great use by pharmaceutical companies and commercial 
tools exist for the development of this type of model for a variety of drugs 
(http://www.iconplc.com/technology/products/nonmem/;http://www.pharsight.com/products/
prod_winnonlin_home.php;http://www.mathworks.co.uk/products/simbiology/; 
http://www.lixoft.eu/products/monolix/product-monolix-overview/). A large variety in PK 
and PD modelling software exists either as commercial or free available software packages 
for training purposes. Most software packages focus on one type of drug, or specific drug 
delivery, such as intravenous or oral doses. An overview of PK/PD software can be found 
here: http://www.boomer.org/pkin/soft.html. These tools use methods such as Monte Carlo 
expectation-maximization and Markov Chain Monte Carlo Bayesian  next to classical 
likelihood to fit models to many different types of data. Some of the tools allow only non-
compartmental analysis (Winnonlin, Nonmem) whereas others allow for the fit of 
physiological based PK models (Simbiology, Monolix). Most of these software (Nonmem, 
Winnonlin) benefit from the integration of inter-individual variability allowing the 
consideration of a large pool of data for the estimation of the PK model parameters.  
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However, the ability of these models to accurately predict the drug profile for a newly studied 
patient is rather questionable. The major source of model uncertainty is due to the fact that 
the values of the variables are based on the interpretation of the mean concentration profile of 
a group of patients. This “mean-concentration” profile in most cases is not representative of 
the behaviour of patients in the group studied let alone the whole patient population. 
Furthermore, since these models are empirical and include the concentration profile in the 
body as a totality, they do not account for more detailed phenomena taking place at the 
tumour location, for example, by linking the concentration profile to a detailed PD model of 
drug mechanism when it is activated intracellularly and acts.  
These drawbacks are satisfied to a certain extend by the physiological based PK (PBPK) 
models. A physiological model is a high compartmental model that considers all the organs 
reacting with the drug. The model is derived from the equilibrium balances in these organs. 
The entire physiological model is described in figure 2.8 while for each drug the organs that 
do not affect the drug are neglected. PBPK models depend on two types of information; the 
patient physiological and the drug biochemical information. Physiological parameters consist 
of the body organ volume (Vi) and the blood flow rate in the body organs (Qi). These 
parameters have been extensively measured and are correlated to patient characteristics such 
as sex, age, body mass index and cardiac output (Chouker et al., 2004; Pichardo et al., 2007; 
Brody, 1945; Brown et al, 1962; Wennesland et al., 1959).  Moreover, the biochemical 
parameters are the parameters for the calculation of the drug metabolism rate. One common 
assumption in PBPK models is that the metabolism follows Michaelis-Menten kinetics and 
the required parameters are the drug maximal velocity (Vmax) and the Michaelis affinity 
constant (km).  
In the last decades, remarkable progress has been noted regarding the experimental design for 
the parameters of PBPK models. Initially for the PK model, metabolism information was 
only available from animal experiments and scaling was used afterwards for the 
approximation of the equivalent human values. However, there is a level of uncertainty in this 
method as humans are much more complex than other species and such a comparative 
relationship can only give a rough estimate of a human value and not the accuracy required. 
Established methods now exist to correlate PBPK parameters to in vitro and allometric data 
(Jones et al., 2009; Chaturvedi et al., 2001) with commercial tools for the calculation of these 
parameters for given drugs (http://www.cyprotex.com/home/, http://www.simulations-
plus.com/, http://www.simcyp.com/).  
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A level of detail can be added to the PBPK models by further separating each compartment 
(i.e. organ) into vascular, interstitial and intracellular components. The vascular component 
consists of the part of the organ with the blood vessels from which the drug transists within 
the organ (interstitial) and before it reaches the cell (intracellular). This tri-partite 
modification would introduce a multitude of parameters, including the physiochemical 
characteristics of drug chemicals within the interstitial and vascular components (Schmitt, 
2008, Peyret, Krishnan, 2012; Yun, Edginton, 2013). More elegant future models would 
combine this level of information with cellular information to provide cellular-level PBPK 
models that would be able to give insight of probable correlation between patient cell 
characteristics and the different PK profile (Caldwell et al., 2012). 
 
Figure 2.8: Representation of a physiological PK model with organs represented as one-
compartment models. Adapted from (Saltzman, 2001). 
In the literature, both compartmental and physiological models for cancer drugs are available 
and some references are listed in Table 2.3. Both compartmental and physiological models 
range from simple to more detailed models that are based on fewer assumptions.  For 
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example for the case of Ara-C anti-leukemic agent, 1-compartmental model is developed and 
presented in the work of (Hijiya et al., 2006).  This model describes 1 state, the drug 
concentration in the entire body, and includes two parameters i.e. the elimination rate 
constant and the systemic volume. On the other hand, for the same drug a physiological PK 
model is presented in the work of (Dedrick, 1972). This model describes the concentration 
state in 7 compartments including the liver, the kidney, the heart, the blood, the bone marrow, 
the gut and the lean muscle. The model depends on 21 parameters that comprise of the blood 
flow rate, volume, metabolism rate and clearance of each considered compartment. This 
example is used to explain that physiological models allow for a greater window of model 
accuracy and states inclusion, however, they require a larger amount of information for the 
accurate estimation of the model parameters. The level of detail added to the model depends 
on the data availability and the model purpose.  
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Table 2.3: PK models for cancer drugs 
Compartmental Models  
Eight-compartmental model for methotrexate (MTX) 
(Reich et al.,1977) 
Multicompartmental model for doxorubicin 
 
(Reich et al., 1977) 
Three-compartmental model for idarubicinol 
(Looby et al., 1997) 
Two-compartmental model for methotraxate 
(Hijiya et al., 2006) 
Two-compartmental model for etoposide 
(Hijiya et al., 2006) 
Two-compartmental model for teniposide 
(Hijiya et al., 2006) 
One-compartmental model for Ara-C (Hijiya et al., 2006) 
Two-compartment model for etoposide 
(Relling et al., 1998) 
Two-compartmental pharmacokinetic model for etoposide 
(Panetta et al., 2002) 
Compartmental modelling of cyclosporine, etoposide and 
mitoxantrone 
(Lacayo et al., 2002) 
Two-compartment model of idarubicin 
(Gillies et al., 1987) 
Three-compartment model of mitoxantrone 
(Richard et al., 1992) 
Physiological Models  
Physiological model for Ara-C  (Morrison et al., 1975) 
Physiological model for Ara-C (Ara-C) (Dedrick et al., 1972) 
Physiological model for thriopental (Bischoff, Dedrick, 1968) 
Physiological model for methotrexate (Himmelstein, Lutz, 1979) 
Physiologican model for adriamycin / doxorubicin (Himmelstein, Lutz, 1979) 
Physiological model for actinomycin-d (Lutz et al., 1977) 
Physiological model for adriamycin (Chen et al., 1979) 
Physiological model for cis-dichlorodiammine-platinum (Chen et al., 1979) 
Physiological model for cyclotidine (Chen et al., 1979) 
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2.4.4 Pharmacodynamic (PD) modelling 
 
PD models of anticancer drugs describe the effect of drugs that enter the cell and affect its 
function. Because of the complexity of the drug mechanism of action, detailed PD models are 
not in use. Empirical expressions relating drug concentration to drug effect are preferable 
(Holford, 1982) and the accuracy of the PD model is highly dependent on precision of the PK 
model. 
In general, PD is the study of dose-response relationships. For the development of PD models 
for anti-cancer agents, tumour cells are exposed in vitro in different drug concentrations and 
drug effect curves are obtained. These data are then used to fit empirical PD models which 
are listed in Table 2.4 below. An example of a common dose-response curve is presented in 
figure 2.9. The drug effect curves are of utmost importance, especially for the early clinical 
trial phases, for the determination of maximal dose effect as well as for estimation of the 
effective drug dosing window.  
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Figure 2.9: Schematic representation of an illustrative example of PD dose-response curves 
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The most widely used models are the drug effect models. These models relate drug 
concentration to drug effect which, for the purposes of this study, is the number of dead cells. 
These models contain estimated parameters from real-life data and drug effect depends only 
on the drug concentration (Table 2.4). 
Table 2.4: Formulas of PD models (Holford et al., 1982) 
Model Model Equations Description 
Linear Model oECSE   E: drug effect 
C: drug concentration 
S: slope parameter 
Eo: initial drug effect  
Log-linear Model ICSE  log  E: drug effect 
C: drug concentration 
S: slope parameter 
I: constant  
Emax Model 
CEC
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EE o


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E: drug effect 
C: drug concentration 
Emax: maximum drug effect 
Eo: initial drug effect from previous application 
EC50 : concentration producing half of the 
maximum drug effect 
Sigmoid Emax model 
nn
n
CEC
CE
E



50
max  
E: drug effect 
C: drug concentration 
Emax: maximum drug effect 
Eo: initial drug effect from previous application 
EC50: concentration producing half of the maximum 
drug effect 
n: constant affecting the shape of the drug effect-
concentration curve 
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Chapter 31 
 
Mathematical Model Formulation 
 
3.1 Introduction 
 
In this chapter, chemotherapy treatment is presented and analysed from a process systems 
viewpoint. Section 3.2 presents framework for the design of personal optimised 
chemotherapy protocols by combining drug information together with patient and disease 
characteristics in order to develop the proper optimal dosing schedule for each individual. A 
major objective of the current project is to develop a mathematical model able to capture 
disease dynamics under chemotherapy for a patient case study. Section 3.3 presents the 
developed mathematical model for two chemotherapy protocols, the LDAC and the DA 
protocols as presented in section 2.3. The mathematical model depends on patient and disease 
characteristics that are analysed in detail, as well. Section 3.4 presents the sensitivity analysis 
results of the system, where the ranges of the inter-patient variability of the parameters 
considered in the model are collected from the literature and analysed with aim to identify the 
most crucial patient/disease dependent information that controls the treatment outcome, i.e. 
the level of leukemic cell population. After the sensitivity analysis, simulation results of two 
hypothetical patient case studies are presented and analysed in section 3.5 for the treatment of 
these patients under the two analysed chemotherapy protocols (LDAC and DA protocols).  
  
                                                 
1
 Work in this chapter has been published in Pefani E., Panoskaltsis N., Mantalaris A., Georgiadis M. C., 
Pistikopoulos E. N.. Design of optimal patient-specific chemotherapy protocols for the treatment of Acute 
Myeloid Leukemia (AML). Computers and Chemical Engineering Journal, 2013; 57: 187-195. 
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3.2. Framework for the development of optimal personalised chemotherapy 
protocols 
 
Models aiming to describe the actions of chemotherapy should consist of mathematical 
expressions for all steps of drug treatment, from administration to intracellular action. The 
general framework for the derivation and function of such a mathematical model is described 
in figure 3.1.  
To start, the initial dose load given to the patient in combination with the administration route 
and injection rate will be used for the calculation of treatment inflow (figure 3.1: box 1), the 
main input for the PK model.  
The PK model (figure 3.1: box 2) depends on patient-specific characteristics and is comprised 
of the set of drug mass balances in patient organs for the calculation of the drug concentration 
profile. This profile is the main input for the PD model.  
The PD model (figure 3.1: box 3) calculates the number of both normal and cancer cells 
which have died due to drug administration which are then successively subtracted from the 
starting number of cells (figure 3.1: box 4) in order to calculate the number of each cell type 
which remain following the chemotherapy cycle.  
Thereafter, a new optimisation problem will be introduced and solved only if there are 
tumour cells still present (in this model) and normal cells are in sufficient number such that 
the patient can tolerate another chemotherapy cycle.  
Within this framework, optimal chemotherapy cycles will be designed which aim to 
effectively control the treatment schedule (inflow, dose load) in order to eradicate the 
maximum possible number of cancer cells while maintaining normal cells within predefined 
limits. The optimal treatment will be different, defined case-by-case, based on physiological 
characteristics of the patient (determining drug kinetics) and cell characteristics (determining 
the diseased and normal population dynamics).  
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Figure 3.1: Framework for the derivation of optimal personalised chemotherapy protocols. 
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3.3 Physiologically based patient model for the treatment of AML with 
DNR and Ara-C 
 
The need for more personalised treatment design has been previously presented (Undevia et 
al., 2007; Garattini, 2006; Essers, Trumpp, 2010). The main sources of inter- and intra- 
patient variability are in the cellular kinetics of the tumour and normal cell populations and 
the kinetics of the anti-cancer agents upon entering the human body. Thus, the desired 
mathematical model for the simulation of patient behaviour and tumour response during 
chemotherapy should consist of three parts: (i) the cell cycle model, which is the target of 
drug action, (ii) PK and (iii) PD aspects that provide the complete description of drug 
diffusion and action after administration.  
In this section, a mathematical model is formulated to simulate the chemotherapeutic action 
of two anti-leukemic drugs, DNR and Ara-C, commonly used in clinical practice for the 
treatment of AML. The model describes the dynamic interactions of leukemic and normal 
cells exposed to chemotherapeutic drugs by a system of ordinary differential equations.  
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3.3.1 Mathematical model for IV and SC dose applications of DNR and Ara-C anti-
leukemic agents 
 
In this section the developed mathematical model is described in subsections I to VI. Table 
3.1 lists the model parameters and includes the unit of the parameters and their description. 
Table 3.1: List of model parameters 
 
  
Symbol Unit Description 
dose mg
 
Drug dose in mg 
duration min Dose duration 
u mg/m
2 
Drug dose in mg/m
2 
weight kg Patient weight 
height cm Patient height 
ka min
-1
 Absorption rate 
kb - Bioavailability 
kl,Ara-C min
-1
 Ara-C liver elimination rate 
kk,Ara-C L/min Ara-C clearance rate by the kidneys 
kk,DNR L/min DNR clearance rate by the kidneys 
kl,DNR min
-1
 DNR elimination rate in liver 
Vi L Volume of body organs B: blood, H:heart,Li:liver, 
K:kidney, M:bone marrow, Le: lean muscle 
ViT L Volume of organ tissue 
Qi L/min Blood flow rate of body compartments i 
Emax,Ara-C - Ara-C maximum drug effect 
E50,Ara-C mg/L Ara-C concentration at half drug effect 
Emax,DNR - DNR maximum drug effect 
E50,DNR Mg/L DNR concentration at half drug effect 
slopeDNR - slope scaling factor for DNR PD action 
γ min
-1
 the death rate of cells in proliferation phase 
δ min
-1
 the death rate of cells  in non-proliferation phase  
τ min the duration of proliferation phase 
βο min
-1
 the maximum recruitment rate 
θ cells/kg 
cell population of growth phase when 
2
o   
n - Scale factor depicting the sensitivity of the transition rate 
to the cell population of growth phase 
k1 min
-1
 Transition rate of cells from G1- to S- phase 
k2 min
-1
 Transition rate of cells from S- to G2M- phase 
k3 min
-1
 Transition rate of cells from   G2M- to G1- phase 
µG1, µS, µG2M min natural apoptosis time constants for each cell cycle phase 
TG1, TS, TG2M min Duration  constants for each cell cycle phase 
Tc min Duration of the whole cell cycle 
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(equation 3.3) 
 
The inflow rate (In,j) is the rate of the administered dose applied over the dosage duration.  
The dose is adjusted to the patient by its multiplication with the body surface area (bsa), 
calculated by Mosteller empirical equation  3.3 as is currently done in clinical practice. These 
equations are used for the calculation of the inflow rate given the treatment schedule 
characteristics i.e. the dose load and duration of administration. Moreover, these two 
characteristics comprise the control variables for the optimisation problem. 
II. Pharmacokinetic model 
For both drugs, DNR and Ara-C, physiologically based PK models are used to calculate drug 
concentration of the active metabolite in specific human organs at each time point. Initially, 
the drug is injected into the blood and circulates to the whole body. The mass balance for the 
blood compartment is: 
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(equation 3.4) 
 
 
where CB,j is the concentration of drug j in the blood compartment, VB is the total patient 
blood volume, Qi is the blood flow in organs i: heart (H), liver (Li), BM (M), Le (lean), Ci,j is 
the concentration of drug j in organs i, QK is the kidney blood flow, CK,j is the drug 
concentration in the kidneys and inflow is the treatment inflow as calculated in equation 3.1. 
The metabolic action takes place in the liver and then the active metabolite is circulated in the 
body via the blood. The mass balance in body organ i is as follows: 
iTjijijiijBi
ji
i VCkCQCQ
dt
dC
V  ,,,,
,
 
 
(equation 3.5) 
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The drug is transmitted via the blood to the organs. The term k,i,j is the elimination rate of the 
drug j in the body organs i and has a non-zero value only for the liver.  
After drug elimination and action, the drug is excreted through urine with clearance rate (kK,j 
) from the kidneys. An extra factor is introduced in the mass balance of the kidneys (equation 
3.6) to account for the drug clearance (kK,j) . The cumulative excretion is calculated by 
(equation 3.7). 
iTjBkKjjiijBi
ji
i VCkCQCQ
dt
dC
V  ,,,
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(equation 3.6) 
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(equation 3.7) 
 
 
III. Pharmacodynamic model 
The PD model is used for the calculation of drug effect, i.e. is the fraction of cells killed  due 
to drug action per unit time. The PD model is shown in equation 3.8 where the main input is 
drug concentration at the location of the tumour, which for AML is the concentration in BM 
(CM,j) and is calculated by the PK model.  
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(equation 3.8) 
  
Emax,j, E50,j and slope are the PD parameters that depend on the drug j and are validated using 
clinical data.  
IV. Cancer Cell cycle model 
A dynamic model is used for the description of the cell cycle through chemotherapy 
treatment. The selected compartments are the cells in G1 phase, S-phase, and combined G2 
and M phases. G1 is the first compartment after the starting point of the cell cycle and lasts 
TG1 hours. Afterwards, the cell proceeds to S-phase (DNA replication). This phase lasts TS 
hours and the cell is transferred to the last compartment, G2 and M that last TG2M hours and 
results in two newborn cells. The mathematical model consists of the mass balances between 
these compartments and is described by the following equations, 
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(equation 3.11) 
  
where G1, S, G2M represent the cell population in cell cycle compartments, k1, k2, k3 are the 
transition rates between cell phases and effect,j is calculated by the PD model (equation 3.8) 
and is the percentage of each cell cycle population killed by the anticancer drug. This 
parameter has physical meaning only if a drug acts on a particular cell phase i.e. for drug 
Ara-C the effect will be 0 for phases G1 and G2M, whereas for DNR the effect will be 0 only 
for phase G2M. The transition rates are functions of the duration of the cell cycle phases and 
are calculated by the following equations, 
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(equation 3.14) 
where µG1, µS, µG2M are the natural apoptosis time constants for each cell cycle phase.  
 
As the cell cycle is a dynamic model, the solution depends on the initial state. The initial 
distribution of the cell population in the cell phases is difficult to measure and will be 
estimated by the following equations, 
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where TC is the total cell cycle time and N(0) is the initial number of cancer cells in the 
modelled cell cycle population.  
V. Normal cell cycle model 
The normal stem cell reserve contains cells which can replicate, differentiate or die. These 
cells are grouped into two compartments, proliferating (P) and non-proliferating (Q) cells. 
Non-proliferating cells are G1 phase cells grouped together with quiescent cells. These cells 
are activated and transmitted to the proliferating compartment at a rate (β(Q)) that is 
reciprocal to the number of quiescent cells (equation 3.20), i.e. when the number of cells is 
low, more cells will be activated in order to preserve the stem cell population. The set of 
mathematical equations expressing the behaviour of normal cells are as follows, 
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nn
n
o
Q
Q




 )(
 
(equation 3.20) 
 
Where γ is the death rate in proliferative phase, δ is the death rate in non-proliferative phase, τ 
is the duration of proliferation, βο is the maximum recruitment rate, θ is the cell population of 
growth phase when 
2
o   and n is a positive parameter depicting the sensitivity of the 
transition rate to the cell population of growth phase. 
 
VI. Drug subcutaneous route 
Sc route is an alternative route of drug delivery where the drug is injected into the 
individual‟s subcutaneous tissue. In this type of drug administration, the drug inflow reaches 
the systemic circulation with a certain time delay (absorption rate) and in a decreased amount 
(bioavailability) as some of the initial drug given is being bound during drug absorption from 
the sc to the blood compartment (figure 3.2).  
For the case of sc dosing, two main differences are included in the model: 
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 An absorption rate  
 A bioavailability term. 
For the model of the SC route, equation 3.4 will be replaced by equations 3.4a and 3.4b that 
account for drug bioavailability (kb) and absorption delay (ka). 
SkIn
dt
dS
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(equation 3.4a) 
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Figure 3.2: Schematic representation of Ara-C PK model following either i.v. or sc 
administration route 
3.3.2 Patient and disease characteristics 
 
The available patient information consists of the patient physiological characteristics i.e. 
patient sex, age, height and weight. These characteristics are used in the current model for the 
calculation of organ blood flow (Qi) and organ volume (Vi), variables used by the PK model 
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(equations 3.4-3.7). These variables are varying for patients with different anatomical and age 
characteristics and empirical expressions exist in the literature, which relate these patient 
characteristics to the two variables, Qi and Vi. The expressions incorporated in the current 
presented model are listed below. 
Blood flow equals the cardiac output and is distributed to the body organs. The expression 
used for the calculation of cardiac output is adapted from the work of (Brody, 1945) and 
depends on the body weight, 
4
3
)(2.0min)/( kgweightltputCardiacOut   (equation 3.21) 
Data provided by (Dedrick et al., 1971) are then used to calculate the percentage of cardiac 
output reaching various body organs (Table 3.2).  
Table 3.2: Organ blood flow variability (Dedrick et al., 1971)   
Body Organ Blood flow (L/min) 
Heart 0.06·CO* 
Kidneys 0.31·CO* 
Liver 0.36·CO* 
BM 0.044·CO* 
Lean (1-0.2-0.07-0.044)·CO*=0.686·CO* 
*CO: cardiac output 
 
The heart volume depends on the number of heart chambers and the stroke volume (SV), that 
is the volume pumped from each chamber of the heart at each heartbeat and is calculated by 
equation 3.22. 
SVchamberVH   (equation 3.22) 
 
Both for males and females, the number of chambers is 4; for males, stroke volume is 70ml 
and for females 60ml. Thus, the calculated heart volumes will be 0.28 L and 0.24 L for males 
and females, respectively.   
The blood volume depends on patient physiological characteristics of height and weight and 
separate expressions exist for female blood volume (VB,F) (Brown et al., 1962) and for male 
blood volume (VB,M) (Wennesland et al., 1959) as shown in equations 3.23 and 3.24, 
respectively. 
1369)(46.38)(52.16)(,  kgweightcmheightmlV FB  (equation 3.23) 
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2820)(6.31)(5.28)(,  kgweightcmheightmlV MB  (equation 3.24) 
 
Liver volume is calculated by equation 3.25 and depends on the body surface area and an age 
factor that is calculated depending on the age range an individual belongs to, as described in 
equation 3.25 (Yuan et al., 2008) 
4.2473.487.949)(  ageBSAmlVL  (equation 3.25) 
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Kidney volume is dependent on the weight factor of an individual (Cohen et al., 2007) and is 
calculated by equation 3.26 below, 
113)(96.2)(  kgweightmlVK  (equation 3.26) 
 
Equations for the BM and the lean muscle are not available as expressions of individual 
characteristics and the mean values will be used, VM=2 L and Vlt=27 L, as found in (Dedrick 
et al.et al., 1971). Moreover, for the individual volumes of liver and kidney tissue, values 
used are as reported in (Dedrick et al., 1971). 
As far as disease-specific information is concerned, the current presented model is a dynamic 
model, hence it depends on the initial state which depends on the blast percentage and the 
BM cellularity at the beginning of each chemotherapy cycle (explained later in this chapter). 
Moreover, the proliferation rate and the duration of each cell cycle phase are important 
factors that affect tumour expansion and characterise the aggressiveness of the disease which 
differs between different patients.  
3.3.3 Model Assumptions 
 
Cell cycle 
Cell cycle is the process under which the cell replicates its genetic material to divide into two 
daughter cells. This is a complex process where numerous phenomena take place and cell-
cycle phases serve only as checkpoints between the different states of the cells. Particularly 
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the cell cycle is separated into four phases: the G1-phase, the S-phase, the pre-mitotic phase 
(G2-phase) and the mitosis phase (M-phase) as has already been described in Chapter 2.  
Compartmental cell cycle models, including cell cycle phases in separate compartments, are 
sufficient to describe cell kinetics under the effect of chemotherapy, that is the ultimate 
purpose of the current developed mathematical model. These compartmental models consist 
of the mass balances between compartments included in the model and the leading 
parameters are the initial condition of each cell cycle phase, the duration of each cell cycle 
phase and the transition rate between phases.  
For purposes of chemotherapy optimisation, both the leukemic population (treatment 
objective) and the normal population (toxicity restriction) will have to be modelled. The 
major difference between these two populations lies on the different proliferation rate - 
leukemic cells exhibit a higher proliferative capacity that enables the cells to expand at a 
higher and faster rate compared with that of the normal population. In contrast, normal cells 
have a lower proliferation rate and a higher percentage of the population is in the non-
proliferating state ready to be reactivated at times of population depletion.  
This difference in population dynamics is mathematically expressed by consideration of 
different compartmental models and different transition rates between cell cycle phases. For 
the case of normal cell cycle, a two-compartmental model has been used including cells in 
non-proliferating and in proliferating state (figure 3.3). A feedback function is assumed for 
the transition rate of non-proliferating normal cells into proliferation. This transition rate is 
reciprocal to the number of non-proliferating normal cells, i.e. a decrease of proliferating 
cells exposed to chemotherapy provokes a higher transition rate of cells into proliferation in 
order to replenish the number of normal cells lost. This mathematical model for the normal 
cell population is a well-established model extensively used in the literature (Andersen, 
Mackey, 2001; Colijn, Mackey, 2005). 
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Figure 3.3: Representation of compartmental model for the normal cell population 
However, this model is limited in the description of normal cell kinetics under the influence 
of chemotherapy and is not able to predict population recovery after treatment completion. 
For the case of AML, this recovery period ranges between patients and has mean duration of 
approximately 25 days. During this interval period, the normal population is recovering with 
dynamics that have not yet been examined and constitute a “black-box” process that is 
monitored through the level of platelets, leukocyctes and erythrocyte cells in patient blood 
samples.   
Moreover, a three compartmental model is used for the leukemic population (figure 3.4). The 
first compartment includes cells in the G0- and G1- phases. Leukemic cells in their highest 
percentage will be proliferating, but this compartment of cells prior to proliferation will 
control proliferation as it adds a time delay in the proliferation process. The second 
compartment includes cells in S-phase and the third compartment merges cells in the G2 - and 
M- phases. The transition rates between the succeeding cell phases are expressions of the 
duration of each cell-cycle phase. 
 
Figure 3.4: Representation of compartmental model for the AML cell population 
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Pharmacokinetics 
A lumped compartmental model is used for the PK model development. This compartmental 
model includes body organs in compartments and a set of mass balances amongst them is 
constructed to describe the dynamic profile of drug concentration within the included organs.  
Flow-limitation formation is assumed for the description of the compartments, accepting that 
drug concentration in the blood outflow from a compartment will be in equilibrium with drug 
concentration in the tissue. This is a valid assumption often made for the development of PK 
models; however, it is not fundamental and is based on the lack of detailed physiological 
information, such as for membrane permeabilities, diffusion coefficients and tissue surfaces.  
Moreover, for the incorporation of drug metabolism and elimination, parameters of 
elimination rate in the liver and the clearance rate through the kidneys are used. These 
parameters are calculated by using the drug concentration in plasma samples and the drug 
concentration in urine, respectively. The choice to include only these two types of parameters 
for purposes of the current analysis is because they are measured by well-established methods 
by pharmaceutical companies and are the only parameters provided in protocols of product 
characteristics. Undoubtedly, more complex phenomena take place from drug administration 
to drug distribution in the tumour location; however, patient variability determining in these 
phenomena would definitely be depicted in the drug plasma concentrations and the drug 
concentration in urine samples, which are the only two measurements available from the in-
vivo system i.e. the human body undergoing treatment.  
In summary, the leading principle behind the current model development is to include 
phenomena governed by parameters measured in clinical practice (patient physiological 
characteristics, treatment schedule, leukemic blast percentage in BM aspirate, BM cellularity) 
and parameters provided by pharmaceutical companies (drug half-life, elimination rate, 
clearance rate), with cell cycle duration times acquired from published literature. 
3.4 Model Sensitivity Analysis 
 
To gain a further understanding of the model and the crucial parameters that highly affect the 
treatment outcome i.e. the level of leukemic cells, a global sensitivity analysis and Quasi 
Monte-Carlo based high dimensional model representation using Sobol‟s indices was 
performed using the GUI-HDMR software (Ziehn, Tomlin, 2009). The output of interest is 
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the number of leukemic cells and the parameters checked are the cell cycle times, and the PK 
and PD parameters listed in Table 3.2.  
Specifically, the drug elimination rates in the liver were included for the studied drugs as 
significant inter-patient variability has been reported as has patient variability for DNR 
kidney clearance rate(ULCH, 2009; BC cancer agency, 2007). However, there is no measured 
variability of the kidney clearance rate for Ara-C at the doses used in this protocol, and this 
parameter is not included in the sensitivity analysis.  For the inter-patient variability of PD 
parameters, the work of (Quartino et al., 2007) has been used that includes analysis of PD 
action of DNR and Ara-C on BM samples of 179 patients with AML. Moreover, the cell 
cycle parameter ranges are as previously reported (Raza et al., 1990) with evaluation of the 
cell kinetics in 54 patients diagnosed with AML.  
For the calculation of parameters sensitivity index (SI), 40,000 simulations were run of all the 
possible combinations of the tested parameters within their assigned ranges. The SI results 
are presented in Table 3.3. The SA results clearly indicate that the duration of the cell cycle 
phases is the most crucial parameter where Tc has an effect of 60.4% on the treatment 
outcome and Ts has 27.05% effect. The limit for a parameter is considered to be a crucial 
factor affecting  the measured variable is at least 10%.  
Table 3.3: PK, PD, cell cycle parameters and inter-individual ranges used for model sensitivity 
analysis and sensitivity index results 
 Symbol Default 
value 
Range Ref. Sensitivity Index 
PK kl,Ara-C 0.069 0.067-0.07 (UCLH, 2009) 0.0007 
 kk,DNR 1.5 0.036-1.7 ( BC Cancer 
Agency, 2007) 
0.017 
 kl,DNR 0.015 0.014-0.017 ( BC Cancer 
Agency, 2007) 
0.000085 
PD Emax,Ara-C 0.83 0.79-0.86 (Quartino, 2007) 0.0003 
 E50,Ara-C 0.29 0.25-0.33 (Quartino, 2007) 0.0049 
 Emax,DNR 0. 91 0.88-0.93 (Quartino, 2007) 0.00925 
 E50,DNR 0.09 0.076-0.1 (Quartino, 2007) 0.0928 
 slopeDNR 1.23 1.06-1.4 (Quartino, 2007) 0.000468 
Cell 
Cycle 
Ts 15 6-43 (Raza, 1990) 
0.2705 
 TC 60 18-211 (Raza, 1990) 0.604 
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3.5 Simulation results for two hypothetical patient case studies 
 
3.5.1 Model parameters for the patient case studies 
 
The set of parameters used for all patient case studies are the drugs pharmacologic 
information, i.e. PK and PD for the two drugs, and the parameters for the normal cell 
population. Tables of these parts of the model are listed in Tables 3.4 and 3.5 below.  
Table 3.4: Pharmacology (PK – PD) parameters for Ara-C and DNR anti-leukemic agents 
 
Moreover, for the normal cell population published data (Andersen, Mackey, 2001) are used 
and listed in Table 3.5. 
 
 
 
 
 Symbol Value Description Reference 
PK kl,Ara-C 0.069  min
-1
 Ara-C liver 
elimination rate 
(UCLH, 2009) 
 kk,Ara-C 0.09 Ara-C clearance 
rate by the kidneys 
(UCLH, 2009) 
 kk,DNR 1.5 
 
   
 DNR clearance rate 
by the kidneys 
( BC Cancer 
Agency, 2007) 
 kl,DNR 0.015  min
-1
 DNR elimination 
rate in liver 
( BC Cancer 
Agency, 2007) 
 ka 0.21  min
-1
 Ara-C Absorption 
rate 
(Slevin et al., 
1981) 
PD Emax,Ara-C 0.83 Ara-C maximum 
drug effect 
(Quartino et al., 
2007) 
 E50,Ara-C 0.29 
  
 
 Ara-C 
concentration at 
half drug effect 
(Quartino et al., 
2007) 
 Emax,DNR 0. 91 DNR maximum 
drug effect 
(Quartino et al., 
2007) 
 E50,DNR 0.09 
  
 
 DNR concentration 
at half drug effect 
(Quartino et al., 
2007) 
 slopeDNR 1.23 slope scaling factor 
for DNR PD action 
(Quartino et al., 
2007) 
68 
 
Table 3.5: Parameters of the compartmental model for the normal BM cell population 
Symbol Value Description Reference 
γ 0.00007 min-1 the death rate of cells 
in proliferation phase 
(Andersen,Mackey, 
2001) 
δ 0.0001 min-1 the death rate of cells  
in non-proliferation 
phase 
(Fister, Panetta, 
2000) 
τ 4032 min the duration of 
proliferation phase 
(Andersen,Mackey, 
2001) 
βο 0.0021 min
-1
  the maximum 
recruitment rate 
(Andersen,Mackey, 
2001) 
θ 0.5·106 cells/kg cell population of 
growth phase when 
2
o   
(Andersen,Mackey, 
2001) 
n 4 Scale factor depicting 
the sensitivity of the 
transition rate to the 
cell population of 
growth phase  
(Andersen, 
Mackey,2001) 
The information that will be modified for each patient case study is as follows, 
 Patient physiological characteristics (sex, age, weight) 
 Patient disease characteristics (initial tumour burden, duration of cell cycle phases) 
 Treatment schedule 
The presented model is used for the simulation analysis of two different chemotherapy 
protocols, the LDAC and DA protocols, consistent with current clinical practice.  
The LDAC protocol consists of (sc) Ara-C doses of 20 mg administered every 12 hrs for 10 
days.The DA protocol includes DNR doses of 60 mg/m
2
 administered for 1 hr IV infusion on 
days 1, 3 and 5 of the chemotherapy cycle and Ara-C doses of 100 mg/m
2
 administered every 
12 hrs for 10 days. These two protocols are simulated for two patient case studies using data 
previously reported (Clarkson et al., 1967). Table 3.6 lists the cell population and 
physiological characteristics of the two patient case studies. 
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Table 3.6: Hypothetical patient case study based on published data (Clarkson et al, 1967) 
Physiological Patient Characteristics 
 Sex Age (yrs) Height (m) Weight (kg) 
Patient H1 F 61 1.60 70 
Patient H2 F 68 1.60 70 
AML population characteristics 
 Tumour 
burden 
(blasts/kg) 
G0G1-phase 
duration (hrs) 
S-phase 
duration (hrs) 
G2M-phase 
duration (hrs) 
Patient H1 2.6·10
9
 61 19 3.62 
Patient H2 1.6·10
9
 24 22 3.47 
  
Induction treatment includes 4 chemotherapy cycles of either LDAC or DA with interval 
periods between chemotherapy cycles when no drug is supplied. As has already been 
mentioned, this period is a recovery period with mean duration of 25 days during which the 
patient receives no treatment. During this period, daily blood tests take place to monitor the 
patient‟s blood and immune system recovery, i.e. the recovery of the level of leukocytes, 
platelets and erythrocytes. It impossible to derive the same measurements for the 
leukemic/blast population as the number of BM aspirations must be limited for patient safety 
and ethical reasons. This “black box” period increases the uncertainty for the analysis of the 
clinical data as the behaviour of the leukemic cells is unknown.  
Based on clinical experience, a valid assumption during this interval period is that a 1-log 
disease increase will occur. In our model, this is expressed by cell cycle times Ts and Tc 
equal to 40 hours and 211 hours, respectively. These values are taken from published work 
(Raza et al., 1990) and represent cell cycle times required for the leukemic cell population to 
have a slower proliferation rate. This assumption has been made, since post-chemotherapy 
administration, the BM microenvironment has been affected by the same drugs used to kill 
the tumour and is therefore more hostile towards the expansion of cells, including leukemic. 
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3.5.2 Simulation results of Patient H1 undergoing LDAC and DA induction treatments  
 Simulation results of the LDAC protocol for patient H1 
1
st
 Chemotherapy Cycle 
In this section simulation results are presented for Patient H1 with physiological and disease 
characteristics presented in Table 3.6. Figure 3.5 presents the normal and leukemic 
population dynamics for the 1
st
 chemotherapy cycle with LDAC.  
Patient H1 under 1st cycle LD protocol
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Figure 3.5: Patient H1 behaviour over the first cycle (days 1-11) of LDAC induction treatment 
A decrease of 1.6·10
11
 leukaemic cells results as the population declines from 1.82·10
11
 to 
2.14·10
10
 cells. Normal cells decreases as well from 1.9·10
10
 cells initially to 3.8·10
9
 cells by 
cycle completion representing a 1.52·10
10
 variance. The main objective, even from the 1
st
 
cycle of induction chemotherapy treatment, is to reduce the leukemic population to a level 
lower than that of the normal cell population. This objective is not achieved for Patient H1 
after the 1
st
 cycle of LDAC and the chemotherapy cycle is not successful.  
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2
nd
 Chemotherapy Cycle 
At the beginning of the 2
nd
 chemotherapy cycle, the leukemic cell population equals 
2.44·10
11
 cells, which is already higher than that of the leukemic initial state at the point of 
diagnosis, i.e. the initial population at the beginning of the 1
st
 cycle (1.82·10
11
 cells). The 
behaviour of the normal and leukemic cell populations over the 2
nd
 chemotherapy cycle from 
day 36 to day 46 of treatment is presented in figure 3.6. 
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Figure 3.6: Patient H1 behaviour over the 2
nd
 cycle (days 36-46) of LDAC induction treatment 
Over the 2
nd
 chemotherapy cycle, leukemic cell number decreases from 2.44·10
11
 to 
2.87·10
10
 cells, with a variance of 2.15·10
11
 cells. Moreover, normal cells will have the same 
dynamics as the initial population and the applied protocol is the same as that for the 1
st
 
chemotherapy cycle. At completion of the 2
nd
 chemotherapy cycle, the leukemic population is 
still higher than that of the normal population with a difference of 2.5·10
10
 cells.  
3
rd
 Chemotherapy Cycle 
After the 2
nd
 chemotherapy cycle, one more recovery period without chemotherapy treatment 
occurs for 25 days. Over this period, both normal and leukemic cell populations will increase, 
since cells are left without the effects of cytotoxic treatment. The normal population is 
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assumed to fully recover during this period i.e. the state at the beginning of the 3
rd
 cycle will 
be similar that at the beginning of the 1
st
 chemotherapy cycle (1.9·10
10
 cells). The estimated 
initial leukemic population at the beginning of the 3
rd
 cycle is 3.27·10
11
 cells. This cell 
population is even higher compared with that of the initiating populations at the start of 
chemotherapy cycles 1 and 2.  
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Figure 3.7: Patient H1 behaviour over the third cycle (days 71-81) of LDAC treatment 
Over the 3rd chemotherapy cycle,  leukemic population decreases down to 3.85·10
10
 cells, 
with a variance of 2.88·10
11
 cells. Moreover, normal cells will have the same dynamics as 
that over the 1
st
 chemotherapy cycle since the initial normal population will be the same as 
well as when the chemotherapy schedule is administered (At completion of the 3
rd
 
chemotherapy cycle, the leukemic burden is still higher than that of the normal population 
with a difference of 3.47·10
10
 cells, indicating that this cycle is not successful (figure 3.7).  
4
th
 Chemotherapy Cycle 
The increasing leukemic population present at the beginning of all chemotherapy cycles 
together with the sustained difference between leukemic and normal cells (higher leukemic 
cell number than that of normal cells) are clear indicators that this protocol is not effective for 
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Patient H1. At the start of the 4
th
 chemotherapy cycle, the leukemic population is higher than 
that of the previous cycles (4.39·10
11
 cells). Leukemic cells decrease over the 4
th
 and last 
chemotherapy cycle but are still maintained to a level higher than that of the normal cell 
population (figure 3.8). 
Time (days)
106 108 110 112 114 116
C
e
ll
 N
u
m
b
e
r
0
1e+11
2e+11
3e+11
4e+11
5e+11
Leukemic Cells
Normal Cells
 
Figure 3.8: Patient H1 behaviour over the 4
th
 cycle (days 106-116) of LDAC treatment 
The simulated behaviour profile of Patient H1 undergoing the full course of standard LDAC 
treatment is presented in figure 3.9 and the numbers of leukemic and normal cell populations 
are listed in Table 3.7. 
In summary, Patient H1 shows resistance to LDAC from the first chemotherapy cycle as the 
disease burden declines by less than 1-log during treatment. At the beginning of the 2
nd
 
chemotherapy cycle, the tumour load is 2.44·10
11
 cells (Table 3.7), higher than that at 
diagnosis, i.e. 1.82·10
11
 cells (Table 3.7). This trend is maintained throughout treatment and 
by the end of a course of LDAC, the disease burden is 5.89·10
11
 cells indicating that this 
protocol is not efficient for this case study. The leukemic population is not decreasing to a 
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level lower than that of hypoplasia and the leukemic population is constantly higher than that 
of the normal.  
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Figure 3.9: Patient H1 cell population dynamics during a course of treatment with LDAC  
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Table 3.7: Simulation results for the full course of treatment of Patient H1 with LDAC. 
Date 
Leukemic population over 
simulation with LD protocol 
Normal population over 
simulation with LD protocol 
Beginning of 1
st
 cycle 1.82·10
11
 1.9·10
10
 
End of 1
st
 cycle 2.14·10
10
 3.8·10
9
 
Beginning of 2
nd
 cycle 2.44·10
11
 1.9·10
10
 
End of 2
nd
 cycle 2.87·10
10
 3.8·10
9
 
Beginning of 3
rd
 cycle 3.27·10
11
 1.9·10
10
 
End of 3
rd
 cycle 3.85·10
10
 3.8·10
9
 
Beginning of 4
th
 cycle 4.39·10
11
 1.9·10
10
 
End of 4
th
 cycle 5.17·10
10
 3.8·10
9
 
BM aspirate after 4
th
 cycle 5.89·10
11
  
 
 Simulation results of the DA protocol for Patient H1 
1
st
 Chemotherapy Cycle 
As previously presented, Patient H1 shows resistance when treated with the LDAC protocol. 
This is due to the long duration of the G0G1-phase (61 hrs) resulting in a high percentage of 
cells being in the inactive phase (GoG1-phase) unaffected by Ara-C (an S-phase specific 
drug). In this part, patient H1 will be treated with DA; the results are expected to be better 
since higher doses of chemotherapy will be applied and, more importantly, DNR will be 
administered which acts on cells in G0-phase. 
Figure 3.10 presents the leukemic and normal cell populations for the first cycle using the DA 
protocol. Leukemic cells decrease from 1.82·10
11 
cells initially to 7.7·10
7
cells. The resulting 
cell number at treatment completion is below the BM hypoplasia level (1·10
9
 cells). Normal 
cell number decreases from 1.9·10
10
 to 3.7·10
8
 cells and from the 5
th
 day, the normal 
population is higher than the leukemic population, thereby reaching another important 
objective of induction chemotherapy treatment.  
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Figure 3.10: Patient H1 behaviour over the first cycle (days 1-11) of DA induction treatment 
Over the cycle, the leukemic population undergoes a 3-log reduction, whereas normal cells 
show a 2-log reduction under the same applied chemotherapy protocol. This difference is due 
to the feedback mechanism which enables normal non-proliferating cells to replace the 
population loss by proceeding faster into the proliferation state.  
Figure 3.11 presents the normal proliferating and non-proliferating cell populations during 
the 1
st
 chemotherapy cycle of DA induction treatment. Cells undergoing proliferation are 
susceptible to the effects of chemotherapy and is the reason that the cell number declines 
quickly over the first three days when they become undetectable. After the 3
rd
 day, the 
proliferating cell population starts increasing again and this is due to the higher population 
transitioning from the non-proliferating cell compartment.  
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Figure 3.11: Normal proliferating and non-proliferating cell populations of Patient H1 
undergoing the 1
st
 cycle of DA induction treatment 
The decrease rate of the normal population presents a peak on days 1, 3 and 5 when iv doses 
of both agents (Ara-C and DNR) are applied. This rapid decline in cell number will provoke a 
higher transition of non-proliferating cells to proliferate (figure 3.12).    
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Figure 3.12: Transition rate from normal non-proliferating to proliferating cell population of 
Patient H1 under the 1
st
 cycle of DA induction treatment 
2
nd
 Chemotherapy Cycle 
The initiating leukemic cell number at the start of the 2
nd
 chemotherapy cycle will be higher 
than the resulting leukemic population number at completion of the 1
st
 chemotherapy cycle 
because of the 25-day recovery period during which the patient is left without chemotherapy 
treatment. Over the 2
nd
 chemotherapy cycle, leukemic cells decrease from 7.8·10
8
 to 3.3·10
5
 
cells. Normal cells will have the same response as during the 1
st
 chemotherapy cycle since the 
population is assumed to fully recover during the 25-day interval period and the same 
protocol is applied.  As shown in figure 3.13, the normal population is much higher than that 
of the leukemic population, which is one of the most important objectives of chemotherapy 
treatment since it will result in a healthier BM with normal function. Leukemic cells are 
lower than the hypoplasia and remission level of 1·10
9
 cells and the two objectives of the 
induction treatment have already been achieved.  
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Figure 3.13: Patient H1 behaviour over the second cycle (days 36-46) of DA treatment. 
3
rd
 Chemotherapy Cycle 
Although the treatment objectives have been achieved from the first two chemotherapy 
cycles, there is still residual disease left so simulation results will be presented for the full 
course of treatment. Figure 3.14 presents the normal and leukemic populations undergoing 
the 3
rd
 chemotherapy cycle of DA.  
Leukemic cells increase over the recovery period between the 2
nd
 and 3
rd
 chemotherapy 
cycles, and the initial population prior to the 3
rd
 cycle is 3.4·10
6
 cells. After completion of the 
3
rd
 cycle, leukemic cells are decreased to 1430 cells, whereas the normal cell population is 
much higher at 3.7·10
8
 cells.  
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Figure 3.14: Patient H1 behaviour over the third cycle (days 71-81) of DA treatment. 
4
th
 Chemotherapy Cycle 
By completion of the 3
rd
 chemotherapy cycle, the leukemic population was decreased to 1430 
cells which, after the 25-day recovery period increased to 1.5·10
4
 cells, and represents the 
initial condition of the 4
th
 and last chemotherapy cycle (figure 3.15). After the 4
th
 
chemotherapy cycle, only 6 leukemic cells are left and the disease is practically completely 
eradicated. Normal cells will have the same dynamics as for all the chemotherapy cycles i.e. 
to 3.7·10
8
 cells, that is higher than the leukemic cell burden and will result in a healthy 
functioning BM.  
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Figure 3.15: Patient H1 behaviour over the fourth cycle (days 106-116) of DA treatment. 
The full length profile of patient H1 undergoing DA treatment is presented in figure 3.16 and 
the cell population numbers are listed in Table 3.8 below.  
In summary, the DA protocol simulation results clearly demonstrate that this protocol is 
appropriate for Patient H1 case study. The disease is decreasing and BM hypoplasia is 
achieved from the 1
st
 chemotherapy cycle as leukemic cells are less than 10
9
 cells, the 
hypoplasia and remission level. Moreover, for this protocol, leukemic cells are decreased to a 
level wherein, even after the 1
st
 cycle, their number is less than that of normal cells (Table 
3.8) which is a major objective of chemotherapy treatment. After the full course of treatment 
(four cycles of chemotherapy), leukemic cells are near-fully eradicated and the normal 
population is high enough for the BM to start functioning normal to produce healthy blood 
cells.  
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Figure 3.16: Patient H1 cell population dynamics under the full-length course of treatment with 
the DA clinical protocol 
Table 3.8: Simulation results for the full course of treatment of patient H1 under the DA clinical 
protocol 
Date 
Leukemic population over 
simulation with DA protocol 
Normal population over 
simulation with DA protocol 
Beginning of 1
st
 cycle 1.82·10
11
 1.9·10
10
 
End of 1
st
 cycle 7.7·10
7
 3.7·10
8
 
Beginning of 2
nd
 cycle 7.8·10
8
 1.9·10
10
 
End of 2
nd
 cycle 3.3·10
5
 3.7·10
8
 
Beginning of 3
rd
 cycle 3.4·10
6
 1.9·10
10
 
End of 3
rd
 cycle 1430 3.7·10
8
 
Beginning of 4
th
 cycle 1.5·10
4
 1.9·10
10
 
End of 4
th
 cycle 6 3.7·10
8
 
BM aspirate after 4
th
 cycle 64  
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3.5.3 Simulation results of Patient H2 using LDAC and DA treatment protocols 
 
 Simulation results of the LDAC protocol for patient H2 
1
st
 Chemotherapy Cycle 
Figure 3.17 presents the normal and leukemic cells‟ behaviour after the 1st chemotherapy 
cycle of LDAC. Both populations decrease under the influence of drug action and, over the 
final days, the normal population is higher than that of the leukemic population. In particular, 
leukemic cell number decreases from 1.12·10
11
 to 5.8·10
8
 cells and the normal cell number 
decreases from 1.99·10
10 
to 3.8·10
9
 cells. 
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Figure 3.17: Patient H2 behaviour over the first cycle (days 1-11) of LDAC induction treatment 
 
2
nd
 Chemotherapy Cycle 
Over the 25-day recovery period after the 1
st
 chemotherapy cycle, both normal and leukemic 
populations increase and at the beginning of the 2
nd
 chemotherapy cycle, there are 7.2·10
9
  
leukemic cells with a normal cell population of 1.99·10
10
 cells. Figure 3.18 demonstrates the 
normal and leukemic populations over the 2
nd
 chemotherapy cycle. Normal cells are higher 
than that of leukemic for the entire duration of the 2
nd
 chemotherapy cycle. The dynamics of 
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the normal population are the same as that over the 1
st
 chemotherapy cycle since the same 
protocol is applied i.e. the cell population decreases from 1.99·10
10 
to 3.8·10
9
 cells. 
Moreover, the leukemic population decreases from 7.2·10
9 
to 3.74·10
7
 cells, with a difference 
of 3.76·10
9
 cells less than that of the normal cell population. 
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Figure 3.18: Patient H2 behaviour over the second cycle (days 36-46) of LDAC treatment. 
3
rd
 Chemotherapy Cycle 
The leukemic population increases to 4.6·10
8
 cells at the beginning of the 3
rd
 chemotherapy 
cycle. The population thereafter decreases to 2.4·10
6
 cells at completion of the 3
rd
 
chemotherapy cycle (figure 3.19). During the 3
rd
 chemotherapy cycle, leukemic cells are 
maintained at a lower state compared with that of the normal cell population, which is an 
indicator of the efficiency of LDAC for the treatment of Patient H2.  
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Figure 3.19: Patient H2 behaviour over the third cycle (days 71-81) of LDAC treatment. 
4
th
 Chemotherapy Cycle 
The dynamics of normal and leukemic cell populations over the last cycle of the LDAC 
protocol are presented in figure 3.20, below. Leukemic cells are still lower than that of the 
normal population for the 4
th
 cycle as they were from the last days of the 1
st
 chemotherapy 
cycle and thereafter. In particular, the leukemic population increases to 2.96·10
7
 cells during 
the recovery period between the 3
rd
 and 4
th
 cycles and then decreases to 1.5·10
5
 cells. Normal 
cells will have the same dynamics as in the previous chemotherapy cycles since the initial 
population is assumed to be the same for all cycles and the same chemotherapy schedule is 
applied. In that sense, the normal population will decrease from 1.99·10
10
 to 3.8·10
9
 cells 
making a 4-log difference compared with that of the leukemic cell population in the BM.  
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Figure 3.20: Patient H2 behaviour over the fourth cycle (days 106-116) of LDAC treatment 
In summary, the presented simulation results demonstrate a successful treatment outcome for 
Patient H2 over the LDAC protocol. The leukemic cell population decreases from the first 
chemotherapy cycle to a lower level compared with that of the normal cell population. This is 
an important objective for the chemotherapy treatment as it will allow for normal cells to start 
proliferating and functioning normally resulting in an improved blood and immune system 
for the patient to be able to tolerate the remainder of chemotherapy treatment. Moreover, the 
disease decreases and BM hypoplasia is achieved from the 2
nd
 chemotherapy cycle as 
leukemic cells are less than 10
9
 cells, the level of hypoplasia and morphologic remission. 
The profile of Patient H2 undergoing the full course of standard LDAC treatment simulation 
is presented in figure 3.21 and the numbers of the leukemic and normal cell populations are 
listed in Table 3.9. 
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Figure 3.21: Patient H2 cell population dynamics under the full course of LDAC treatment. 
Table 3.9: Simulation results for the full course of treatment of patient H2 using the LDAC 
clinical protocol 
Date 
Leukemic population over 
simulation with LD protocol 
Normal population over 
simulation with LD protocol 
Beginning of 1
st
 cycle 1.12·10
11
 1.99·10
10
 
End of 1
st
 cycle 5.8·10
8
 3.8·10
9
 
Beginning of 2
nd
 cycle 7.2·10
9
 1.99·10
10
 
End of 2
nd
 cycle 3.74·10
7
 3.8·10
9
 
Beginning of 3
rd
 cycle 4.6·10
8
 1.99·10
10
 
End of 3
rd
 cycle 2.4·10
6
 3.8·10
9
 
Beginning of 4
th
 cycle 2.96·10
7
 1.99·10
10
 
End of 4
th
 cycle 1.5·10
5
 3.8·10
9
 
BM aspirate after 4
th
 cycle 1.9·10
6
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 Simulation results of the DA protocol for patient H2 
1
st
 Chemotherapy Cycle 
Figure 3.22 presents the leukemic and normal cell population dynamics during the 1
st
 
chemotherapy with combination of Ara-C and DNR drugs (DA protocol). The leukemic 
population decreases from 1.12·10
11
 to 4.8·10
5
 cells, whereas normal cells decrease from 
1.99·10
10
 to 3.7·10
8
 cells. Induction treatment objectives are achieved from the 1
st
 
chemotherapy cycle as leukemic cells are below the 1·10
9
 cells, the hypoplasia level, and 
the leukemic population is less than that of the normal population (figure 3.22).  
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Figure 3.22: Patient H2 behaviour over the first cycle (days 1-11) of DA induction treatment. 
2
nd
 Chemotherapy Cycle 
Consistent with clinical practice, a 25-day recovery period is allowed between the 1
st
 and the 
2
nd
 chemotherapy cycle in order to enable recovery of the normal population. Over this 
period, leukemic cells increase to 4.8·10
6
 cells and the normal cell population is assumed to 
have repopulated and equals 1.99·10
10
 cells. Figure 3.23 presents the dynamics of the normal 
and leukemic populations during the 2
nd
 chemotherapy cycle. Normal cell number is higher 
than that of the leukemic for the entire duration of the treatment cycle. In particular, the 
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normal cell population decreases to 3.7·10
8
 cells, whereas the leukemic population decreases 
to 20 cells. 
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Figure 3.23: Patient H2 behaviour over the second cycle (days 36-46) of DA treatment. 
3
rd
 Chemotherapy Cycle 
The leukemic population increases to 200 cells by the beginning of the 3
rd
 chemotherapy 
cycle and one more chemotherapy cycle is applied. Over the 3
rd
 chemotherapy cycle 
leukemic cells become undetectable and, according to the simulation results, the BM only 
consists of normal cells (figure 3.24). 
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Figure 3.24: Patient H2 behaviour over the third cycle (days 71-81) of DA treatment. 
The profile of Patient H2 undergoing the full course of standard DA treatment simulation is 
presented in figure 3.25 and the numbers of the leukemic and normal cell populations are 
listed in Table 3.10. 
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Figure 3.25: Patient H2 cell population dynamics under the full course of treatment with the DA 
clinical protocol 
Table 3.10: Simulation results for the full course of treatment of Patient H2 with DA clinical 
protocol 
Date 
Leukemic population over 
simulation with LD protocol 
Normal population over 
simulation with LD protocol 
Beginning of 1
st
 cycle 1.12·10
11
 1.99·10
10
 
End of 1
st
 cycle 4.8·10
5
 3.7·10
8
 
Beginning of 2
nd
 cycle 4.8·10
6
 1.99·10
10
 
End of 2
nd
 cycle 20 3.7·10
8
 
Beginning of 3
rd
 cycle 200 1.99·10
10
 
End of 3
rd
 cycle 0 3.7·10
8
 
Beginning of 4
th
 cycle -  
End of 4
th
 cycle -  
BM aspirate after 4
th
 cycle -  
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For Patient H2, both protocols are efficient at decreasing the level of leukemic cells to below 
the hypoplasia level of 10
9
 cells, which is the ultimate purpose of chemotherapy treatment. 
However, over the DA protocol, the leukemic population becomes undetectable from 
completion of the 3
rd
 cycle, whereas residual disease remains after completion of LDAC. The 
residual disease equals 1.9·10
6
 cells, which is still less than the desired level of less than 10
9
 
cells. This difference in the leukemic population is due to the increased toxicity of the DA 
protocol that results in a decreased number of normal cells as well. The calculated normal 
population reduction is 1-log after the LDAC protocol and a 2-log reduction after the DA 
protocol. Moreover, for both chemotherapy protocols, the leukemic population is decreased 
from the very first chemotherapy cycle to a level at which the normal population is higher. 
This is an important objective for the chemotherapy process as it will allow the normal cells 
to start proliferating and functioning normally resulting in an improved blood and immune 
system in order to enable the patient to tolerate the remainder of chemotherapy treatment. 
3.6 Discussion 
 
A mathematical model is developed and presented for the full course of treatment using two 
chemotherapy protocols currently used in standard clinical practice i.e. 
 the LDAC protocol of (sc) Ara-C doses of 20 mg applied every 12 hrs for 10 days 
  the DA protocol of DNR doses of 60 mg/m
2
 applied for 1-hr IV infusion on days 1, 3 
and 5 of the chemotherapy cycle and Ara-C doses of 100 mg/m
2
 IV administered 
every 12 hrs for 10 days, also starting from day 1.  
Sensitivity analysis takes place in the current work using collectible data from the open 
literature in order to define the inter-patient variability of the PK, PD and the cell cycle 
parameters. The results show that the cell cycle times are crucial model parameters that 
highly affect the disease treatment outcome.  
Simulation results are presented applying the two studied protocols to two patient case 
studies with characteristics published in (Clarkson et al., 1967). Patient H1 is a more difficult 
case study with more aggressive cell population kinetics. Specifically, this patient shows a 
higher initial tumour burden together with a lower proliferation phase and a prolonged non-
proliferation state of cells unaffected by the chemotherapy agents. Simulation results of this 
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patient show successful treatment outcome for the DA protocol and unsuccessful for the 
LDAC protocol over which leukemic cells are still increasing. In contrast, patient H2 is a 
case study with successful treatment outcome for both protocols. Of note, complete disease 
eradication is simulated for this patient under the DA protocol. 
The simulation results appear to suggest that the DA protocol should be applied for the  
treatment of both patients. This protocol affords more toxicity and leads to a greater reduction 
of leukemic burden while the normal population is within acceptable limits. However, 
considering solely the AML population kinetics is not sufficient for proper treatment design. 
In clinical practice, treatment preference also takes account of the patient physiologic state to 
determine whether the patient is able to tolerate the toxicity of chemotherapy. This patient 
physiologic state is determined by the clinician responsible for the treatment design who also 
relies on other parameters such as kidney and liver function together with the age and the 
health history of each individual. For this reason, the purpose of the current work is not to 
compare the two studied protocols but to optimise and analyse them separately in order to 
derive leukaemia-specific and patient-specific personalised treatments for AML. The 
optimisation algorithm of the chemotherapy process for AML is discussed in the next chapter 
and results are presented of the optimisation of the LDAC and DA protocols for the two 
hypothetical patients presented in this chapter. 
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Chapter 42 
 
Chemotherapy process as an optimisation problem 
 
This chapter presents an algorithm for the optimization of the chemotherapy process as a 
scheduling problem. The algorithm is presented in section 4.1 and afterwards is solved for the 
two patients presented in Chapter 3 for both intensive and non-intensive treatment protocols 
with maximal and minimal thresholds set for efficacy and toxicity, respectively. For iv Ara-
C, total drug administration is set between 50mg – 4000mg with infusion duration between 1 
min to 24 hours. The window for DNR dose optimisation is stricter due to potential toxic 
effects and the only independent variable is the dose which varies between 30mg – 90mg per 
infusion. For sc Ara-C, the maximum dose per day is 40mg, and doses are permitted up to 
four times daily for a maximum period of 20 days.  
This optimisation problem was formed and solved using gPROMS (gPROMS, 2003) and the 
optimised treatment protocols for the two studied patient case studies over the protocols are 
presented in section 4.2 of this chapter. 
4.1 Optimisation scheduling algorithm of chemotherapy process 
The aim of remission induction therapy is to achieve the rapid restoration of normal BM 
function. By treatment completion, the leukemic population should be reduced to a level of 
approximately 10
9 
cells at which point BM hypoplasia is achieved. Moreover, the normal 
population should be higher than that of the leukemic population and a 3-log reduction is the 
maximum permissible level of population reduction. Treatment design will be mainly based 
on the control of four schedule parameters: 
 the drug use, 
 the dose load,  
 the dose duration and  
 the number of dose applications.  
                                                 
2
 Work in this chapter is presented in 
Pefani E., Panoskaltsis N., Mantalaris A., Georgiadis M. C., Pistikopoulos E. N.. Chemotherapy Drug 
Scheduling for the Induction Treatment of patients diagnosed with Acute Myeloid Leukemia. Accepted for 
publication in the Transactions of Biomedical Engineering Journal.  
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The optimisation algorithm is presented below (table 4.1):  
Table 4.1: Chemotherapy process optimisation algorithm 
Objective function 
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*n is the number of dose application; j is the drug; tn,j is the duration of each dose application; 
un,j is the dose load of each application; Cellsleuk,n,j is the number of leukemic ; Cellsnor,n,j is 
the number of normal cells; effectn is the the PD effect of drug j over application n; CMn,j: is 
the BM concentration; Inflown,j: is the inflow of drug j during application n; n  is the 
duration between two succeeding dose applications; NA is the total number of applications; tf 
time at the end of last dose. 
The objective function is the minimisation of the leukemic (Cellsleuk) cells at the end of the 
last dose subject to the treatment schedule that is defined by the drug use (j), the dose load 
(un,j), the dose duration (tn,j) the number of applications (NA) and the interval period between 
two succeeding dose applications (
n ). The four first parameters are the optimisation 
schedule variables, whereas the interval period between two doses is a design variable 
calculated by the frequency of doses i.e. if two or four doses will be applied daily as defined 
by clinicians. The control parameters define the drug inflow that has physical meaning only 
for the periods of chemotherapy treatment, whereas the value of the inflow is set to 0 for the 
periods between two succeeding chemotherapy cycles. 
The feasible optimisation solutions are defined by the set of the equality and inequality 
constraints. Equality constraints consist of the expressions used to calculate the number of 
leukemic (Cellsleuk) and normal (Cellsnor) cells throughout the treatment. Both cell 
populations are functions of the drug PD effect (effectn) that is defined by the drug 
concentration profile at the tumour location i.e. the BM (CM,n,j). The drug concentration 
profile is determined by the treatment inflow, a variable calculated by the schedule and the 
)(min
,,, ,,
fleuk
NAtuj
tCells
jnjn
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design parameters. Moreover, the inequality constraints consist of constraints on the number 
of normal cells that will have to be higher than a 3-log reduction throughout the treatment 
(path-constraint) and by treatment completion they will have to be higher than the number of 
leukemic cells (end-point constraint). 
4.2 Optimisation Results for the two hypothetical patients 
4.2.1 Optimisation results of Patient H1 over the LDAC and DA treatment protocols  
 
 Optimisation results of the LDAC protocol for patient H1 
Simulation results for Patient H presents resistance to LDAC and, at treatment completion, 
the disease burden is higher than at disease presentation (at the start of cycle 1). The 
optimisation problem for this case is formulated with a maximum dose load per day of 40 mg 
and up to four daily dose applications are permitted for a maximum period of 20 days. This 
optimisation problem is solved for the four chemotherapy cycles and the optimisation 
schedules are listed in Table 4.2. 
Table 4.2: Optimal LDAC induction treatment protocol for Patient H1 
 
 
 
 
 
 
 
1
st
 Chemotherapy Cycle 
The optimisation problem for the 1
st
 chemotherapy cycle of patient H1 over the LDAC 
protocol suggests daily infusions of the same total dose i.e. 40 mg applied for double the 
time-period, 20 days in total (Table 4.2). The double dose load is therefore suggested with 
total Ara-C dose equal to 800 mg. Over the 1
st
 chemotherapy cycle leukemic cells decrease 
from 1.82·10
11
 cells to 1.2·10
9
 cells and normal cells decrease from 1.9·10
10
 to 8.9·10
8
 cells. 
Figure 4.1 presents the leukemic and normal population dynamics over the optimisation and 
simulation protocols.  
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application 
Schedule 
SC Ara-C     
1
st
 Cycle 40 mg 24-hr SC 1 daily application 
for days 1-20 
2
nd
 Cycle 40 mg 24-hr SC 1 daily application 
for days 1-20 
3
rd
 Cycle 40 mg 24-hr SC 1 daily application 
for days 1-10 
4
th
 Cycle 40 mg 24-hr SC 1 daily application 
for days 1-10 
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Figure 4.1: Optimisation results for patient H1 over the 1
st
 cycle of LDAC. The black straight 
line represents the leukemic population over the simulation protocol with a duration of 10 days 
(day 1 to 11), whereas the dashed line is for the optimisation protocol with duration of 20 days 
(day 1 to 21).  
Due to the increased toxicity of the optimisation protocol, leukemic and normal cell 
populations further decrease in the optimisation protocol. Particularly, there is a further 
decrease of 2.02·10
10
 leukemic cells achieved at a cost of losing 2.9·10
9
 normal cells.  The 
optimisation objective is to achieve a BM with a higher normal population than leukemic 
population from the 1
st
 chemotherapy cycle. However, due to the aggressiveness of the 
leukemic population of patient H1, such a solution is infeasible and this constraint had to be 
relaxed for an optimal solution to be found. Hence, for this patient, over the 1
st
 cycle, the 
difference between the normal and leukemic population is decreased to the maximum 
possible level and over the 2
nd
 cycle, the normal population is higher, indicating a healthier 
BM. 
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2
nd
 Chemotherapy Cycle 
The schedule of the 2
nd
 chemotherapy cycle is the same as that of the 1
st
 chemotherapy cycle 
i.e. 40 mg applied as daily infusions for 20 days (Table 4.2). The dynamics of the normal and 
leukemic cell populations are presented  in figure 4.2. Due to the increased toxicity of the 1
st
 
chemotherapy cycle, the initial burden of the leukemic population over the optimisation 
protocol is lower. The leukemic population is further decreased by the 2
nd
 chemotherapy 
cycle and by cycle completion, there is a further population reduction of 2.86·10
10
 cells 
compared with that of the simulation protocol. Normal population dynamics are the same for 
the 1
st
 and the 2
nd
 chemotherapy cycles since the same schedule is applied. Moreover, during 
the optimisation protocol, BM hypoplasia is achieved since leukemic cells are less than the 
hypoplasia level (1·10
9
 cells).  
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Figure 4.2: Optimisation results for patient H1 over the 2
nd
 cycle of LDAC. The black straight 
line represents the leukemic population over the simulation protocol with a duration of 10 days 
(day 36 to 46), whereas the dashed line is for the optimisation protocol with duration of 20 days 
(day 46 to 66). 
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3
rd
 Chemotherapy Cycle 
The same total dose as with the simulation protocol is suggested for the 3
rd
 chemotherapy 
cycle i.e. daily amount of 40 mg. The cycle duration is 10 days and the doses will be applied 
as daily infusions rather than rapid bolus doses. The comparison of the simulation and 
optimisation results for the 3
rd
 cycle is presented in figure 4.3 below. Optimisation results are 
better since the leukemic population is below the hypoplasia level for the entire duration of 
the cycle.  
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Figure 4.3: Optimisation results for patient H1 over the 3
rd
 cycle of LDAC .The black straight 
line represents the leukemic population over the simulation protocol with a duration of 10 days 
(day 71 to 81), whereas the dashed line is for the optimisation protocol with duration of 10 days 
(day 91 to 101). There is a 20 day delay between the optimisation and simulation protocols due 
to the increased duration of the previous 2 cycles of 10 days each.  
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The leukemic population decreases from 9.06·10
8
 cells to 7.2·10
7
 cells and the normal 
population decreases from 1.9·10
10
 cells to 3.79·10
9
 cells. As compared with the simulation 
results, there is a further decrease of 3.8·10
10
 cells, whereas the normal cell population is the 
same. This is expected if we consider that the normal population consists of proliferating 
cells susceptible to treatment and quiescent cells serving as back-up cells at times of BM 
depletion. Since the transition rate of quiescent cells depends on the population depletion, the 
population will be adjusted to account for the loss and the transition rate will be adapted to 
keep the population constant. For the optimal protocol, since dose injection rate is lower and 
constant over the optimal treatment protocol, it will enable a constant transition of quiescent 
cells to proliferation that will result in a more rigid normal cell population recovery over this 
protocol. 
4
th
 Chemotherapy Cycle 
The same schedule as for the 3
rd
 cycle is suggested for the 4
th
 and last cycle of the LDAC 
protocol. Total dose is kept constant and the schedule is changed to include daily dose 
infusion rather than the applied rapid dose applications over the simulation protocol. The 
leukemic population further decreases and at treatment completion, BM consists of 6·10
7
 
leukemic cells and 3.79·10
9
 normal cells (figure 4.4).  
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Figure 4.4: Optimisation results for patient H1 over the 4
th
 cycle of the LDAC protocol. The 
black straight line represents the leukemic population over the simulation protocol with a 
duration of 10 days (day 106 to 116), whereas the dashed line is for the optimisation protocol 
with duration of 10 days (day 126 to 136). There is a 20 days delay between the optimisation and 
simulation protocols due to the increased duration of the previous 2 cycles of 10 days each.  
In summary, Patient H1 shows resistance during the simulation with the LDAC protocol and 
disease burden is decreased over each chemotherapy cycle but over the interval period is 
increasing and by treatment completion the final leukemic population is higher than that at 
diagnosis. For this reason, the optimisation protocol suggests for the two first chemotherapy 
cycles, extended treatment duration to 20 days rather than the 10 days of the simulation 
protocol. For the first two cycles, a total dose increase of 400 mg is suggested and doses are 
administered as continuous daily infusions. Over these two more toxic cycles, the disease 
burden is decreasing more rapidly and, after the 2
nd
 cycle, the leukemic population is below 
the desired hypoplasia level (figure 4.5). For cycles 3 and 4, the total dose is kept at the same 
levels as that for the simulation protocol i.e. 40 mg, but given as continuous 24 hour infusions 
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SC, as well. At treatment completion of the full course of the optimised protocol, there is a 
total 3-log reduction of leukemic cells that equals 6.4·10
8
 cells (Table 4.3). This population is 
below the level of hypoplasia and below the level of normal cells, which is the treatment 
objective.  Normal cells are also reduced more over the first two chemotherapy cycles 
compared with the last two cycles (Table 4.3) as is expected since the first cycles are of 
increased toxicity. Finally, as is presented in figure 4.5, with a total dose increase of 800 mg 
over the entire chemotherapy course, compared with that of the simulation protocol, the 
leukemic population is reduced to a level below the hypoplasia level, whereas the same 
patient was resistant to the simulated LDAC protocol used in current clinical practise. 
Table 4.3: Optimisation results for the full course of LDAC treatment for Patient H1 
Date 
Leukemic population over 
optimisation with LD protocol 
Normal population over 
optimisation with LD protocol 
Beginning of 1
st
 cycle 1.82·10
11
 1.9·10
10
 
End of 1
st
 cycle 1.2·10
9
 8.9·10
8
 
Beginning of 2
nd
 cycle 1.28·10
10
 1.9·10
10
 
End of 2
nd
 cycle 8.58·10
7
 8.9·10
8
 
Beginning of 3
rd
 cycle 9.06·10
8
 1.9·10
10
 
End of 3
rd
 cycle 7.2·10
7
 3.79·10
9
 
Beginning of 4
th
 cycle 7.58·10
8
 1.9·10
10
 
End of 4
th
 cycle 6·10
7
 3.79·10
9
 
BM aspirate after 4
th
 cycle 6.4·10
8
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Figure 4.5: Simulation and optimisation results for Patient H1 over the LDAC protocol. The 
straight line represents the simulation results and the black dashed line represents the 
optimisation results. The figure is separated for the 4 cycles of the optimisation treatment that 
present a lag period compared with the simulation protocol as the first 2 cycles last 10 days 
more for each optimised cycle. Grey cross symbols indicate the start date of each chemotherapy 
cycle for the simulation protocol and black cross symbols indicate the end of each cycle. 
 Optimisation results of the DA protocol for Patient H1 
As has already been mentioned, the purpose of induction chemotherapy treatment is to reduce 
the leukemic population below the hypoplasia level and also below the level of normal cells 
while suffering a maximum 3-log reduction in the number of normal cells. With these 
constraints at the end of the induction treatment, a BM with recovering normal cells and a 
weakend leukemic cell population will be achieved. Simulation results for Patient H1 indicate 
that treatment with DA is successful. For this reason the aim of the optimisation of the 
current protocol should not be to increase the dose load i.e. treatment toxicity, but to use the 
same total dose and optimise in order to identify the optimal schedule of this dose load. This 
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optimisation problem is solved and the optimal protocol suggests daily continuous doses, i.e. 
24 hour iv infusion, of 200 mg/m
2
 instead of 2 doses of 100 mg/m
2
 twice a day, whereas the 
same schedule for DNR is maintained since the toxicity of this drug does not allow for the 
flexibility to find alternative optimisation solutions. Figure 4.6 presents the disease dynamics 
of Patient H1 over the simulation and optimisation results for the DA protocol and Table 4.4 
summarises the results over the optimisation DA treatment protocol. 
Table 4.4: Optimisation results for the full course of treatment of protocol DA for Patient H1 
Date 
Leukemic population over 
optimisation with DA protocol 
Normal population over 
optimisation with DA protocol 
Beginning of 1
st
 cycle 1.82·10
11
 1.9·10
10
 
End of 1
st
 cycle 6.97·10
7
 3.78·10
8
 
Beginning of 2
nd
 cycle 6.6·10
8
 1.9·10
10
 
End of 2
nd
 cycle 2.5·10
5
 3.78·10
8
 
Beginning of 3
rd
 cycle 2.4·10
6
 1.9·10
10
 
End of 3
rd
 cycle 912 3.78·10
8
 
Beginning of 4
th
 cycle 8749 1.9·10
10
 
End of 4
th
 cycle 0 3.78·10
8
 
BM aspirate after 4
th
 cycle -  
 
As illustrated in figure 4.6, the optimal treatment protocol is more effective since leukemic 
cells are further decreased over the full course of treatment. After completion of the 1
st
 
chemotherapy cycle for Patient H1, the leukemic population is further reduced making a 
difference of 7.3·10
6
 cells less. This reduction will successively affect the initial conditions of 
the subsequent chemotherapy cycles resulting in further reduction of the leukemic population 
that is finally undetectable at completion of the optimal treatment schedule (Table 4.4).  
Moreover, the normal population is kept at the same order of magnitude for both the 
simulation and optimisation protocols (Tables 3.7 and 4.4). This is expected if we consider 
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that the normal population consists of proliferating cells susceptible to the treatment and 
quiescent cells kept in reserve for use at times of BM depletion. Since the transition rate of 
quiescent cells depends on the population depletion, the population will be adjusted to 
account for the loss and the transition rate will be adapted to keep the population constant. 
For the optimal protocol, since dose administration rate is lower and constant over the 
optimal treatment protocol, it will enable a constant transition of quiescent cells to enter 
proliferation and will result in a more rigid normal cell population recovery over this 
protocol.  
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Figure 4.6: Simulation and optimisation results for Patient H1 over the DA protocol. The 
straight line represents the simulation results and the black dashed line represents the 
optimisation results. 
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4.2.2 Optimisation results of Patient H2 with LDAC and DA treatment protocols  
 
 Optimisation results of the LDAC protocol for Patient H2 
As has already been presented in the simulation results section, Patient H2 has a successful 
treatment with the LDAC protocol since leukemic cells are successfully lowered to a level 
less than the BM hypoplasia level and the number of normal cells. For this patient, the 
optimisation problem will be to keep the total dose constant i.e. 400 mg total and check if 
there is an improved treatment schedule. This optimisation problem is solved and the 
optimised protocol suggests daily continuous infusions sc of 40 mg for 10 days rather than 2 
doses of 20 mg daily for 10 days that is applied in current clinical practice. 
The comparison of the Patient H2 cell populations over the simulation and optimisation 
treatment protocols is presented in figure 4.7 and the resulted populations are listed in detail 
in Table 4.5. 
Table 4.5: Optimisation results for the full course treatment of LDAC for Patient H2 
Date 
Leukemic population over 
optimisation with LDAC  
Normal population over 
optimisation with LDAC  
Beginning of 1
st
 cycle 1.12·10
11
 1.99·10
10
 
End of 1
st
 cycle 2.25·10
8
 3.79·10
9
 
Beginning of 2
nd
 cycle 2.42·10
9
 1.99·10
10
 
End of 2
nd
 cycle 4.8·10
6
 3.79·10
9
 
Beginning of 3
rd
 cycle 5.23·10
7
 1.99·10
10
 
End of 3
rd
 cycle 1.05·10
5
 3.79·10
9
 
Beginning of 4
th
 cycle 1.1·10
6
 1.99·10
10
 
End of 4
th
 cycle 3400 3.79·10
9
 
BM aspirate after 4
th
 cycle 3.6·10
4
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As presented in figure 4.7, over the optimal protocol, a reduction of the leukemic population 
is achieved although the total dose is kept constant. This difference is increasing as the 
chemotherapy cycles are accumulating and is due to the lower initial leukemic numbers of 
cycles 2 to 4. By treatment completion, the leukemic population is further reduced to 
1.86·10
6
 cells fewer than that of the simulation protocol. Moreover, the normal population is 
kept to the same order of magnitude for both protocols. This is expected if we consider that 
the normal population consists of proliferating cells susceptible to the treatment and quiescent 
cells serving as back-up in times of BM depletion. Since the transition rate of quiescent cells 
depends on the population depletion, the population will be adjusted to the loss and the 
transition rate will be adapted to keep the population constant. For the optimal protocol, since 
dose administration rate is lower and more frequent over the optimal treatment protocol, it 
will enable a lower and constant transition of quiescent cells to the proliferating state that will 
result in a more rigid normal cell population recovery over this protocol. 
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Figure 4.7: Optimisation results for Patient H2 over the LDAC protocol with daily continuous 
infusions sc of 40 mg for 10 days (optimisation results: black dashed line) instead of doses every 
12 hrs of 20 mg for 10 days (simulation results: straight line). 
108 
 
 Optimisation results of the DA protocol for Patient H2 
Simulation results of Patient H2 over the DA protocol show that the patient reached the 
desired BM state. For this reason, the aim of the optimisation of the current protocol would 
not be to increase the dose load i.e. treatment toxicity, but to use the same total dose and 
optimise in order to identify the optimal schedule of this dose load. This optimisation 
problem is solved and the optimal protocol suggests daily continuous infusion doses of 200 
mg/m
2
 iv Ara-C instead of 2 doses of 100 mg/m
2
 twice a day, whereas the same schedule for 
DNR is kept since the toxicity of this drug does not allow flexibility for alternative 
optimisation solutions.  
Figure 4.8 presents the disease dynamics of Patient H2 over the simulation and optimisation 
results for the DA protocol and Table 4.6 summarises the results over the optimisation DA 
treatment protocol.  
Table 4.6: Optimisation results for the throughout treatment of protocol DA for Patient H2 
Date 
Leukemic population over 
optimisation with DA protocol 
Normal population over 
optimisation with DA protocol 
Beginning of 1
st
 cycle 1.12·10
11
 1.99·10
10
 
End of 1
st
 cycle 3.6·10
5
 3.78·10
8
 
Beginning of 2
nd
 cycle 3.4·10
6
 1.99·10
10
 
End of 2
nd
 cycle 0 3.78·10
8
 
Beginning of 3
rd
 cycle -  
End of 3
rd
 cycle -  
Beginning of 4
th
 cycle -  
End of 4
th
 cycle -  
BM aspirate after 4
th
 cycle -  
 
As illustrated in figure 4.8, the optimal treatment protocol is more effective as leukemic cells 
are further reduced during the full course of treatment. After completion of the 1
st
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chemotherapy cycle for Patient H2, the leukemic population is further reduced to 1.2·10
5
 
cells. This difference leads to a decreased number of the initial leukemic population for the 
2
nd
 chemotherapy cycle over which the disease becomes undetectable and there is no need for 
a 3
rd
 chemotherapy cycle.  
Moreover, the normal population is kept to the same order of magnitude for both protocols. 
This is expected if we consider that the normal population consists of proliferating cells 
susceptible to the treatment and quiescent cells serving as back-up cells in times of BM 
depletion. Since the transition rate of quiescent cells depends on the population depletion, the 
population will be adjusted to the loss and the transition rate will be adapted to keep the 
population constant. For the optimal protocol, since dose injection rate is lower and constant 
over the optimal treatment protocol, it will allow a constant transition of quiescent cells to the 
proliferating state that will result in a more rigid normal cell population recovery over this 
protocol.  
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Figure 4.8: Optimisation results for Patient H2 over the DA protocol with continuous daily 
infusion doses of 200 mg/m
2
 iv Ara-C for 10 days (optimisation results: straight line) instead of 
doses every 12 hrs of 100 mg/m
2
 for 10 days (simulation results: dashed line). 
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4.3 Discussion 
 
In this chapter, the mathematical model presented in Chapter 3 is used as an optimisation 
problem application. The benefits of optimisation are presented and a scheduling optimisation 
problem is developed for the optimisation of chemotherapy process.  
The objective is to reduce the leukemic population to a level of approximately 10
9 
cells at 
which BM hypoplasia and morphologic remission is achieved. Moreover, the normal 
population should be higher than the leukemic population and a 3-log reduction is the 
maximum level of population reduction permitted per chemotherapy cycle. In this way, rapid 
restoration of normal BM function will be achieved which is the aim of remission-induction 
therapy.  
This optimisation problem is solved using gPROMS for the two patient case studies. For the 
DA protocol, the optimisation problem is comprised of scheduling problem with the same 
total dose as the simulation protocol but with possibly an improved schedule. This is due to 
the fact that both patients receive a successful treatment after this protocol and there is no 
need for dose load increase. The optimisation schedule suggests that Ara-C should be 
administered in continuous iv infusion of 200 mg/m
2
 daily for 10 days instead of a rapid 
bolus of 100 mg/m
2
 applied twice a day for 10 days as is used in standard clinical practice. 
The resulting protocol shows improvement of the treatment outcome where Patient H1 has 
complete disease eradication at completion of the 4 cycles and Patient H2 has full disease 
eradication after the 2
nd
 cycle.  
For the LDAC protocol, two optimisation problems were solved, one for each patient. For 
Patient H1, increased dose intensity was suggested since this patient had unsuccessful 
treatment outcome over the simulation results. A total dose increase of 400 mg in each of the 
first two cycles is suggested given as 40 mg daily continuous infusions sc over 20 days. 
Moreover, for cycles 3 and 4 the total dose is similar to that in the simulation protocol, i.e. 
400 mg, but with different treatment schedule that includes daily continuous sc infusions of 
40 mg. Following this protocol, Patient H1 has a successful treatment with leukemic cells 
reduced to a level lower than the hypoplasia level as desired.  
Lastly, a scheduling optimisation problem was formed and solved for the LDAC protocol of 
Patient H2. This patient has a successful treatment over the simulation results so the aim of 
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optimisation is to use the same total dose but optimise the applied treatment schedule. The 
resulted schedule suggests 4 cycles of chemotherapy with daily continuous sc infusional 
doses of 40 mg applied for 10 days instead of 20 doses of 20 mg applied every 12 hrs sc as 
used in the simulation protocol. Under this optimised protocol, the leukemic population is 
further reduced compared with that of the simulation results.  
Treatment outcome is highly dependent on the duration of the S-phase (Ts) and the total 
cycle duration (Tc). For this reason, in Appendix A, the dynamics of the leukemic cell 
population in the particular cell phases are presented for the two patients. Patient H1 is 
characterised by a high duration of the GoG1-phase which results in a high percentage of cells 
being in this phase. Under the LDAC protocol, only Ara-C is applied and therefore does not 
affect cells in the GoG1-phase. For this reason, this treatment is unsuccessful for this patient 
case study as it is not able to kill cells in the most abundant cell phase resulting in disease 
relapse (Appendix A: figures A1 – A4). In contrast, when the DA protocol is applied to the 
same population, the treatment outcome is successful. The reason for this is that DNR acts on 
and reduces cells in the GoG1-phase, and also a higher dose of Ara-C is administered, which 
results in the reduction of more S-phase cells and GoG1- G2M- cells successively (Appendix 
A: figures A5-A8). Patient H2 is characterised by a lower duration of the GoG1-phase and 
thus a lower population exists in this phase. For this reason, the LDAC protocol presents a 
better treatment outcome results for this case study compared to Patient H1. Moreover, the 
DA protocol is more efficient for this patient, as well, due to its increased toxicity (Appendix 
A: figures A9-A15).  
For the optimisation results, the common  trend across all results is that continuous infusional 
doses (iv or sc) are preferred for both protocols. The most interesting case is the optimisation 
of Patient H1 under the LDAC protocol. As discussed earlier, this protocol was unsuccessful 
for Patient H1; however, optimisation allows the desired results to be obtained. The 
optimisation protocol suggests prolonging cycles 1 and 2 by 10 more days compared with 
that in the simulation protocol and doubling the total dose load i.e. 800 mg total dose increase 
over the course of therapy. Moreover, cycles 3 and 4 use the same total dose as for the 
simulation but continuously applied. For the optimisation protocol, cells in S-phase are 
continuously decreasing faster than in the simulation protocol. This decrease will 
successively affect cells in the other two phases as fewer cells will be transitioned from the S-
phase.  Treatment outcome is much improved over the first two chemotherapy cycles where 
more toxic doses are applied but, overall, the results for this protocol are better and the 
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desired induction treatment objectives are achieved (Appendix A: figures A16-A19). For the 
optimisation of the remaining patient case studies i.e. Patient H1 under the DA protocol and 
Patient H2 under both protocols, the optimisation problem was to use the same total dose but 
under optimal dosing schedule. For all these cases, the suggested schedule is to use the same 
dose load but continuously infused for Ara-C and the same schedule for DNR. Under this 
schedule a lower but constant concentration is applied to cells in S-phase which results in a 
higher reduction of cells in this phase and in succession leads to the reduction of cells in all 
phases (Appendix A: figures A19 – A30). 
In summary, the optimisation protocols appear to be more efficient disease management than 
the simulated protocols applied in clinical practice. Under these optimised protocols, 
according to model results, BM hypoplasia is achieved for all patients and the normal 
population is higher than that of the leukemic for all the applied chemotherapy cycles.  
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PART II: 
Model Analysis with Patient Data 
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Chapter 53 
 
Model Analysis with Patient Data  
 
5.1 Introduction 
 
A mathematical model and an optimisation algorithm have been developed and presented in 
the previous chapter which is able to capture normal and leukemic cell population dynamics 
under induction chemotherapy treatment for AML. For the personalisation of treatment 
design, individual parameters are used in the model that consists of physiological patient 
characteristics (sex, age, body mass index) and disease characteristics (initial tumour burden, 
cell population kinetic information). Sensitivity analysis of the model parameters is also 
performed and the results identify that cell cycle parameters are the critical parameters that 
control the treatment outcome.  
In this chapter, the anonymised health records of 6 patients diagnosed with AML and treated 
under the LDAC and DA protocols are used for purposes of model analysis. In particular, 
patient characteristics (sex, age, BMI) are used together with disease characteristics (blast 
percentage measurements from BM aspirates, BM cellularity factor) for the estimation of cell 
cycle distribution times for each patient. Moreover, the already presented optimisation 
problem is solved for the two types of chemotherapy protocols, the low dose Ara-C protocol 
where sc low doses of Ara-C are applied as twice daily short doses and the DA protocol 
where short intravenous doses of Ara-C and DNR are applied daily. These protocol types are 
optimised for all the patients studied in this work.  
Section 5.2 presents the clinical data used for model analysis, then section 5.3 presents the 
parameter estimation results for the calculation of the patient specific cell cycle times. 
Moreover, optimisation results are presented and analysed in section 5.4 of this chapter. 
Section 5.5 presents the explanation of the optimisation results by illustrating the different 
                                                 
3
 Work in this chapter has been submitted for publication to Cancer Research. 
Pefani E., Panoskaltsis N., Mantalaris A., Georgiadis M. C., Pistikopoulos E. N.. Mathematical modelling and 
optimal scheduling of induction chemotherapy treatment of Acute Myeloid Leukemia (AML) with 
Daunorubicin (DNR) and Cytarabine (Ara-C) agents.    
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concentration profiles for the optimisation and simulation protocol and their effect on the cell 
population. Lastly, concluding remarks of this chapter are discussed in section 5.6. 
5.2 Patient data and model analysis assumptions  
5.2.1 Patient Data 
 
The project was submitted to and approved by the North West London Hospitals Trust  
(RD12.012) for the provision of anonymised health records of patients diagnosed with AML 
and treated within Northwick Park Hospital using DNR and Ara-C anti-leukemic agents 
under either i.v. or sc doses applied as per standard clinical practice (protocols available in 
Appendix B).  
5.2.2 Model Analysis Assumptions 
 
The required input data for a treatment protocol simulation consists of patient, disease, drug 
and treatment schedule information. Patient information includes the physiological patient 
characteristics of sex, age, weight and height that are used in order to calculate the volume of 
the body organs and the organ blood flow rate. Both the volume and the blood flow rate of 
the organs are important parameters that differ between patients and affect the drug PK 
profile. Disease information includes the blast percentage in the marrow aspirate and the BM 
cellularity, both of which are pieces of information acquired in routine clinical practice 
during the course of AML diagnosis and during the course of treatment. As extra information 
to what is currently used in clinical practice, the cell cycle characteristics of S-phase duration 
and the total cell cycle duration will be assessed. Moreover, for model simulation, drug 
information is required of the drugs that will be used for the treatment protocol. The required 
drug information is available in the product specification provided by the pharmaceutical 
company producing each drug. The PK drug information includes the elimination rate in the 
kidneys and the liver and the clearance rate by the kidneys. The PD drug response is defined 
by parameters that relate the drug concentration to the PD effect. PD model parameters 
include the drug concentration at the half drug effect, the concentration at the maximum drug 
effect as well as the slope scaling factor. Lastly, the treatment schedule for each 
chemotherapy cycle for the drugs applied is needed. Schedule information consists of the 
dose load, the dose duration, the number of dose applications and the duration of the 
chemotherapy cycle applied.   
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The clinical data of the 6 patients under LDAC and DA treatment protocols were used for 
model analysis purposes. The clinical data is comprised  the  patient physiological 
characteristics, the blast percentage and cellularity in the BM aspirate at diagnosis, the 
chemotherapy treatment protocol and the blast percentage together with marrow cellularity of 
the marrow examinations after the applied chemotherapy protocol (Appendix B).  
Since the model involves the number of leukemic cells, assumptions were made in order to 
convert the blast % into the number of leukemic cells: 
i. Conversion of % blast into leukemic cells is calculated by the formula, 
DBBPCFCells leukemic     
where CF is the cellularity factor of each patient, BP is the measured blast percentage in the 
BM aspirate and DB is the disease burden. For the calculation of these factors the below 
assumptions are used.  
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CellsDB 12101 (Williams et al., 1983) 
ii. Leukemic cell population is assumed to be constant from the biopsy sampling 
point until the first application of chemotherapy. At the point of disease diagnosis, 
the leukemic cell population is assumed to have already reached its maximum, 
and until the first cycle of treatment, the leukemic population will preserve the 
same order of magnitude of leukemic cells.  
iii. BM at the point of diagnosis is hypercellular. 
iv. The tumour cell burden in AML is 1 trillion cells (Williams et al., 1983). BM 
hypoplasia is the objective of induction chemotherapy, with 2- 3-log reduction in 
cell number. 
As far as the drug information is concerned, the PK parameters for DNR and Ara-C agents 
were as reported in the latest reports of the British Cancer agency and the University College 
of London Hospital NHS Foundation Trust (BC cancer agency, 2007; ULCH, 2009). 
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Moreover, for the PD information, the published results of PD action of DNR and Ara-C on 
BM samples of 179 patients with AML were used (Quartino et al., 2007). 
These are the assumptions made in order to use the available data for model analysis. The 
next section presents the method and the results of the estimation of the cell cycle distribution 
times for each patient. 
5.3 Estimation of patient cell cycle distribution parameters 
 
In this section, data presented in Appendix B of the health record of 6 AML patients are used 
for the estimation of leukemic cell cycle parameters that are the critical model parameters as 
indicated by the sensitivity analysis results. One important assumption the estimation is based 
on is the cell cycle times during the interval period between two successive chemotherapy 
cycles. As has already been mentioned, this period is a recovery period lasting 20-30 days 
during which  the patient receives no treatment.  
Under this assumption, for the interval period between two cycles when no treatment is 
applies the leukemic cell cycle parameters are set to Ts=40hrs and Tc=211hrs. The provided 
leukemic population measurement at the end of this interval period together with the duration 
of this period are then used for the calculation of the leukemic population at the beginning of 
the recovery period, that is the leukemic population at completion of the last applied 
chemotherapy cycle.  
 
The calculated leukemic population at the end of the chemotherapy cycle together with the 
provided initial tumour burden at the beginning of each chemotherapy cycle and the 
treatment schedule are subsequently used to estimate the leukemic cell cycle parameters (Ts, 
Tc) under chemotherapy. 
 
This parameter estimation problem is solved using gPROMS (gPROMS, 2003) and the fitted 
cell cycle for the 6 patients are listed in Table 5.7 and are presented in figures 5.1 to 5.6, 
whereas the leukemic cells in exact numbers for all patients are listed in Tables 5.1 to 5.6.  
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5.3.1 Cell cycle estimation for Patient P001 
 
P001 is a female patient with a diagnosis of secondary AML. Physiological characteristics are 
75 years old, 152 cm height and 56kg. BM aspirate shows a 21% blast percentage and the 
designed treatment for this patient is the LDAC protocol with 4 cycles of 10 days.Two doses 
of 20mg are administered sc to the patient daily. Patient reaction to this chemotherapy 
protocol is very promising for the first three cycles where the blast percentage is reduced to 
14% after the first chemotherapy cycle, then is reduced to 4% after the second cycle and to 
5% after the third cycle. However, after the 4
th
 cycle, the leukemic population is recovering 
and there is a disease relapse with a blast percentage as high as 15% by induction treatment 
completion.  
The fitted cell cycle times for P001 are listed in Table 5.7. For the 1
st
 cycle, Ts is equal to 13 
hrs and Tc is 45 hrs. For the second cycle Ts equals 16 hrs and Tc 40 hrs, whereas for the 3
rd
 
cycle Ts is fitted to 11 hrs and the whole cell cycle time to 45 hrs. Lastly, over the 4
th
 cycle 
Ts equals 18 hrs and there is an increase of the Tc hrs to 65 hrs, an indicator of disease 
relapse over this chemotherapy cycle. Figure 5.1 presents the leukemic cell dynamics over 
the full course of treatment for this patient and Table 5.1 lists the leukemic cell populations 
for P001 for model simulation compared with the clinical data.    
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Figure 5.1: Comparison of simulation results and clinical data for Patient P001. 
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Table 5.1: Leukemic population of Patient P001 based on model analysis and clinical data  
Date Leukemic Population 
(simulation) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 2·10
11 
cells  
1
st
 cycle end date: Day 10 9.95·10
9 
cells  
BM Aspirate after 1
st
 Cycle 
Day 36  
1.33·10
11
 cells 1.33·10
11
 cells 
2
nd
 cycle start date: Day 37 1.47·10
11
 cells  
2
nd 
cycle end date: Day 47 3.8·10
9 
cells  
BM Aspirate after 2
nd
 Cycle 
Day 70  
3.84·10
10 
cells 3.8·10
10
 cells  
3
rd
 cycle start date: Day 69 3.82·10
10 
cells  
3
rd
 cycle end date: Day 79 6.13·10
9 
cells  
BM Aspirate after 3
rd
 Cycle 
Day 91 
2 ·10
10
 cells 2·10
10
 cells 
4
th
 cycle start date: Day 105 8.7·10
10
 cells  
4
th
 cycle end date: Day 115 6.7·10
9
 cells  
BM Aspirate after 4
th
 Cycle 
Day 146 
1.44·10
11
 cells 1.43·10
11
 cells 
5.3.2 Cell cycle estimation for patient P002 
 
The second patient case study is Patient P002. P002 is a female patient 72 years old with 150 
cm height and 47 kg weight. This patient is diagnosed with secondary AML and the blast 
percentage in the BM aspirate is 83%. The designed treatment for this patient is the LDAC 
protocol and due to clinical complications, this patient received only the 1
st
 out of the 4 
planned chemotherapy cycles. Data available for the 1
st
 chemotherapy cycle reveal that the 
patient responded well to the treatment since the leukemic population is reduced and the blast 
percentage is 4% after the completion of the 1
st
 chemotherapy cycle.  
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The fitted cell cycle times are listed in Table 5.7 for this patient. The resulting Ts parameter 
is 21 hrs, whereas the whole cell cycle duration is 45 hrs. Figure 5.2 presents the leukemic 
cell dynamics for the full treatment this patient received in comparison with the available 
clinical data. Moreover, Table 5.2 lists the leukemic cell population numbers after model 
simulation together with the clinical data measurements.  
 
Figure 5.2: Comparison of simulation results and clinical data for Patient P002  
Table 5.2: Leukemic population of Patient P002 based on model analysis and clinical data. 
Date Leukemic Population 
(model) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 7.9·10
11
 cells  
1
st
 cycle end date: Day 10 8.6·10
8
 cells  
BM Aspirate after 1
st
 Cycle 
Day 48 
3. 8·10
10
 cells 3. 8·10
10
 cells 
 
5.3.3 Cell cycle estimation for Patient P006 
Patient P006 is a female patient 71 years old, 160 cm height and 57 kg weight. This patient is 
diagnosed with de novo AML and the blast percentage in the BM aspirate at disease 
diagnosis is 36%. This patient received 4 chemotherapy cycles of LDAC and the treatment 
outcome was successful. Specifically, after the 1
st
 chemotherapy cycle the blast percentage is 
reduced to 3%, after the 2
nd
 cycle it is further reduced to 2% and after the 3
rd
 cycle is 
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maintained at 2% with an increased cellularity factor (from 1 to 3) showing that the 
cellularity is increased but the disease is still maintained to the same order of magnitude. 
Lastly, after the 4
th
 chemotherapy cycle complete remission is achieved, with leukemic cells 
dropping to the hypoplasia level.   
For the 1
st
 chemotherapy cycle, the S-phase duration of the leukemic population is fitted to 20 
hrs and the whole cell cycle duration to 33 hrs. Moreover, for the 2
nd
 chemotherapy cycle the 
fitted cell cycle times are 14 hrs duration of the S-phase and 46 hrs of the whole cell cycle. 
Over the 3
rd
 chemotherapy cycle there is disease relapse as discussed earlier which results in 
increase of the cell cycle duration to 68 hrs, whereas Ts is 14 hrs. Lastly, for the 4
th
 
chemotherapy cycle Ts is fitted to 20 hrs and Tc to 40 hrs. Figure 5.3 presents the leukemic 
cell dynamics compared to the clinical data for the full length treatment of this patient and 
Table 5.3 lists the leukemic population cell number and the clinical data for all the 
chemotherapy cycles.  
 
Figure 5.3: Comparison of simulation results and clinical data for Patient P006  
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Table 5.3: Leukemic population of Patient P006 based on model analysis and clinical data 
Date Leukemic Population 
(model) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 3.42·10
11 
cells  
1
st
 cycle end date: Day 10 2.15·10
8 
cells  
BM Aspirate after 1
st
 Cycle 
Day 42 
6.1·10
9
 cells 6·10
9
 cells 
2
nd
 cycle start date: Day 42 6.1·10
9
 cells  
2
nd 
cycle end date: Day 52 6.4·10
8
 cells  
BM Aspirate after 2
nd
 Cycle 
Day 70 
3.95·10
9
 cells  4·10
9
 cells  
3
rd
 cycle start date: Day 74 5.87·10
9
 cells  
3
rd
 cycle end date: Day 84 1.46·10
9
 cells  
BM Aspirate after 3
rd
 Cycle 
Day 110 
1.89·10
10
 cells 1.89·10
10
 cells 
4
th
 cycle start date: Day 109 1.89·10
10
 cells  
4
th
 cycle end date: Day 119 6.77·10
7
 cells  
BM Aspirate after 4
th
 Cycle 
Day 145 
9.7·10
8
 cells 1·10
9
 cells 
 
 
5.3.4 Cell cycle estimation for Patient P011 
 
P011 is a male 24 years of age with 170 cm height and 59.5 kg weight. The diagnosis is 
secondary AML with a leukemic blast percentage in the BM of 56%. This patient received 
one cycle of DA induction with combination Ara-C and DNR anti-leukemic agents. Two 
daily doses (at 12 hour intervals) of 100 mg/m
2
 of Ara-C were administered by iv bolus for 
10 days combined with 3 doses of 60 mg/m
2
 DNR applied on days 1, 3 and 5 by 1 hour iv 
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infusion. Treatment outcome is positive in terms of leukemic population reduction for this 
patient and the blast percentage is reduced to 3% at completion of the 1
st
 chemotherapy cycle.  
The fitted cell cycle times for the one cycle this patient received are listed in Table 5.7. Ts 
duration is fitted to 9 hrs and the whole cell cycle duration is fitted to 53 hrs. Figure 5.4 
presents the leukemic population dynamics for the simulation results and the clinical data 
available. Moreover, Table 5.4 lists the leukemic population numbers for the simulation and 
the available clinical data.  
 
Figure 5.4: Comparison of simulation results and clinical data for Patient P011  
Table 5.4: Leukemic population of Patient P011 based on model analysis and clinical data 
Date 
Leukemic Population 
(model) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 5.32·10
11 
cells  
1
st
 cycle end date: Day 10 1.62·10
8 
cells  
BM Aspirate after 1
st
 Cycle 
Day 48 
6.06·10
9
 cells 6·10
9
 cells 
 
5.3.5 Cell cycle estimation for Patient P016 
 
P016 is the 5
th
 patient case study. P016 is a male patient with a diagnosis of secondary AML. 
Physiological characteristics are 80 years old, 167.5 cm height and 79.3kg. BM aspirate 
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shows a leukemic blast percentage of 90% and the treatment for this patient is a combination 
of the DA and LDAC treatment protocols, due to complications during treatment. 
Specifically, treatment design combined one cycle of the DA protocol as the 1
st
 
chemotherapy cycle and one cycle of LDAC as the 2
nd
 and last cycle for this patient case. The 
patient responded well to the induction treatment as blast percentage reduced to 1% after the 
1
st
 cycle and after the 2
nd
 cycle leukemic population was maintained at 1% with a lower 
cellularity factor. Although the disease was reduced BM hypoplasia was not achieved for this 
patient. 
The fitted cell cycle times for the one cycle this patient received are listed in Table 5.7. Ts 
duration is fitted to 10 hrs and the whole cell cycle duration is fitted to 54 hrs. For the 2
nd
 
chemotherapy cycle, Ts is fitted to 14 hrs and the whole cell cycle duration to 45 hrs. Figure 
5.5 presents the leukemic population dynamics for the simulation results and the clinical data 
available. Moreover, Table 5.5 lists the leukemic population numbers for the simulation and 
the available clinical data.  
 
Figure 5.5: Comparison of simulation results and clinical data for Patient P016. 
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Table 5.5: Leukemic population of Patient P016 based on model analysis and clinical data 
Date 
Leukemic Population 
(model) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 8.55·10
11 
cells  
1
st
 cycle end date: Day 10 3.29·10
8 
cells  
BM Aspirate after 1
st
 Cycle 
Day 45 
9.46·10
9
 cells 9.5·10
9
 cells 
2
nd
 cycle start date: Day 66 7.62·10
10
 cells  
2
nd 
cycle end date: Day 76 3.96·10
8 
cells  
BM Aspirate after 2
nd
 Cycle 
Day 101 
4·10
9 
cells 4·10
9 
cells 
5.3.6 Cell cycle estimation for patient P026 
 
Lastly, the last patient case is patient P026. This patient is a female patient 45 years old, of 
169.3 cm height and 94.8 kg weight. The patient is diagnosed with de novo AML and a blast 
percentage of 71% is reported at diagnosis. P026 received two chemotherapy cycles of the 
DA protocol. The 1
st
 cycle combined doses of 80 mg/m
2
 of Ara-C applied twice a day as iv 
applications for 10 days, with doses of 70 mg/m
2
 of DNR applied on days 1, 3 and 5. 
Reduced toxicity is applied on the 2
nd
 chemotherapy cycle for which same dose of Ara-C is 
applied but for 8 days duration and also the dose of DNR is reduced to 40 mg/m
2
 applied 
same days as for the 1
st
 chemotherapy cycle. This patient had a successful treatment outcome 
as BM hypoplasia is achieved from the 1
st
 chemotherapy cycle and maintained after the 2
nd
 
chemotherapy cycle.  
For the 1
st
 chemotherapy cycle, the S-phase duration of the leukemic population is fitted to 15 
hrs and the whole cell cycle duration to 47 hrs. Moreover, for the 2
nd
 chemotherapy cycle the 
fitted cell cycle times are 15 hrs duration for S-phase and 40 hrs for the whole cell cycle. 
Figure 5.6 presents the leukemic cell dynamics compared with the clinical data for the full 
length treatment of this patient and Table 5.6 lists the leukemic population cell number and 
the clinical data for all the chemotherapy cycles. 
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Figure 5.6: Comparison of simulation results and clinical data for Patient P026 
 
Table 5.6: Leukemic population of Patient P026 based on model analysis and clinical data 
Date 
Leukemic Population 
(model) 
Leukemic Population 
(data) 
1
st
 cycle start date: Day 1 6.75·10
11 
cells  
1
st
 cycle end date: Day 10 1.24·10
7 
cells  
BM Aspirate after 1
st
 Cycle 
Day 48 
4.7·10
8 
cells <1·10
9
 cells 
2
nd
 cycle start date: Day 56 1.05·10
9
 cells  
2
nd 
cycle end date: Day 64 3.8·10
4
 cells  
BM Aspirate after 2
nd
 Cycle 
Day 116 
2·10
6 
cells <1·10
9
 cells  
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Table 5.7: Cell cycle times fitted for the clinical data of 6 patients undergoing LDAC and DA 
protocols (Appendix B) 
 Patient number Ts (hrs)* Tc (hrs)* 
Patients under 
LD protocol 
   
 001 (1
st
 cycle) 13 45 
 
  001 (2
nd
 cycle) 16 40 
 
 001 (3
rd
 cycle) 11 45 
 
 001 (4
th
 cycle) 18 65 
 
 002 (1
st
 cycle) 21 45 
 
 006 (1
st
 cycle) 20 33 
 
  006 (2
nd
 cycle) 14 46 
 
 006 (3
rd
 cycle) 14 68 
 
 006 (4
th
 cycle) 20 40 
 
 016 (2
nd
 cycle) 14 45 
 
Patients under 
DA protocol 
   
 011 (1
st
 cycle) 9 53 
 
 026 (1
st
 cycle) 15 47 
 
  026 (2
nd
 cycle) 15 40 
 
 016 (1
st
 cycle) 10 54 
 
mean  15 47.5 
 
range  (9 – 21) (33 – 68) 
 
 
The results show inter- and intra-patient variability of the cycling times that are different 
between patients and between the chemotherapy cycles of the same patient. The mean 
calculated time for Ts is 15 hrs with a range between (9 -21) hrs and for Tc the mean value is 
47.5 hrs with variability within (33 – 68) hrs.  
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Another observation from the fitted cell cycle results is that the longer Tc times were 
indicative of disease relapse (P001 4
th
 cycle, P006 3
rd
 cycle). This relation between Tc and 
disease increase has a scientific explanation as the longer cycling times are indicative of 
longer GoG1-phase. It is well-reported (Lewin et al., 2007; Komarova, Wodarz, 2005; 
Michor, 2008) that GoG1-phase is a factor related to disease resistance and relapse since cells 
in this phase are not affected by the drugs and they form residual disease after treatment 
completion. The reverse relationship was observed for Ts time where the longer Ts indicated 
lower numbers of leukemic cells. The longer S-phase duration is linked to a higher 
percentage of cells in this phase that respectively increases the probability of the leukemic 
cells to be affected and eradicated by anti-leukemic S-phase specific drugs as DNR and Ara-
C.  
Moreover, a very interesting point in the cell cycle distributions is that patients successfully 
treated under the LDAC protocol are characterised by a shorter Tc duration as compared with 
patients undergoing DA protocol. An interesting fact in clinical practice is that patients who 
receive a low dose of sc treatment may present as good treatment results (that is, induction of 
remission) as do patients who receive much higher doses of DNR and Ara-C intravenously 
administered and who undergo greater toxicity. In order to capture this fact, the model uses a 
lower duration of non-proliferating phase for the cases of patients with successful results of 
low dose Ara-C treatment. Physically, this means that for a patient to be successfully treated 
by a low dose treatment an explanatory scenario is that the majority of his/her cells will be in 
proliferation, thus, susceptible to the drug. 
5.4 Optimal induction treatment design for the studied patients 
 
The aim of remission induction therapy described by the current presented model is to 
achieve the rapid restoration of normal BM function. By treatment completion, the leukemic 
population should be reduced to a level of approximately 10
9 
cells at which point BM 
hypoplasia is achieved. Moreover, the normal population should be higher than that of the 
leukemic population and a 3-log reduction is the maximum permissible level of normal 
population reduction. This optimisation problem is formulated and solved for the patient case 
studies who failed the induction treatment according to the provided clinical data i.e. P001, 
P002, P011, P016, for the case of the DA and LDAC protocols, as well as for the patients 
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with acceptable treatment outcome for whom the optimisation objective is to seek an 
alternative and optimal dosing schedule. 
The required information for each patient case study is the physiological patient 
characteristics and tumour characteristics (initial tumour burden) which are clinically 
provided. Moreover, the cell cycle kinetic information of the S-phase and total cycle duration 
is required which is estimated using the available clinical data and the parameters for each 
patient are listed in Table 5.7 in the previous section.  
For iv Ara-C, total drug administration is set between 50mg – 4000mg, with infusion duration 
between 1 min to 24 hours. The window for DNR dose optimisation is stricter due to 
potential toxic effects and the only independent variable is dose with 30mg – 90mg per 
infusion. For sc Ara-C, the maximum dose per day is 40mg and doses are permitted up to 
four times daily for a maximum period of 20 days (BC cancer agency, 2007; Milligan et al, 
2006).  
 
This optimisation problem was formed and solved using gPROMS (gPROMS, 2003) and the 
optimised treatment protocols for the six studied patient case studies are presented and 
analysed below. 
5.4.1 Optimal personalised chemotherapy protocol for Patient P001  
 
P001 is a patient case study treated with LDAC protocol. Treated according to standard 
clinical practice, this patient‟s disease burden decreased over the first 3 chemotherapy cycles. 
However, over the last cycle there is disease relapse and at the point of the BM aspirate done 
at treatment completion, leukemic cells are as high as at diagnosis. For this patient, the 
optimisation problem is solved and results are listed below for all chemotherapy cycles.  
1
st
 Chemotherapy Cycle 
The optimisation problem for this patient is solved and the suggested protocol for the four 
chemotherapy cycles is to administer 40 mg of Ara-C as daily continuous infusions for 10 
days (Table 5.8). Over this optimal protocol, the total dose will be constant but the dose 
schedule will differ.  
Although the same total dose is used per cycle the optimised protocol succeeds in further 
reducing the leukemic population. Specifically, after the 1
st
 chemotherapy cycle, the leukemic 
130 
 
population is further reduced by 6.25·10
9
 cells and the population equals 3.7·10
9
 cells. This 
reduced population is less than that of the normal population with a difference of 1·10
8
 cells 
(Figure 5.7). 
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Figure 5.7: Patient P001 behaviour over the 1
st
 chemotherapy cycle (days 1-11) and the recovery 
period afterwards (days 11-38) for the simulation and optimisation chemotherapy protocols. 
The dashed line is for the leukemic cell population over the optimised protocol; the straight 
black line is for the leukemic cell over the simulation of the clinical applied protocol; the circle 
signs are for the normal population at the start and end date of the optimisation protocol; the x 
signs are for the normal population at the start and end date of the simulation protocol and the 
grey line represents the BM hypoplasia objective. 
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Table 5.8: Optimal LDAC induction treatment protocol for Patient P001 
 
2
nd
 Chemotherapy Cycle 
The leukemic population is increased to 4.86·10
10
 cells after completion of the 1
st
 
chemotherapy cycle due to the necessary recovery period with no treatment between the two 
cycles. This population is decreased over the 2
nd
 optimised chemotherapy with daily 
infusional doses of 40 mg for 10 days. Leukemic cells are further decreased in the optimal 
protocol compared with that of the simulation protocol and for the optimal schedule, the level 
of leukemic cells is below the hypoplasia level (figure 5.8). In particular, at the end of the 2
nd
 
cycle, the leukemic and normal populations have 9.34·10
7
 and 3.8·10
9
 cells respectively.. 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
SC Ara-C     
1
st
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
2
nd
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
3
rd
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
4
th
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
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Figure 5.8: Patient P001 behaviour over the 2
nd
 chemotherapy cycle (days 38-48) and the 
recovery period afterwards (days 38-71) for the simulation and optimisation chemotherapy 
protocols. The dashed line is for the leukemic cell population over the optimised protocol; the 
straight black line represents leukemic cells over the simulation of the clinically applied 
protocol; the circle signs are for the normal population at the start and end date of the 
optimisation protocol; the x signs are for the normal population at the start and end date of the 
simulation protocol and the grey line represents the BM hypoplasia objective. 
3
rd
 Chemotherapy Cycle 
Figure 5.9 illustrates the cell population dynamics over the simulation and optimisation of the 
3
rd
 chemotherapy cycle. For the simulation protocol, the leukemic population is reduced but 
is higher than that of the normal population indicating that the cycle purpose is not achieved. 
Moreover, BM hypoplasia is not achieved as cells are above the 1·10
9
 cells target. In contrast, 
over the optimisation cycle, the leukemic population is further reduced and is lower than the 
hypoplasia level for the whole length of the treatment and interval period. At cycle 
completion, the leukemic population equals 3.68·10
7
 cells and the normal population is 
3.8·10
9
 making a 2-log difference between the 2 populations. 
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Figure 5.9: Patient P001 behaviour over the 3
rd
 chemotherapy cycle (days 71-81) and the 
recovery period afterwards (days 81-107) for the simulation and optimisation chemotherapy 
protocols. The dashed line represents the leukemic cell population over the optimised protocol; 
the straight black line represents the leukemic cells over simulation of the clinically applied 
protocol; the circle signs are for the normal population at the start and end date of the 
optimisation protocol; the x signs are for the normal population at the start and end date of the 
simulation protocol and the grey line represents the BM hypoplasia objective 
4
th
 Chemotherapy Cycle 
Figure 5.10 presents the normal and leukemic cell population dynamics after the simulation 
and optimisation chemotherapy protocol for the last cycle. Over the optimisation protocol, 
patient treatment outcome is much improved and induction treatment is successful, whereas 
treatment relapse is noted over the simulation protocol. In particular, over the simulation 
protocol, the leukemic population is higher than that of the normal and higher than the BM 
hypoplasia level. At simulation treatment completion, the leukemic population equals 6.7·10
9
 
cells. However, after the optimisation chemotherapy protocol, the leukemic population is 
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further decreased and equals 1.53·10
7
 cells. This population is lower than the desired 
hypoplasia level and also lower than the normal population that equals 3.8·10
9
 cells. 
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Figure 5.10: P001 behaviour over the 4
th
 chemotherapy cycle (days 107-117) and the recovery 
period before the last BM aspirate (days 117-150). The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents the leukemic cells 
during simulation of the clinically applied protocol; the circle and x signs are for the normal 
population at the start and end date of the optimisation and the simulation protocol, 
respectively. 
In summary, for P001, the same total dose is used per cycle for the optimised protocol that 
suggests total doses of 40 mg applied as daily 24 hour sc infusions for 10 days instead of 2 
daily sc bolus doses of 20 mg applied over the clinically applied protocol. This optimisation 
protocol succeeds in further reducing the leukemic population. Specifically, after the 1
st
 
chemotherapy cycle, the leukemic population is further reduced by 6.25·10
9
 cells. This 
reduced population is less than the normal population with a difference of 1·10
8
 cells. The 
reduced leukemic population at completion of the 1
st
 cycle successively affects the initial 
state of the 2
nd
 cycle, that is 4.86·10
10
 cells instead of 1.47·10
11
 cells that was obtained during 
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the simulation results. This reduced population will be further reduced over the remaining 
chemotherapy cycles. By treatment completion, the leukemic population equals 2.9·10
8
 cells 
that is less than the level of BM hypoplasia, equal to 1·10
9
 cells, the objective of induction 
treatment. In contrast, over the simulation results disease relapse is noticed and the leukemic 
population increased to its initial state at diagnosis. Figure 5.11 presents the comparison of 
the simulation and optimisation protocols for the full course of treatment and Table 5.9 lists 
the leukemic and normal cell numbers for each chemotherapy cycle. 
Table 5.9: Leukemic and normal cell populations for P001, over the simulation and optimisation 
treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
2·10
11
 2·10
10
 2·10
11
 2·10
10
 
End of 1
st
 cycle 9.95·10
9
 3.8·10
9
 3.7·10
9
 3.8·10
9
 
Beginning of 2
nd
 
cycle 
1.47·10
11
 2·10
10
 4.86·10
10
 2·10
10
 
End of 2
nd
 cycle 3.8·10
9
 3.8·10
9
 9.34·10
7
 3.8·10
9
 
Beginning of 3
rd
 
cycle 
3.8·10
10
 2·10
10
 8.6·10
8
 2·10
10
 
End of 3
rd
 cycle 6.13·10
9
 3.8·10
9
 3.68·10
7
 3.8·10
9
 
Beginning of 4
th
 
cycle 
8.7·10
10
 2·10
10
 4.35·10
8
 2·10
10
 
End of 4
th
 cycle 6.7·10
9
 3.8·10
9
 1.53·10
7
 3.8·10
9
 
BM aspirate after 
4
th
 cycle 
1.44·10
11
  2.9·10
8
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Figure 5.11: Patient P001 behaviour for the full course of treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell population 
over the optimised protocol; the straight black line represents leukemic cells during simulation 
of the clinically applied protocol; the circle signs are for the normal population at the start and 
end date of the optimisation protocol; the x signs are for the normal population at the start and 
end date of the simulation protocol and the grey line represents the BM hypoplasia objective 
5.4.2 Optimal personalised chemotherapy protocol for Patient P002  
 
P002 is a patient case study treated with the LDAC protocol. For this patient, data are 
available only for the 1
st
 chemotherapy cycle (Appendix B). Over this cycle, leukemic cells 
are decreasing and by cycle completion, normal cells are higher than leukemic cells as shown 
in the simulation results in Table 5.2. The optimisation problem for this case study would be 
to possibly achieve BM hypoplasia from the 1
st
 chemotherapy cycle. 
This optimisation problem is solved and the protocol suggests 40 mg of Ara-C as daily 24 
hour continuous infusions sc for 13 days (Table 5.10).  
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Table 5.10: Optimal LDAC induction treatment protocol for Patient P002 
This protocol suggests an increase of the total dose by 120 mg (i.e. total dose of 520 mg). 
This increased dose load and the optimal continuous drug schedule results in a further 
reduction of the leukemic population (Figure 5.12). Specifically, a further reduction of the 
leukemic population is achieved with a difference of 5.6·10
8
 cells (Table 5.11). The normal 
population is reducing as well and there is a cost of 1.2·10
9
 cells less over the optimised 
protocol. However, BM hypoplasia is achieved with 1·10
9
 cells making a difference of 
3.68·10
10
 cells less when compared with that of the simulation results (Table 5.11). 
Table 5.11: Leukemic and normal cell populations for P002, over the simulation and 
optimisation induction treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
7.9·10
11
 1.68·10
10
 7.9·10
11
 1.68·10
10
 
End of 1
st
 cycle 8.6·10
8
 3.2·10
9
 3·10
8
 2·10
9
 
BM aspirate after 
1
st
 cycle 
3.78·10
10
  1·10
9
  
 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
SC Ara-C     
1
st
 Cycle 40 mg 24-hr SC One daily application for 
days 1-13 
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Figure 5.12: Patient P002 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. Duration of the simulation protocol is 10 days from days 
(1-11) and the end is indicated by a vertical straight line. The vertical dashed line indicates the 
end of the optimisation cycle with 13 days duration. The dashed line represents the leukemic cell 
population over the optimised protocol; the straight black line represents leukemic cells during 
the simulation of the clinically applied protocol; the circle signs are for the normal population at 
the start and end date of the optimisation protocol; the x signs are for the normal population at 
the start and end date of the simulation protocol and the grey line represents the BM hypoplasia 
objective 
5.4.3 Optimal personalised chemotherapy protocol for Patient P006  
 
P006 has a successful treatment outcome with the LDAC protocol. This patient presents a 3-
log leukemic population reduction over the 1
st
 chemotherapy cycle where leukemic cells are 
reduced to 2.15·10
8
 cells and the normal population is reduced to 5·10
9
 cells. Therefore, 
treatment is effective from the 1
st
 cycle since leukemic cells are below the desired hypoplasia 
level and below the normal population level. For  the succeeding three chemotherapy cycles, 
the leukemic population is further reduced and by the time of the BM aspirate after the 4
th
 
139 
 
chemotherapy cycle, the leukemic population equals 9.7·10
8
 cells which is close to, but less 
than, the desired hypoplasia level.  
Since, treatment is successful for this patient, the objective of the optimisation is to optimise 
the treatment schedule while keep the same total drug load as that used in the clinically 
applied protocol i.e. 40 mg of sc Ara-C daily for 10 days. As in the case of the previously 
optimised patients undergoing LDAC treatment, the optimisation results suggest that for the 4 
chemotherapy cycles a daily sc continuous infusion of 40 mg for 10 days is ideal (Table 
5.12).  
Table 5.12: Optimal LDAC induction treatment protocol for Patient P006 
Table 5.13: Leukemic and normal cell populations for P006, over the simulation and 
optimisation induction treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
3.4·10
11
 2.64·10
10
 3.4·10
11
 2.64·10
10
 
End of 1
st
 cycle 2.15·10
8
 5·10
9
 6.9·10
6
 5·10
9
 
Beginning of 2
nd
 
cycle 
6.13·10
9
 2.64·10
10
 1.55·10
8
 2.64·10
10
 
End of 2
nd
 cycle 6.4·10
8
 5·10
9
 3.1·10
6
 5·10
9
 
Beginning of 3
rd
 
cycle 
5.87·10
9
 2.64·10
10
 2.56·10
7
 2.64·10
10
 
End of 3
rd
 cycle 1.46·10
9
 5·10
9
 2.5·10
6
 5·10
9
 
Beginning of 4
th
 
cycle 
1.89·10
10
 2.64·10
10
 3·10
7
 2.64·10
10
 
End of 4
th
 cycle 6.77·10
7
 5·10
9
 8641 5·10
9
 
BM aspirate after 
4
th
 cycle 
9.7·10
8
  1.05·10
5
  
 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
SC Ara-C     
1
st
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
2
nd
 Cycle 40 mg 24-hr SC  One daily application for 
days 1-10 
3
rd
 Cycle 40 mg 24-hr SC  One daily application for 
days 1-10 
4
th
 Cycle 40 mg 24-hr SC  One daily application for 
days 1-10 
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Table 5.13 lists the leukemic and normal population cell number throughout the simulation 
and optimisation protocols and figure 5.13 presents the cell dynamics over the two protocols 
(simulation and optimisation).  
At the end of the 1
st
 chemotherapy cycle using the optimisation protocol, the leukemic 
population is further reduced to 6.9·10
6
 cells, making a difference of 2.08·10
8
 cells less 
compared with that of the simulation protocol. In contrast, the normal population is similar 
under both the simulation and the optimisation protocol. This is a result noted and explained 
for all the previous patient case studies for which no increase of dose load was suggested. 
This is due to the assumption made for the normal cell population that the majority of cells 
exist in the non-proliferating state with the ability to enter the cell proliferation state when 
population depletion occurs. For the cases when the same dose load is administered with 
changed schedule, proliferating cells will reduce more quickly but non-proliferating cells will 
replace this loss. Thus difference in the population of normal cells is noticed only for a 
different dose load.   
After, the interval period, the leukemic population is increased and equals 1.55·10
8
 cells for 
the optimisation case, whereas the normal population is equal to the initial population (at 
diagnosis) since full population recovery is assumed for the interval period. During the 2
nd
 
chemotherapy cycle, the leukemic population is reduced and at cycle completion equals 
3.1·10
6
 cells, that is 6.4·10
8
 cells less compared with that of the simulation protocol. The 
reduced leukemic population combined with successive rounds of optimal chemotherapy 
cycles results in a difference in the initiating leukemic population burden at the beginning of 
the 3
rd
 chemotherapy cycle. For the optimisation protocol, the leukemic cell population 
equals 2.56·10
7
 cells, whereas for the simulation protocol it is 5.87·10
9
 cells. At completion 
of the optimisation cycle, the leukemic population for the optimisation protocol equals 
2.5·10
6
 cells making a difference of 1.45·10
9
 cells compared with that of the simulation 
protocol. By completion of the 4
th
 and last chemotherapy cycle, the leukemic population 
equals 8641 cells for the optimisation protocol and 6.8·10
7
 for the simulation protocol. 
Moreover, at the last BM aspirate sample analysis, the leukemic population will be 1.05·10
5
 
cells for the optimisation protocol and 9.7·10
8
 cells for the simulation protocol. This 
difference in the cell population is impressive especially if we consider that the same dose 
load is applied with a different dosing schedule and demonstrates the usefulness of 
optimisation technique for treatment design. Comparison of P006 cell dynamics for the two 
protocols is illustrated in figure 5.13. 
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Figure 5.13: Patient P006 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell population 
over the optimised protocol; the straight black line represents leukemic cells during simulation 
of the clinically applied protocol; the circle signs are for the normal population at the start and 
end date of the optimisation protocol; the x signs are for the normal population at the start and 
end date of the simulation protocol and the grey line represents the BM hypoplasia objective  
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5.4.4 Optimal personalised chemotherapy protocol for Patient P011  
 
Patient 011 is a patient case study treated with the DA protocol and results of the 1
st
 
chemotherapy cycle are only available for model analysis. As shown in the simulation results 
(Table 5.15), with the clinically applied protocol, this patient case study shows reduction of 
the leukemic population and leukemic cells are less than normal cells. The optimisation 
problem for this case study is to further minimise the leukemic population in order to reach 
BM hypoplasia from the 1
st
 chemotherapy cycle. This problem is solved and the optimal 
protocol suggests 250 mg/m
2
 of continuous daily iv infusions of Ara-C for 10 days combined 
with 90 mg/m
2
 of DNR administered as bolus doses on days 1,3 and 5 (Table 5.14). 
Table 5.14: Optimal DA induction treatment protocol for Patient P011 
This is a more toxic chemotherapy protocol as the daily amount of Ara-C is increased by 50 
mg/m
2
, which gives a total dose load increase of 500 mg/m
2
 over 10 days and the total 
increase for DNR is 90 mg/m
2
. By chemotherapy cycle completion over the optimised 
protocol, a further reduction of the leukemic population is achieved with a difference of 
1.02·10
8
 cells (Table 5.15). The normal population is reducing as well and there is a cost of 
1.29·10
8
 cells less over the optimised protocol. However, BM hypoplasia is achieved (figure 
5.14) at the point of the BM aspirate where leukemic cells equal 1·10
9
 cells and there is a 
difference of 5·10
9
 cells less compared with that of the simulation results (Table 5.15).  
 
 
 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
DA protocol     
DNR 90 
mg/m
2 
1 hr IV One daily applications on 
days 1, 3 and 5  
Ara-C 250 
mg/m
2 
24-hr IV 1 daily application, for days 
1-10 
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Table 5.15: Leukemic and normal cell populations for P011, over the simulation and 
optimisation induction treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
5.32·10
11
 2.12·10
10
 5.32·10
11
 2.12·10
10
 
End of 1
st
 cycle 1.63·10
8
 3.79·10
8
 6.1·10
7
 2.5·10
8
 
BM aspirate after 
1
st
 cycle 
6·10
9
  1·10
9
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Figure 5.14: Patient P011 behaviour for the full length treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell population 
over the optimised protocol; the straight black line represents leukemic cells during simulation 
of the clinically applied protocol; the circle signs are for the normal population at the start and 
end date of the optimisation protocol; the x signs are for the normal population at the start and 
end date of the simulation protocol and the grey line represents the BM hypoplasia objective 
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5.4.5 Optimal personalised chemotherapy protocol for Patient P016  
 
Patient 016 was treated with the DA protocol for the 1
st
 chemotherapy cycle and with LDAC 
for the 2
nd
 cycle due to clinical complications during treatment. As shown in the simulation 
results, this patient has a reduction of the leukemic burden from the 1
st
 chemotherapy cycle 
and normal cells are higher than leukemic cells. However, by the completion of the 2
nd
 cycle, 
residual disease exists and BM hypoplasia is not achieved. For this reason the optimisation 
problem is solved for both chemotherapy cycles.  
1
st
 Chemotherapy Cycle 
For the 1
st
 chemotherapy cycle, Ara-C is suggested to be continuously administered over 24 
hour daily infusions iv. The total dose of Ara-C is kept constant to what was used in the 
simulation protocols i.e. 200 mg/m
2
 daily dose load. For DNR the same schedule is followed 
with a dose increase to 90 mg/m
2
 (Table 5.16).  
Table 5.16: Optimal schedule of the 1
st
 chemotherapy cycle for Patient P016 
Under this chemotherapy protocol, the leukemic population is further minimised and by 
completion of the 1
st
 cycle, the leukemic population is 2.43·10
8
 cells less with a cost of 
2.3·10
8
 normal cells (figure 5.15).  
 
 
 
 
 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
DA protocol     
DNR 90 
mg/m
2 
1 hr IV One daily applications on 
days 1,3 and 5  
Ara-C 200 
mg/m
2 
24-hr IV 1 daily application, for days 
1-10 
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Figure 5.15: Patient P016 behaviour over the 1
st
 chemotherapy cycle (days 1-11) and the 
recovery period prior the 2
nd
 chemotherapy cycle (days 11-67). The dashed line represents the 
leukemic cell population over the optimised protocol; the straight black line represents leukemic 
cells during simulation of the clinically applied protocol; the circle signs are for the normal 
population at the start and end date of the optimisation protocol; the x signs are for the normal 
population at the start and end date of the simulation protocol and the grey line represents the 
BM hypoplasia objective 
2
nd
 Chemotherapy Cycle 
For the 2
nd
 chemotherapy protocol, the schedule suggested includes daily doses of 40 mg of 
Ara-C applied as daily 24 hour sc continuous infusions for 10 days (Table 5.17).  
Table 5.17: Optimal LDAC induction treatment protocol for Patient P016 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
SC Ara-C     
1
st
 Cycle 40 mg 24-hr SC One daily application for 
days 1-10 
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Figure 5.16 presents the normal and leukemic cell dynamics. The leukemic population has a 
further decrease of 3.2·10
8
 cells and the normal population remains at the same order of 
magnitude. This is expected if we consider that the normal population consists of 
proliferating cells susceptible to the treatment and quiescent cells serving as back-up cells at 
times of BM depletion. Since the transition rate of quiescent cells depends on the population 
depletion, the population will be adjusted to the loss and the transition rate will be adapted to 
keep the population constant. For the optimal protocol, since dose injection rate is lower and 
constant over the optimal treatment protocol, it will enable a constant transition of quiescent 
cells to enter proliferation that will result in a more rigid normal cell population recovery 
over this protocol. Moreover, by treatment completion, the leukemic population is reduced by 
3.3·10
9
 cells resulting in BM hypoplasia as the final population is lower than the 1·10
9
 cells 
limit (Table 5.18). 
Table 5.18: Leukemic and normal cell populations for P016, over the simulation and 
optimisation DA followed by LDAC treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
8.55·10
11
 2.83·10
10
 8.55·10
11
 2.83·10
10
 
End of 1
st
 cycle 3.29·10
8
 5.5·10
8
 8.6·10
7
 3.2·10
8
 
Beginning of 2
nd
 
cycle 
7.62·10
10
 2.83·10
10
 1.82·10
10
 2.83·10
10
 
End of 2
nd
 cycle 3.96·10
8
 5.39·10
9
 7.6·10
7
 5.35·10
9
 
BM aspirate after 
2
nd
 cycle 
4·10
9
  7·10
8
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Figure 5.16: Patient P016 behaviour over the 2
nd
 chemotherapy cycle (days 67-77) and the 
recovery period prior to the BM aspirate at treatment completion (days 77-100). The dashed 
line represents the leukemic cell population over the optimised protocol; the straight black line 
represents leukemic cells during simulation of the clinically applied protocol; the circle signs are 
for the normal population at the start and end date of the optimisation protocol; the x signs are 
for the normal population at the start and end date of the simulation protocol and the grey line 
represents the BM hypoplasia objective 
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5.4.6 Optimal personalised chemotherapy protocol for Patient P026  
 
Patient 026 received two chemotherapy cycles of the DA protocol and had a successful 
treatment outcome. Specifically, this patient received one cycle of 10 days with rapid 
infusion boluses of 80 mg/m
2
 of Ara-C twice a day for 10 days and doses of 70 mg/m
2
 of 
DNR iv over 1 hour on days 1, 3 and 5. The 2
nd
 chemotherapy cycle lasted for 8 days with 
doses of Ara-C 80 mg/m
2
 administered every 12 hours iv bolus and a decreased dose of DNR 
equal to 40 mg/m
2 
administered again on days 1, 3 and 5 by iv infusion over 1 hour. The 
leukemic population according to the clinical data is decreasing and by completion of the 2
nd
 
chemotherapy cycle BM hypoplasia is achieved. Since chemotherapy treatment is successful 
for this patient, the optimisation problem is to use the same dose load and propose the 
optimal treatment schedule. As in the previous patient case studies, the results of this 
optimisation problem suggest continuous dose administration of Ara-C by 24 hour infusion 
and the same 3 day iv schedule for DNR (Table 5.19). 
Table 5.19: Optimal schedule of the full-length treatment for Patient P026 
 
Table 5.20 below lists the leukemic and normal cell population in numbers during the 
simulation and the optimisation protocol, whereas figure 5.17 demonstrates the cell 
population dynamics during the two protocols. 
Protocol Dose 
Load 
Dose 
Duration 
Application 
route 
Application Schedule 
1
st
 Cycle      
DNR 70 
mg/m
2 
1 hr IV One daily applications on 
days 1,3 and 5  
Ara-C 160 
mg/m
2 
24-hr IV 1 daily application, for days 
1-10 
2
nd
 Cycle     
DNR 40 
mg/m
2 
1 hr IV One daily applications on 
days 1,3 and 5  
Ara-C 160 
mg/m
2 
24-hr IV 1 daily application, for days 
1-8 
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Table 5.20: Leukemic and normal cell populations for P026, during the simulation and 
optimisation DA treatment protocols 
Date 
Leukemic 
population over 
simulation 
Normal 
population 
over 
simulation 
Leukemic 
population over 
optimisation 
Normal 
population over 
optimisation 
Beginning of 1
st
 
cycle 
6.75·10
11
 3.38·10
10
 6.75·10
11
 3.38·10
10
 
End of 1
st
 cycle 1.25·10
7
 4.52·10
8
 8.05·10
6
 4.52·10
8
 
Beginning of 2
nd
 
cycle 
1·10
9
 3.38·10
10
 2.66·10
8
 3.38·10
10
 
End of 2
nd
 cycle 3.8·10
4
 9.97·10
8
 6030 9.97·10
8
 
BM aspirate after 
the 2
nd
 cycle 
2·10
6
  8.4·10
5
  
 
As shown in figure 5.17, the optimisation protocol leads to a better treatment outcome 
compared with that of the simulation protocol. After the 1
st
 chemotherapy protocol, the 
leukemic population is reduced to 8.05·10
6
 cells, making a difference of 4.4·10
6
 cells less 
than the clinically applied (simulation) protocol. Furthermore, the residual disease after the 
2
nd
 cycle with the optimisation protocol is 6030 cells and with the simulation is 3.8·10
4
 cells. 
At the point of the BM aspirate after treatment completion, the leukemic population for the 
optimisation protocol is 8.4·10
5
 cells making a difference of 1.16·10
6
 cells less than the final 
outcome from the simulation protocol. As far as the normal population is concerned, the 
simulation and optimisation cycles present the same results. As explained earlier, the normal 
cell population is dose-dependent i.e. the population dynamics will differ for protocols of 
different toxicity and not for protocols with same dose load and different schedule of 
administration. This point is apparent in this patient case study where normal population 
dynamics differ between the simulation and optimisation results for the 1
st
 chemotherapy 
cycle where there is a dose increase for the optimisation protocol. However, normal 
population results are the same for the simulation and optimisation of the 2
nd
 chemotherapy 
cycle where the same dose load is applied under different schedule.   
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Figure 5.17: Patient P026 behaviour for the full course of treatment over the simulation and 
optimisation chemotherapy protocols. The dashed line represents the leukemic cell population 
over the optimised protocol; the straight black line represents leukemic cells during simulation 
of the clinically applied protocol; the circle signs are for the normal population at the start and 
end date of the optimisation protocol; the x signs are for the normal population at the start and 
end date of the simulation protocol and the grey line represents the BM hypoplasia objective 
5.5 Cytarabine (Ara-C) is more effective when given in continuous daily 24-
hour infusions than in short 12-hourly infusions 
 
For all the patient case studies undergoing treatment simulations with both the LDAC and the 
DA protocols, the optimal schedule for administration of Ara-C is the daily continuous 24 
hour infusions of the drug rather than the short bolus 12-hourly doses. The difference in the 
effectiveness of the two protocols (continuous vs short bolus doses) is due to the different 
concentration profiles in the BM.  
In figure 5.18, the concentration profile of Ara-C in BM is presented for the first day after the 
administration of two short bolus doses of 20 mg every 12-hrs and after the application of 1 
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daily dose of 40 mg as continuous 24 hour infusion, both schedules given sc. In the standard 
protocol, there are high concentration peaks at the point of dose administration which 
thereafter exponentially decrease (figure 5.18). In contrast, during the optimised treatment 
protocol a constant infusion rate is suggested for Ara-C that is lower compared with the peaks 
of the standard treatment protocol but is of longer duration. This difference in the schedule 
will provoke different dynamics in the cell population and especially the cells in S-phase 
where the drug acts. 
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Figure 5.18: Comparison of the concentration profile in BM over the 1
st
 day of the LDAC 
standard protocol and over the optimised protocol 
In figure 5.19, the dynamics of cells in S-phase are presented for the 1
st
 day of the standard 
and optimised protocols. Cells in S-phase are decreasing sharply after the first dose 
application but as the drug concentration declines, the cell population starts increasing and 
thereafter decreases again due to the second dose application. In contrast, during the 
optimised protocol, the cell population decreases at a slower rate compared with that of the 
standard protocol. However, the drug concentration is constantly present in the S-phase 
population that results in a constant death rate due to drug action and so there are no 
oscillations in the dynamics of the S-phase population. Leukemic cells in this phase over the 
optimised protocol are continuously decreasing and by the end of the 1
st
 day, the leukemic 
cell population reaches a lower state compared with that of the standard treatment protocol.  
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Figure 5.19: S-phase dynamics over the 1
st
 day of the LDAC standard protocol and over the 
optimised protocol. The straight black line represents the model simulation of the standard 
protocol and the grey dashed line represents the optimisation results. Over the continuous daily 
infusions of Ara-C for the optimised protocol, a constant concentration profile is maintained 
that results in a continuous death rate of cells in S-phase which, from the end of the 1
st
 day, 
reach a lower state compared with that of the simulation results of standard treatment. 
  
5.6 Concluding Remarks 
 
For model analysis, clinical data of 6 patients who underwent chemotherapy are used for the 
estimation of cell cycle time distribution. The patient data is comprised of disease 
characteristics (tumour burden, cell cycle times, normal cell population) as well as patient-
specific characteristics (gender, age, weight and height). The estimated mean S-phase 
duration (Ts) is 15 hrs (range: 9-21 hrs) and mean whole cell cycle duration (Tc) is 47.5 hrs 
(range: 33-68 hrs).  
The estimated data reveals a clear relationship of cell cycle times to treatment outcomes. 
Specifically, low Ts duration combined with high Tc duration indicates worse treatment 
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outcomes, whereas the reverse combination is indicative of a good response to treatment. 
This patient variability in tumour kinetics and its effect on the diverse patient clinical 
outcome has been experimentally tested and proven elsewhere (Stryckmans et al., 1970; 
Cheung et al., 1972; Hayes et al., 1977; Raza et al., 1987; Lampkin et al., 1969; Preisler et al., 
1993; Chiorino, Lupi, 2002). 
In order to improve the effectiveness of AML therapy and reduce its toxicity, treatment with 
chemotherapy is presented as an optimal control problem with the main aim of obtaining a 
treatment schedule which maximises leukemic cell, kill yet minimises death of the normal 
cell population in the BM. By the end of treatment, the leukemic population should be 
reduced to a level of approximately 10
9 
cells at which point BM hypoplasia is also achieved.  
Out of the 6 patients studied, 2 patients had a successful treatment with leukemic hypoplasia 
achieved, 2 had a reduction of leukemic cells without achieving the hypoplasia target and two 
had disease progression on chemotherapy. The optimisation algorithm is formulated and 
solved for all patients for both intensive and non-intensive treatment protocols with maximal 
and minimal thresholds set for efficacy and toxicity, respectively. For iv Ara-C, total drug 
administration is set between 50mg – 4000mg with infusion duration between 1 min to 24 
hours. The window for DNR dose optimisation is stricter due to potential toxic effects and the 
only independent variable is dose with 30mg – 90mg per infusion. For sc Ara-C, the 
maximum dose per day is 40mg and doses are permitted up to four times daily for a 
maximum period of 20 days. 
Optimisation results obtained for the 6 patients indicate that continuous infusions are more 
effective for leukemia cell kill than are rapid infusions. For non-intensive chemotherapy, 
40mg of Ara-C in continuous infusion sc is better than daily divided doses with BM leukemic 
hypoplasia achieved for all patient case studies. For the intensive protocol, dose increase of 
DNR to 90 mg/m
2
 combined with Ara-C daily infusion iv is the optimal chemotherapy 
regimen. Ara-C doses differ between patients and the optimal dose range is between 200 to 
250 mg/m
2
.  
Using the optimisation protocol, the leukemic cell population is further reduced and the 
treatment outcome is improved. The reason for this difference in the cell population dynamics 
for the different dosing schedule is due to the effect that schedule has on the Ara-C 
concentration profile. For the Ara-C continuous infusion, the concentration profile will 
increase and reach a peak that will be constant for the full length treatment. The existence of 
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sufficient drug concentration constantly at the tumour location causes constant cell death 
which, according to the model, leads to higher death of the leukemic population in total as 
compared with that of the simulation results in which short bolus doses of higher dose load 
are used. Appendix C includes the cell population profiles of cells in the S-phase, GoG1- 
phase and G2M-phase for all patients. This difference in the cell dynamics of the cell phases 
is clearly shown since, during the constant drug dosing, the cells in S-phase are further 
minimised which in turn reduces cells in the two other cell cycle compartments successively.   
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Chapter 6 
Conclusions and Future Directions 
 
6.1 Project Summary  
 
We have developed a model for the simulation of patients with AML undergoing treatment 
with two standard chemotherapy protocols, one intensive and the other non-intensive: (a) 
Daunarubicin (DNR) and Cytosine Arabinoside (Ara-C) used in standard intravenous (iv) 
doses (DA 3+10) and (b) low dose Ara-C (LDAC) administered subcutaneously (sc).  
The model has been implemented in the gPROMS environment (gPROMS, 2003) and 
consists of a model simulator and an optimiser. The requiring information as input for both 
the simulator and the optimiser consist of patient, disease and drug information. Patient 
information includes the physiological patient characteristics of sex, age, weight, height, 
whereas disease information is the clinically available BM information such as the blast 
percentage in the marrow aspirate and the BM cellularity. As extra information to what is 
currently used in clinical practice, the cell cycle characteristics of the S-phase duration and 
the total cell cycle duration were used. Moreover, PK information of drug elimination rate in 
the liver and kidneys is required as is available in the product specification supplied by the 
pharmaceutical company producing this drug. PD information is also required that consist of 
the fitted parameters of the measured drug effect on the cell cycle population and are the drug 
concentration at the maximum PD effect together, the concentration at the half of the 
maximum effect and the slope parameter that is a scale factor affecting the shape of the 
curve.  
The developed mathematical model is afterwards used as a system for sensitivity analysis 
between the cell cycle, the PK and PD parameters in order to identify the crucial factor that 
mainly affects the clinical treatment outcome. Inter-patient variability bounds are collected 
from the literature for the cell cycle, PK and PD parameters. Sensitivity analysis results show 
the cell cycle times as the crucial model parameters that highly affect the disease treatment 
outcome.  
The developed mathematical model is used for various simulation analyses under two 
chemotherapy protocols of chemotherapy induction treatment for AML, one intensive and the 
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other non-intensive: (a) DNR and Ara-C used in standard intravenous (iv) doses (DA 3+10) 
and (b) low dose Ara-C (LDAC) administered sc.  
For the clinical data, the project is submitted and approved by the North West London 
Hospitals Trust for the provision of health records of patients diagnosed with AML and 
treated within Northwick Park Hospital using DNR and Ara-C anti-leukemic agents under 
either i.v. or sc doses applied (protocols available in Appendix B). For the patient data, the 
duration of the cell cycle phases were fitted using the leukemic cell population numbers 
derived by the given patient blast percentage of the BM aspirate. The patient data is 
comprised of disease characteristics (tumour burden, cell cycle times, normal cell population) 
as well as patient-specific characteristics (gender, age, weight and height). The estimated 
mean S-phase duration (Ts) is 15 hrs (range: 9-21 hrs) and mean whole cell cycle duration 
(Tc) is 47.5 hrs (range: 33-68 hrs). The estimated data reveal a clear relationship of cell cycle 
times to treatment outcomes. Specifically, low Ts duration combined with high Tc duration 
indicates worse treatment outcomes, whereas the reverse combination is indicative of a good 
response to treatment.  This patient variability in tumour kinetics and its effect on the diverse 
patient clinical outcome has been experimentally tested and proven elsewhere (Stryckmans et 
al., 1970; Cheung et al., 1972; Hayes et al., 1977; Raza et al., 1987; Lampkin et al., 1969; 
Preisler et al., 1993; Chiorino, Lupi, 2002). This relationship between Tc and disease increase 
has a scientific explanation as the longer cycling times indicate longer GoG1-phase. It is 
well-reported (Lewin et al., 2007; Komarova, Wodarz, 2005; Michor, 2008) that GoG1-phase 
is a factor related to disease  resistance and relapse since cells in this phase are not affected 
by the chemotherapy drugs and form residual disease after treatment completion. The reverse 
relationship was observed for Ts time where the longer Ts indicated lower leukemic cell 
numbers. The longer S-phase duration is linked to a higher percentage of cell population in 
this phase that respectively increases the probability of the leukemic cells to be affected and 
eradicated by anti-leukemic S-phase specific drugs as DNR and Ara-C. 
The aim of remission-induction therapy described by the current presented model is to 
achieve the rapid restoration of normal BM function. By treatment completion, the leukemic 
population should be reduced to a level of approximately 10
9 
cells, at which point BM 
hypoplasia is achieved. Moreover, the normal population should be higher than the leukemic 
population and a 3-log reduction is the maximum permissible level of population reduction. 
This optimisation problem is formulated and solved for both of the chemotherapy protocols 
studied, the intensive and non-intensive protocols. 
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The optimisation results suggest that continuous dose infusions are more effective than short 
bolus doses in terms of the treatment outcome. This is due to the fact that over the continuous 
dose administration, the anti-leukemic agent is constantly present at the site of the tumour 
population resulting in a constant death rate due to drug action.  
However, the purpose of the current work is not to make an implication for improvement of 
the current medical processes but to show the benefits of an automated system for the 
chemotherapy treatment design. This automated system would give the opportunity to the 
clinician to insert the required information in terms of patient and disease characteristics then 
select the drug and regimen used for the treatment and either simulate an existing protocol or 
use the optimisation option to derive an optimal suggested treatment protocol.  
The end-user of such an automated system will have a tool (a) to simulate and compare the 
endpoints of specific treatment protocols, (b) to track and audit a patient‟s real-time outcome 
with treatment, (c) to empower and enable patients to directly input and influence their own 
treatment programme (e.g. input of side effects and real-time quality of life data) and, (d) to 
calculate and apply the optimal treatment schedule using the integrated optimiser based on 
patient- and leukemia-specific input data with the ultimate result of improved treatment 
outcomes. 
6.2 Key Contributions 
 
The contributions of the work presented in this thesis can be summarised as follows: 
 A mathematical model able to capture AML and normal cell dynamics under 
chemotherapy has been developed. Tumour-specific characteristics, such as tumour 
burden and cell cycle times, as well as patient-specific characteristics, such as gender, 
age, weight and height, are incorporated into the model to gain insights into the cell 
dynamics for the studied patients during treatment. 
 Simulation results are obtained for  patients with AML undergoing treatment with two 
standard chemotherapy protocols, one intensive and the other non-intensive: (a) DNR 
and Ara-C used in standard intravenous (iv) doses (3+10) and (b) low dose Ara-C 
(LDAC) administered subcutaneously (sc). 
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 Sensitivity analysis has been used to identify cell cycle times as the critical personal 
parameters that control the treatment outcome. 
 The project is submitted and approved by the North West London Hospitals Trust for 
the provision of health records of patients diagnosed with AML and treated within 
Northwick Park Hospital using DNR and Ara-C anti-leukemic agents under either 
intravenous (i.v.) or subcutaneous (sc) doses applied. The patient data is comprised of 
disease characteristics (tumour burden, cell cycle times, normal cell population) as 
well as patient-specific characteristics (gender, age, weight and height). 
 The clinical data are used for parameter estimation of the cell cycle times for each 
patient case. The estimated data reveal a clear relationship of cell cycle times to 
treatment outcomes. Specifically, low Ts duration combined with high Tc duration 
indicates worse treatment outcomes, whereas the reverse combination is indicative of 
a good response to treatment. 
 Treatment with chemotherapy is presented as an optimal control problem with the 
main aim of obtaining a treatment schedule which could maximise leukemic cell kill 
yet minimise death of the normal cell population in the BM. By the end of treatment, 
the leukemic population should be reduced to a level of approximately 10
9 
cells at 
which point BM hypoplasia is achieved. The optimisation problem is solved for all 
the studied patients and an optimal treatment protocol is proposed for each case study 
revealing the potential for improved treatment design in AML therapy, dependent on 
disease and patient characteristics, defined on a case-by-case basis.    
6.3 Future Directions  
 
6.3.1 Model elaboration 
 
To obtain a more specific and validated model that is further individually adapted to the 
patient, extra experimental data sets gained by experiments on primary leukemic samples are 
needed. The outcome of these experiments will be specific knowledge concerning the cell 
cycle times of each patient sample together with the pharmacodynamics, toxicity and 
efficacy, of the drugs used. The core of such an experimental design is the leukemic 
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biomimicry, 3D hollow fibre bioreactor, that has been already designed by the group of Prof. 
Mantalaris and Dr Panoskaltsis, BSEL group in Imperial College of London. This bioreactor 
is able, by using a patient BM sample to analyse and estimate in vitro the cell cycle 
distribution and the duration of each cycling phase for a particular patient. In that sense the 
measured cell cycle data will be used together with the clinical performance of the patient in 
order to validate the developed mathematical model. 
Moreover, experiments in the 3D bioreactor will allow the patient‟s BM samples to be tested 
undergoing chemotherapy. Such an experiment would mimic the chemotherapy process in 
vitro and would provide the PD action of the drug on the patient sample that could further 
validate the PD model used. From the acquired knowledge on the pharmacodynamic 
properties of the drugs and the cell cycle, a validated patient–specific and leukaemia–specific 
model will be derived. To close-the-loop, the experimental device can be used for the design 
of an experiment where the optimal personalised protocol will be applied in vitro and the 
optimisation results will be validated.  
Lastly experimental analysis of the patient BM sample will provide the necessary insight into 
the cell cycle, the drug metabolic activity when it enters the cell and the drug mechanism of 
action. These data are not yet available from clinical practice and the information is not 
sufficient in order to develop a detailed mathematical model.  Therefore in vitro experiments 
are required to obtain individual properties of the dominating phenomena (toxicities and 
efficacies).  
 
The combination of mathematical modelling and experimental design will lead to a more 
elaborate version of the developed mathematical model describing cell dynamics during 
chemotherapy treatment for AML which can be expanded to analyse all different types of 
leukemia i.e. ALL, CLL and CML. The proposed platform, illustrated in figure 6.1, would 
help (a) to validate the developed model, (b) to further elaborate this model by including 
more complex phenomena, e.g. drug resistance, that relate patient and disease characteristics 
to treatment outcome and (c) develop this system for other types of leukemia disease, such as 
CLL, CML and ALL.  
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Figure 6.1: Schematic representation of the proposed closed loop system for the design of 
optimal patient- and leukaemia-specific chemotherapy protocols 
6.3.2 The ChemoApp 
 
More than $50b (£32b) is spent annually by large pharmaceutical companies to develop and 
bring new drugs to market (Paul et al., 2010), a process which on average takes 13.5 years (in 
2007). Pre-clinical development accounts for approximately 32% of this cost with 
approximately 63% attributed to bringing the new drug through Phase I-III clinical trials (not 
including costs for exploratory discovery research, post-launch expenses or overheads (Paul 
et al., 2010)). Even if a drug is found to be effective in a clinical trial setting, the efficacy in 
clinical practice may be quite different (Eichler et al., 2010). More than half of 
pharmaceutical drugs coming through the pipeline do not pass Phase I clinical trials either 
due to failure of drug, failure of clinical trial design or failure of drug dose and schedule 
(Thomas, Baker, 2007). These failures not only represent a high cost to the pharmaceutical 
industry and the international healthcare economy, but more importantly also incur high 
personal cost to patients with incurable and debilitating illnesses, such as cancers, which 
currently have inadequate therapy. An ordered and cost-effective strategy to bring such 
drugs to market and use them in appropriately selected patients, e.g. in appropriate model 
systems with the use of molecular and genomic data from the patient and the tumour 
(Rooij, Marsh, 2011; Gonzalez-Angulo, 2010), would enable and justify healthcare costs in 
a market that desperately needs rationalisation.  
Towards this objective, a mathematical tool has been developed and presented in the current 
project as the result of an Advanced ERC grant award (MOBILE-ERC Advanced Grant, 
No:226462), that integrates patient and disease characteristics, to determine the 
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chemotherapeutic effect of a treatment schedule on the patient. The already developed model 
and more elaborated versions will serve as basis for the development of an automated 
advanced tool, i.e., ChemoApp, for the design of optimal personalised treatment protocols 
for acute and chronic leukemia. This tool will provide the ability to simulate and compare 
different treatment protocols, generate an optimal treatment schedule for a patient case study 
and audit patient performance under treatment. Such software will benefit through the: 
(i) Provision to the physician with advice during the treatment design as well as 
investigating the progress of the disease. 
(ii) Ability to the patients to follow their treatment step by step. 
(iii) Improvement in the nationalised healthcare system and the private sector by 
the reduced cost stemming from the more accurate calculated drug doses, the 
limitation of hospital stays, reduction of hospital resources and long-term 
health effects of treatment. 
(iv) Personalisation of the treatment based on tumour and patient-specific data. 
The proposed ChemoApp will be a tool containing: 
 A library of models for both types of leukemia, acute and chronic; 
 Computational engines for optimisation, simulation and parameter estimation; 
 Analytical library for the available individual data provision such as cyclin 
expressions analysis, clinical and experimental data from apparatus for cell cycle 
modelling.  
 
The current developed model will serve as version 0.1 (v.0.1) of the ChemoApp tool and its 
function is illustrated in figures 6.2 to 6.4. The required input information for both the 
simulator and the optimiser consist of patient, disease and drug information. Patient 
information includes the physiological patient characteristics of sex, age, weight, height, 
whereas disease information is the clinically available BM information such as the blast 
percentage in marrow aspirate and the BM cellularity. Extra information to what is currently 
used in clinical practice will be the cell cycle characteristics of S-phase duration and the total 
cell cycle duration. This extra information can be either provided by the analytical library of 
the ChemoApp Tool or can be measured by immunophenotyping on the BM aspirates and 
trephine biopsies taken from each patient at diagnosis (Ki-67 and cyclin analysis). Moreover, 
ChemoApp requires the product names of the drugs that will be used for the treatment 
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protocol. For the selected drugs, ChemoApp will automatically generate PK and PD values as 
given in the product specification by the pharmaceutical company producing this drug. 
However, the end-user will have access to these data and will be able to change the 
information if required. All of this information may be filed and stored in patients‟ electronic 
records for local and central audit purposes as well as for research programmes.  
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Figure 6.2: ChemoApp – Library model version 0.1 (v.0.1) 
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Figure 6.3: ChemoApp – Illustration of simulator for version v.0.1 
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Figure 6.4: ChemoApp – Illustration of optimiser for version v.0.1  
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ChemoApp, has a variety of patient related benefits, benefits to the national economy and 
NHS as well as benefits to the pharmaceutical industry and societal benefits. More 
specifically, as an advanced intelligent computational tool, ChemoApp will enable audit 
analysis, i.e., giving a framework which will enable process improvement via creating a 
database on actions that should be done and on those that are done in practice. Moreover, 
audit analysis provided by ChemoApp, will enable patient involvement in the treatment via 
provision of the possibility of following up his/her clinical case on-line and potentially in 
real-time. Additionally, the optimisation application of ChemoApp, will enable the definition 
of an optimal personalised treatment protocol – based on specific patient characteristics - and 
will provide better insight into disease dynamics as well as the drug desired summary of 
product characteristics (SPC), therefore, increasing the efficiency of the treatment. This is 
crucial both for the patient, i.e., higher efficiency of chemotherapy (personalised) treatment 
as well as for the national economy and the NHS, i.e., accurate prediction of optimal 
treatment will enable more cost-efficient drug use and cost-savings for hospital care for these 
patients, enabling value-for-money in both nationalised and privatised healthcare sectors. 
Moreover, the tool will also provide the possibility of rapid, accurate and cost effective 
design of Clinical Trial phases I & II, therefore, facilitating new drug development and 
faster release of new drugs to market. The latter is of great importance as currently, more than 
$50b (£32b) is spent annually by large pharmaceutical companies to develop and bring new 
drugs to market.  Societal benefits originate from improved treatment design for patients with 
AML and limitation of toxicities which can impact on long-term survivorship due to the 
secondary effects of chemotherapy later in life, as well as by reduced overall costs of drugs 
due to less money spent by the pharmaceutical industry during the drug development phase. 
In summary, the benefits from the development of the software proposed in this project are as 
listed below: 
(i)  ChemoApp provides the physician with advice in real-time during the 
decision making process of leukemia treatment and has the potential to monitor and audit 
progress and amielioration of the disease during treatment. It can also integrate quality of 
life parameters within the system to improve toxicity profile and patient satisfaction 
during and post-treatment. 
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(ii) ChemoApp enables patients to follow their own treatment step by step and 
potentially can enable and empower them to drive their own treatment plan, with their 
treating team. This may in itself have positive outcomes both physically and 
psychologically for patients as they will remain in some control of their environment and 
what has happened to them after such a devastating diagnosis has been made – it is one of 
the most difficult things for patients to come to terms with during treatment. 
(iii) Potential improvement in healthcare (both nationalised and private systems) in 
terms of reduced cost of drugs/treatment and secondary effects due to excessive toxicities 
of treatment. Since therapy will be based on patient- and disease- specific characteristics, 
rather than empirical therapy currently employed, it is anticipated that there will be less 
treatment toxicity, a reduction in hospital resources and long-term toxicity of treatment. 
(iv) Personalised treatment based on tumour and patient-specific data leading to 
better survival outcomes. 
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Appendix A: 
Treatment outcome is highly dependent on the duration of the S-phase (Ts) and the total 
cycle duration (Tc). For this reason in this Appendix the dynamics of the leukemic cell 
population in the particular cell phases are presented for the two patients studied and analysed 
in Part I. 
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A1: Patient H1 under simulation with LDAC protocol 
Table A1: Cells in S-phase, G1-phase and G2M-phase of patient H1 under simulation 
with LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.17E+10 1.34E+11 6.58E+09 
End of 1
st
 Cycle 2.09E+09 1.92E+10 2.43E+08 
Beginning of 2
nd
 
Cycle 
5.59E+10 1.79E+11 8.82E+09 
End of 2
nd
 Cycle 2.80E+09 2.57E+10 3.26E+08 
Beginning of 3
rd
 
Cycle 
7.49E+10 2.40E+11 1.18E+10 
End of 3
rd
 Cycle 3.75E+09 3.44E+10 4.36E+08 
Beginning of 4
th
 
Cycle 
1.00E+11 3.23E+11 1.59E+10 
End of 4
th
 Cycle 5.03E+09 4.62E+10 5.86E+08 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A1: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC simulation protocol  
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Figure A2: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the LDAC simulation protocol  
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Figure A3: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC simulation protocol  
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Figure A4: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC simulation protocol  
A2: Patient H1 under simulation with DA protocol 
Table A2: Cells in S-phase, G1-phase and G2M-phase of Patient H1 under simulation 
with DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.12E+10 1.34E+11 6.50E+09 
End of 1
st
 Cycle 2574654.2 7.46E+07 348131.75 
Beginning of 2
nd
 
Cycle 
1.76E+08 5.76E+08 2.79E+07 
End of 2
nd
 Cycle 
11034.237 319812.78 1491.9939 
Beginning of 3
rd
 
Cycle 
769047.6 2509523.8 121428.57 
End of 3
rd
 Cycle 
48.097878 1394.0555 6.503553 
Beginning of 4
th
 
Cycle 
3392.8572 11071.429 535.7143 
End of 4
th
 Cycle 
0.21219935 6.1502643 0.02869239 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A5: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the DA simulation protocol  
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Figure A6: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the DA simulation protocol  
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Figure A7: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the DA simulation protocol  
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Figure A8: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the DA simulation protocol  
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A3: Patient H2 under simulation of LDAC protocol 
Table A3: Cells in S-phase, G1-phase and G2M-phase of Patient H2 under simulation 
with LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.93E+10 5.60E+10 6.72E+09 
End of 1
st
 Cycle 1.26E+08 4.45E+08 1.35E+07 
Beginning of 2
nd
 
Cycle 
3.17E+09 3.60E+09 4.32E+08 
End of 2
nd
 Cycle 
8119624.5 2.86E+07 870052.2 
Beginning of 3
rd
 
Cycle 
2.02E+08 2.30E+08 2.76E+07 
End of 3
rd
 Cycle 
518754.6 1826699 55586.76 
Beginning of 4
th
 
Cycle 
1.30E+07 1.48E+07 1776000 
End of 4
th
 Cycle 
33380.617 117543.71 3576.8752 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A9: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC simulation protocol  
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Figure A10: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the LDAC simulation protocol  
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Figure A11: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC simulation protocol  
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Figure A12: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC simulation protocol  
A4: Patient H2 under simulation of DA protocol 
Table A4: Cells in S-phase, G1-phase and G2M-phase of Patient H2 under simulation 
with DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.93E+10 5.60E+10 6.72E+09 
End of 1
st
 Cycle 39524.688 439012.44 4868.7617 
Beginning of 2
nd
 
Cycle 
2138400 2430000 291600 
End of 2
nd
 Cycle 
1.7151027 19.049969 0.21127135 
Beginning of 3
rd
 
Cycle 
88 100 12 
End of 3
rd
 Cycle 
7.06E-05 7.84E-04 8.69E-06 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A13: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the DA simulation protocol  
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Figure A14: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the DA simulation protocol  
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Figure A15: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the DA simulation protocol  
A5: Patient H1 under optimisation of LDAC protocol 
Table A5: Cells in S-phase, G1-phase and G2M-phase of Patient H1 under optimisation 
of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.17E+10 1.34E+11 6.58E+09 
End of 1
st
 Cycle 5.77E+07 1.16E+09 8290762.5 
Beginning of 2
nd
 
Cycle 
2.93E+09 9.41E+09 4.63E+08 
End of 2
nd
 Cycle 
3909514.2 8.14E+07 587558.56 
Beginning of 3
rd
 
Cycle 
9.00E+08 6.61E+08 3.25E+07 
End of 3
rd
 Cycle 
7.10E+07 6.70E+07 287523.97 
Beginning of 4
th
 
Cycle 
1.73E+08 5.56E+08 2.74E+07 
End of 4
th
 Cycle 
3296483 5.63E+07 253690.77 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A16: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC optimisation protocol  
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Figure A17: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the LDAC optimisation protocol  
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Figure A18: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC optimisation protocol  
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Figure A19: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC optimisation protocol  
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A6: Patient H1 under optimisation of DA protocol 
Table A6: Cells in S-phase, G1-phase and G2M-phase of Patient H1 under optimisation 
of DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.12E+10 1.34E+11 6.50E+09 
End of 1
st
 Cycle 813636.7 6.63E+07 90931.73 
Beginning of 2
nd
 
Cycle 
6.60E+08 4.87E+08 2.36E+07 
End of 2
nd
 Cycle 
243661.14 240380.83 329.75244 
Beginning of 3
rd
 
Cycle 
542857.1 1771428.6 85714.29 
End of 3
rd
 Cycle 
10.729266 874.11456 1.1991037 
Beginning of 4
th
 
Cycle 
1978.9404 6457.595 312.4643 
End of 4
th
 Cycle 
0.03832092 3.1918411 0.004544233 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A21: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the DA optimisation protocol  
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Figure A22: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the DA optimisation protocol  
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Figure A23: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the DA optimisation protocol  
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Figure A24: Patient H1 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the DA optimisation protocol  
A7: Patient H2 under optimisation of LDAC protocol 
Table A7: Cells in S-phase, G1-phase and G2M-phase of Patient H2 under the 
optimisation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.93E+10 5.60E+10 6.72E+09 
End of 1
st
 Cycle 1.97E+07 1.99E+08 1774969.5 
Beginning of 2
nd
 
Cycle 
1.06E+09 1.21E+09 1.45E+08 
End of 2
nd
 Cycle 
424974.2 4308155.5 38352.02 
Beginning of 3
rd
 
Cycle 
2.30E+07 2.62E+07 3138000 
End of 3
rd
 Cycle 
9184.359 93106.01 828.84735 
Beginning of 4
th
 
Cycle 
504000 624000 72000 
End of 4
th
 Cycle 
289.5426 3035.9255 26.171131 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A25: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC optimisation protocol  
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Figure A26: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the LDAC optimisation protocol  
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Figure A27: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC optimisation protocol  
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Figure A28: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC optimisation protocol  
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A8: Patient H2 under optimisation of DA protocol 
Table A8: Cells in S-phase, G1-phase and G2M-phase of Patient H2 under the 
optimisation of DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
4.93E+10 5.60E+10 6.72E+09 
End of 1
st
 Cycle 20083.977 347152.5 3051.4778 
Beginning of 2
nd
 
Cycle 
1500000 1600000 200000 
End of 2
nd
 Cycle 
0.09313364 0.6952326 0.018685918 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure A29: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the DA optimisation protocol  
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Figure A30: Patient H2 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle of 
the DA optimisation protocol  
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Appendix B: 
Patient Protocols 
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Patient number: 001       
Disease status:  Secondary    
Patient Characteristics:  
Age: 75 years                 Sex: F                 Height: 152 cm         
Body Weight: 56 Kg      BSA: 1.54 m2     
I.  Baseline Characteristics: 
Pre-treatment Data   
Bone Marrow Aspirate  
%Blasts in BM aspirate 21 %         
Prognostic category Intermediate  
Full Blood Count  Date: 12/03/2010 
WBC (x10
9
L) 8.7 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
2 
Day 37 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
3 
Day 69 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
4 
Day 105 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
III. Response to Treatment  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marrow 
Cycle 4 Repeat 
marrow 
Date Day 36 
 
Day 70 
 
Day 91 
 
Day 146 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
3  3  2  3  
Blasts (%) 14  4  5  15  
Marrow 
Response 
PR  CR  CR  Relapse  
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Patient number: 002       
  
Disease status:  Secondary    
 
Patient Characteristics:  
Age: 72 years                 Sex: F                 Height: 150 cm         
 
Body Weight: 47 Kg      BSA: 1.4 m2     
 
I.  Baseline Characteristics: 
Pre-treatment Data   
BM Aspirate  
%Blasts in BM aspirate 83 % 
Prognostic category Intermediate  
Full Blood Count  Date: 06/02/2008 
WBC (x10
9
L) 46.5 
 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
2  
     
 
 
   
 
  
 
   
3  
 
 
   
 
 
   
 
  
 
   
4  
 
 
   
 
 
   
 
III. Response to Treatment  
Marrow examinations  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marrow 
Cycle 4 Repeat 
marrow 
Date Day 48 
 
 
 
 
 
 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
3  
 
 
 
 
 
 
Blasts (%) 4  
 
 
 
 
 
 
Marrow 
Response 
CR  
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Patient number: 006       
  
Disease status:  De Novo    
 
Patient Characteristics:  
Age: 71 years                 Sex: F                 Height: 160 cm         
 
Body Weight: 57 Kg      BSA: 1.59 m2     
 
I.  Baseline Characteristics: 
Pre-treatment Data   
BM Aspirate  
%Blasts in BM aspirate 36 % 
Prognostic category -  
Full Blood Count  Date: 06/02/2008 
WBC (x10
9
L) 1.6 
 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
2 
Day 42 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
3 
Day 74 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
  
 
   
4 
Day 109 
Ara-C 
20 mg 
 SC 10 days, twice a day 
every 12 hrs 
 
 
   
 
III. Response to Treatment  
Marrow examinations  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marrow 
Cycle 4 Repeat 
marrow 
Date 
Day 42 
 
Day 70 
 
Day 
110  
Day 145 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
1  1  3  1  
Blasts (%) 3  2  2  0  
Marrow 
Response 
CR  CR  CR  CR  
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Patient number: 011       
  
Disease status:  Secondary    
 
Patient Characteristics:  
Age: 24 years                 Sex: M                 Height: 170 cm         
 
Body Weight: 59.5 Kg      BSA: 1.68 m2     
 
I.  Baseline Characteristics: 
Pre-treatment Data   
BM Aspirate  
%Blasts in BM aspirate 56 % 
Prognostic category -  
Full Blood Count  Date: 18/10/2011 
WBC (x10
9
L) 0.9 
 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
Ara-C 168 mg 
 
IV 
10 days, twice a day 
every 12 hrs 
DNR 100 mg 
 
IV 
1-hour dose on days 
1,3,5  
 
  
    
2  
 
    
 
    
 
  
    
3  
 
    
 
    
 
  
    
4  
 
    
 
    
 
III. Response to Treatment  
Marrow examinations  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marrow 
Cycle 4 Repeat 
marrow 
Date Day 48 
 
 
 
 
 
 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
1  
 
 
 
 
 
 
Blasts (%) 3  
 
 
 
 
 
 
Marrow 
Response 
CR  
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Patient number: 016       
  
Disease status:  Secondary    
 
Patient Characteristics:  
Age: 80 years                 Sex: M                 Height: 167.5 cm         
 
Body Weight: 79.3 Kg      BSA: 1.92 m2     
 
I.  Baseline Characteristics: 
Pre-treatment Data   
BM Aspirate  
%Blasts in BM aspirate 90 % 
Prognostic category -  
Full Blood Count  Date: 30/06/2010 
WBC (x10
9
L) 3.3 
 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
DNR 95 mg 
 
IV 
1-hour dose on days 
1,3,5 
Ara-C 190 mg 
 
IV 
10 days, twice a day 
every 12 hrs 
 
  
    
2 
Day 66 Ara-C 20  
SC 
10 days, twice a day 
every 12 hrs 
 
    
 
  
    
3  
 
    
 
    
 
    
 
III. Response to Treatment  
Marrow examinations  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marro
w 
Cycle 4 Repeat 
marrow 
Date 
Day 45 
 
Day 
101  
 
 
 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
3  2  
 
 
 
 
Blasts (%) 1  1  
 
 
 
 
Marrow 
Response 
CR  CR  
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Patient number: 026       
  
Disease status:  De novo    
Patient Characteristics:  
Age: 45 years                 Sex: F                 Height: 169.3 cm         
 
Body Weight: 94.8 Kg      BSA: 2.11 m2     
 
I.  Baseline Characteristics: 
Pre-treatment Data   
BM Aspirate  
%Blasts in BM aspirate 71 % 
Prognostic category -  
Full Blood Count  Date: 26/05/2011 
WBC (x10
9
L) 1.2 
 
II. Chemotherapy Treatment Schedule 
 Cycle Date Drugs Doses Dose 
Reduction 
Route Number of days 
and schedule 
given 
1 
Day 1 
DNR 150 mg 
 
IV 
1-hour dose on days 
1,3,5 
Ara-C 170 mg 
 
IV 
10 days, twice a day 
every 12 hrs 
 
  
    
2 
Day 56 
DNR 85 mg 
 
IV 
1-hour dose on days 
1,3,5 
Ara-C 170 mg 
 
IV 
8 days, twice a day 
every 12 hrs 
 
  
    
3  
     
     
 
    
 
III. Response to Treatment  
Marrow examinations  
Completio
n of 
Course 
Cycle 
1 
Repeat 
marro
w 
Cycle 
2 
Repeat 
marrow 
Cycle 
3 
Repeat 
marro
w 
Cycle 4 Repeat 
marrow 
Date 
Day 48 
 
Day 
116    
 
 
Cellularity 
(1= hypo, 
2=normo, 3= 
hyper) 
2  2    
 
 
Blasts (%) 0  0    
 
 
Marrow 
Response 
CR  CR    
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Appendix C: 
Treatment outcome is highly dependent on the duration of the S-phase (Ts) and the total 
cycle duration (Tc). For this reason in this Appendix the dynamics of the leukemic cell 
population in the particular cell phases are presented for the six patients studied and analysed 
in Part II. 
 
  
209 
 
C1: Patient P001 under simulation of LDAC protocol 
Table C1: Cells in S-phase, G1-phase and G2M-phase of patient P001 under the 
simulation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
5.82E+10 1.28E+11 1.33E+10 
End of 1
st
 Cycle 1.65E+09 8.08E+09 2.77E+08 
Beginning of 2
nd
 
Cycle 
6.03E+10 7.57E+10 1.10E+10 
End of 2
nd
 Cycle 
9.95E+08 2.65E+09 1.38E+08 
Beginning of 3
rd
 
Cycle 
9.24E+09 2.67E+10 2.57E+09 
End of 3
rd
 Cycle 
9.39E+08 5.05E+09 1.87E+08 
Beginning of 4
th
 
Cycle 
2.42E+10 5.88E+10 4.03E+09 
End of 4
th
 Cycle 
9.25E+08 5.72E+09 1.15E+08 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
 
Time (days)
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u
m
b
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1.0e+11
1.2e+11
1.4e+11
Cells in S-phase
Cells in G1 - phase
Cells in G2M - phase
 
Figure C1: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC simulation protocol  
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Time (days)
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Figure C2: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the LDAC simulation protocol  
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Figure C3: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC simulation protocol  
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Figure C4: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC simulation protocol  
 
C2: Patient P002 under simulation of LDAC protocol 
Table C2: Cells in S-phase, G1-phase and G2M-phase of patient P002 under the 
simulation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
3.71E+11 3.66E+11 5.30E+10 
End of 1
st
 Cycle 1.87E+08 6.55E+08 2.15E+07 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Time (days)
1 3 5 7 9 11
C
e
ll 
N
u
m
b
e
r
0
1e+11
2e+11
3e+11
4e+11
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Figure C5: Patient P002 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC simulation protocol  
C3: Patient P006 under simulation of LDAC protocol 
Table C3: Cells in S-phase, G1-phase and G2M-phase of patient P006 under the 
simulation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
1.98E+11 1.12E+11 2.97E+10 
End of 1
st
 Cycle 8.87E+07 1.18E+08 1.07E+07 
Beginning of 2
nd
 
Cycle 
1.85E+09 3.86E+09 3.96E+08 
End of 2
nd
 Cycle 
1.23E+08 5.02E+08 1.94E+07 
Beginning of 3
rd
 
Cycle 
1.19E+09 4.42E+09 2.59E+08 
End of 3
rd
 Cycle 
1.75E+08 1.27E+09 2.74E+07 
Beginning of 4
th
 
Cycle 
9.69E+09 7.80E+09 1.42E+09 
End of 4
th
 Cycle 
1.86E+07 4.71E+07 2282685 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C6: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle of 
the LDAC simulation protocol  
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Figure C7: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the LDAC simulation protocol  
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Figure C8: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle of 
the LDAC simulation protocol  
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Figure C9: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle of 
the LDAC simulation protocol  
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C4: Patient P011 under simulation of DA protocol 
Table C4: Cells in S-phase, G1-phase and G2M-phase of patient P011 under the 
simulation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
9.03E+10 4.12E+11 3.01E+10 
End of 1
st
 Cycle 7289276 1.54E+08 2120402.8 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C10: Patient P011 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA simulation protocol  
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C5: Patient P016 under simulation of DA / LDAC protocol 
Table C5: Cells in S-phase, G1-phase and G2M-phase of patient P016 under the 
simulation of DA / LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
1.52E+11 6.55E+11 4.75E+10 
End of 1
st
 Cycle 1.63E+07 3.11E+08 4353955 
Beginning of 2
nd
 
Cycle 
2.35E+10 4.76E+10 5.08E+09 
End of 2
nd
 Cycle 
3.93E+07 3.48E+08 7081176 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C11: Patient P016 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA simulation protocol  
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Figure C12: Patient P016 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the LDAC simulation protocol  
C6: Patient P026 under simulation of DA protocol 
Table C6: Cells in S-phase, G1-phase and G2M-phase of patient P026 under the 
simulation of DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
2.15E+11 4.16E+11 4.31E+10 
End of 1
st
 Cycle 966444.7 1.15E+07 164596.27 
Beginning of 2
nd
 
Cycle 
3.94E+08 5.78E+08 7.88E+07 
End of 2
nd
 Cycle 
3646.3252 34955.99 652.36597 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C12: Patient P026 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA simulation protocol  
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Figure C13: Patient P026 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the DA simulation protocol  
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C7: Patient P001 under optimisation of LDAC protocol 
Table C7: Cells in S-phase, G1-phase and G2M-phase of patient P001 under the 
optimisation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
5.82E+10 1.28E+11 1.33E+10 
End of 1
st
 Cycle 2.77E+08 3.37E+09 2.71E+07 
Beginning of 2
nd
 
Cycle 
1.99E+10 2.50E+10 3.64E+09 
End of 2
nd
 Cycle 
8660943 8.11E+07 860415.2 
Beginning of 3
rd
 
Cycle 
2.06E+08 5.96E+08 5.73E+07 
End of 3
rd
 Cycle 
2544783 3.36E+07 256695.48 
Beginning of 4
th
 
Cycle 
1.21E+08 2.94E+08 2.01E+07 
End of 4
th
 Cycle 
955109.8 1.40E+07 79868.37 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C14: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the LDAC optimisation protocol  
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Figure C15: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the LDAC optimisation protocol  
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Figure C16: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle 
of the LDAC optimisation protocol  
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Figure C17: Patient P001 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle 
of the LDAC optimisation protocol  
C8: Patient P002 under optimisation of LDAC protocol 
Table C8: Cells in S-phase, G1-phase and G2M-phase of patient P002 under the 
optimisation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
3.71E+11 3.66E+11 5.30E+10 
End of 1
st
 Cycle 3739450.2 2.49E+07 591878.75 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C18: Patient P002 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the LDAC optimisation protocol  
C9: Patient P006 under optimisation of LDAC protocol 
Table C9: Cells in S-phase, G1-phase and G2M-phase of patient P006 under the 
optimisation of LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
1.98E+11 1.12E+11 2.97E+10 
End of 1
st
 Cycle 1104074.8 5432401.5 110485.08 
Beginning of 2
nd
 
Cycle 
4.70E+07 9.80E+07 1.01E+07 
End of 2
nd
 Cycle 
266451.8 2849935.5 24962.537 
Beginning of 3
rd
 
Cycle 
5195294 1.93E+07 1129411.8 
End of 3
rd
 Cycle 
160901.05 2365376.5 13430.869 
Beginning of 4
th
 
Cycle 
1.54E+07 1.24E+07 2250000 
End of 4
th
 Cycle 
1089.6929 7181.63 103.36292 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C19: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the LDAC optimisation protocol  
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Figure C20: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the LDAC optimisation protocol  
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Figure C21: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 3
rd
 cycle 
of the LDAC optimisation protocol  
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Figure C22: Patient P006 Cells in S-phase, G1-phase and G2M-phase over the 4
th
 cycle 
of the LDAC optimisation protocol  
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C10: Patient P011 under optimisation of DA protocol 
Table C10: Cells in S-phase, G1-phase and G2M-phase of patient P011 under the 
optimisation of DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
9.03E+10 4.12E+11 3.01E+10 
End of 1
st
 Cycle 1805735.2 5.93E+07 634875.94 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C23: Patient P011 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA optimisation protocol  
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C11: Patient P016 under optimisation of DA / LDAC protocol 
Table C11: Cells in S-phase, G1-phase and G2M-phase of patient P016 under the 
optimisation of DA / LDAC protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
1.52E+11 6.55E+11 4.75E+10 
End of 1
st
 Cycle 1085740.9 8.32E+07 221250.19 
Beginning of 2
nd
 
Cycle 
5.64E+09 1.14E+10 1.21E+09 
End of 2
nd
 Cycle 
2350522.5 6.90E+07 293168.84 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C24: Patient P016 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA optimisation protocol  
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Figure C25: Patient P016 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the DA optimisation protocol  
C12: Patient P026 under optimisation of DA / LDAC protocol 
Table C12: Cells in S-phase, G1-phase and G2M-phase of patient P026 under the 
optimisation of DA protocol 
 
Cells in S-phase Cells in G1-phase Cells in G2M - phase 
Beginning of 1
st
 
Cycle 
2.15E+11 4.16E+11 4.31E+10 
End of 1
st
 Cycle 100510.36 7562396 21018.395 
Beginning of 2
nd
 
Cycle 
9.98E+07 1.46E+08 2.00E+07 
End of 2
nd
 Cycle 
97.1664 5616.5044 34.06412 
*The initial population of cells in the separate phases is calculated by the multiplication of 
the leukemic population at the beginning of each cycle times the percentage of cell 
population in each phase for each cycle (equations 3.15-3.17 section 3.3.1). 
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Figure C26: Patient P026 Cells in S-phase, G1-phase and G2M-phase over the 1
st
 cycle 
of the DA optimisation protocol  
Time (days)
36 38 40 42 44
C
e
ll 
N
u
m
b
e
r
1e+1
1e+2
1e+3
1e+4
1e+5
1e+6
1e+7
1e+8
1e+9
Cells in S-phase
Cells in G1 - phase
Cells in G2M - phase
 
Figure C27: Patient P026 Cells in S-phase, G1-phase and G2M-phase over the 2
nd
 cycle 
of the DA optimisation protocol  
